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ABSTRACT
Outbreaks of shiga-toxin producing Escherichia coli (STEC), namely E. coli O157:H7,
with other multi-drug resistant bacteria (MDRB) alongside the unfortunate dearth in antibiotic
drug development have helped to create a platform in which infections caused by pathogenic
bacteria have become superior. This problem necessitates the development of novel
antimicrobial agents with high potency and low toxicity.
The research presented in this dissertation explores a novel pragmatic therapeutic
approach for control, prevention, and treatment of infectious disease using Active Pharmaceutical Ingredient-based Ionic Liquids (API-ILs) and Groups of Uniform Materials
Based on Organic Salts (GUMBOS). Accordingly, several antiseptic- and antibiotic-based APIILs and GUMBOS were synthesized and characterized using a combination of analytical and
microbiological techniques. Overall, this research presents an advanced alternative to
combination antibiotic therapy by using a novel group of ionic antimicrobial materials that have
controlled pharmacokinetics, improved bioavailabilities, reduced toxicities, multi-modal
properties, and potent antimicrobial spectrum of activity as a viable alternative to combating
bacterial infections.
The first part of this research provides the physical characterization and subsequent in
vitro antimicrobial activity of ampicillin-based ILs consisting of several different quaternary
ammonium compounds (QACs) on Escherichia coli O157:H7, Klebsiella pneumoniae,
Staphylococcus aureus, and Listeria monocytogenes. The synthesized API-ILs were validated
with proton nuclear magnetic resonance spectroscopy (NMR) and elemental analysis. Melting
points, critical micelle concentrations, and solubility were among the other physical properties

xvii

investigated. Improved antibacterial activity was evaluated using Loewe’s Additivity
Mathematical Model and interaction indices were established and compared to mixtures of
precursor QACs and ampicillin.
The second part of the dissertation research focuses on the synthesis and antibacterial
activity of GUMBOS created from an antiseptic and several β-lactam antibiotics. Using anion
metathesis, four β-lactam antibiotic-based chlorhexidine GUMBOS were synthesized prior to
validation using proton and carbon NMR, mass spectrometry, elemental analysis, and absorbance
spectroscopy. Several orders of improvement in in vitro antibacterial activities were obtained on
isolates of Escherichia coli O157:H7, Salmonella typhi, Acinetobacter baumanii, Enterbacter
clocae, Enterbacter aerogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa, Serratia
marscescens, Staphylococcus aureus, Streptococcus mutans Streptococcus facaelis, Micrococcus
luteus, Bacillus cereus, and Methicillin-resistant Staphylococcus aureus. Interaction indices
show the GUMBOS to be synergetic ion-pairs despite additivity and antagonism observed by the
mixtures of antiseptic and antibiotic precursor ions. Furthermore, the mechanisms of action
studies for these materials were defined with emphasis on membrane permeability and
membrane potential. Finally, acute cytotoxicity against fibroblast, endothelium, and cervical
cellular lines in addition to an assessment of intestinal permeability and bioavailability were
completed.
Specific target applications for this work include the reduction of STEC fecal shedding
from ruminant sources, prevention of meningitis onset in neonates by the eradication of Group B.
Streptococci, reduction in catheter-associated bacteremia, and extension of antibacterial efficacy
and spectrum of activity of antibiotics against multi-drug-resistant microbes that colonize in
wound beds.
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1.1

CHAPTER 1 INTRODUCTION
Bacteriology and Infectious Disease

1.1.1 Bacteria
Originally called “animalcules”, bacteria were studied microscopically by Antonie van
Leeuwenhoek during the mid- 17th century.1 They were not known as bacteria until the 1830s
when Christian Gottfried Ehrenbug defined the genus based on his scientific observations as
“non-spore forming rod-shaped bacteria”. 1However, bacteria are defined as single-celled,
prokaryotic microorganisms.1 Bacteria have several morphologies (i.e. spheres, rods, and spirals)
and sizes which range on the scale of microns (Figure 1.1). Most bacteria are spherical, named
cocci, or rod-shaped, called bacilli.1 Slight differences in the morphology from spheres or rods
have led to different classes of bacteria named by their shapes such as comma (Vibrio), spiral
(Spirilla), or coiled (Spirochaetes). The shapes of bacteria are determined by the cell wall and its
cytoskeleton.

1

Aside from morphology, bacteria arrange in ordered arrays that add to their

diverse nomenclature. For example, Streptococci species form chains whereas Staphylococci
species form clusters.

Figure 1.1. Types of bacteria by shape.
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1.1.2 Morphology and Cellular Structure
Bacteria are visually distinguishable using Gram-staining (named after Christian Gram,
Danish scientist and physician, 1853-1938).1 This bacteriological method separates bacteria into
two classes based on their abilities to retain dyes and the physical properties of their cellular
walls. Additionally, this method allows for their morphologies and arrangements to be visualized
microscopically. The principle of Gram-staining is premised on the notion that Gram-positive
bacteria have a thicker cellular wall than Gram-negative.1 Hence, Gram-positive bacteria retain
both the crystal violet and safranin stains while Gram-negative bacteria only show the pink
safranin dye. Examples of Gram-positive bacteria are Staphylococcus and Enterococcus and
examples of Gram-negative bacteria are Escherichia and Salmonella.
Gram-Negative Bacteria

External Outer
Membrane (GramNegative bacteria)

Gram-Positive Bacteria
Flagella

Nucleus

External Cell Wall
(Gram-Positive
bacteria)

Cell Wall

Plasmid
Cytoplasmic
Membrane

Ribosomes

Figure 1.2. Basic components of a bacterial cell.
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Depot Substances

Bacteria are structurally composed of two major parts: intracellular and extracellular
components (Figure 1.2). The intracellular components are enclosed by a hydrophobic cell
membrane which envelopes its essential materials. Prokaryotes are structurally simple as
compared to eukaryotic cells since they do not contain various membrane bound organelles.1
Instead of mitochondria, bacteria use micro-compartments that maintain cellular metabolisms
and membrane potentials which are generated via biochemical reactions across cellular
membranes.1 Bacteria have a nucleoid that stores its genetic material. The only common feature
amongst all cells is the presence of ribosomes which helps to generate proteins and enzymes for
routine function. The intracellular components are protected by a cellular wall composed of
peptidoglycan, which is also the lethal target of beta (β)-lactam antibiotics.1 As previously
mentioned, Gram-staining reveals the structural differences in the extracellular components of
Gram-positive and Gram-negative bacteria. Gram-positive bacteria have a thicker cell wall that
is composed of both peptidoglycan and techoic acid layers, which helps to retain Gram-stains.1
However, Gram-negative bacteria have a thin layer of a peptidoglycan cell wall with a thick
secondary cell membrane composed of lipopolysaccharides and lipoproteins.1 Although the
conventional structure of bacteria contains a cell membrane and cell wall, the thickness and
assembly can vary affecting the bacterium’s susceptibility to many antimicrobial agents.
Additional components on the extracellular framework, can include flagella, fimbriae, and pilli
as well as the production of protective slime layers, but are not characteristic of the bacteria
studied in this research and details about their roles are omitted.
1.1.3 Growth and Reproduction
Bacteria are asexual microorganisms that reproduce via binary fission. Cell growth are
defined as occurring in three phases, i.e. lag phase, logarithmic phase, and stationary phase, prior
to cell death.1 The first phase, called the lag phase, allows the bacteria to adapt to its growth
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environment. This is a slow growth process and has the highest protein synthesis rates prior to
the logarithmic phase. In this phase, the bacteria have become well-adjusted to its environment
and begin to multiply exponentially. The rate at which bacteria multiply is known as the growth
rate which is dependent on the cells splitting rate known as generation time.1 The rate limiting
factor during this phase is the speed in which the key nutrients required for optimal growth are
consumed. Once depleted, bacteria growth becomes static and cells enter into the stationary
phase. This phase causes cells to adapt to the lack of nutrients as they try to survive in a stress
response state.1 Prior to cell death, bacteria express high amounts of genetic information relevant
to DNA repair, antioxidant metabolism, and nutrient transport.
1.1.4 Associations with Other Organisms
Bacteria are highly adaptable and thus are found in a wide variety of environments. They
are capable of forming complex associations with other organisms in which these associations
can be categorized as parasitism, mutualism, and commensalism.1 Within the scope of this
dissertation, only associations based on commensalism and parasitism will be addressed.
Bacteria that exercise commensalism are able to survive without harming or helping the host.
Examples of commensalism lie in the types of bacteria that innocuously reside inside the mouth,
nose, and intestinal tract of mammals.1In any type of benefit to the host, the colonization of these
bacteria prevents the intrusion of harmful bacteria into that site. As a result, some are beneficial
as part of the normal human flora while some bacteria can cause several diseases and infections.
Bacteria that unilaterally deplete the host’s health and detrimentally affect its immune system as
an effort to survive are considered to be opportunistic and are parasitic.1 These bacteria
proliferate at the expense of the host causing its exposure to various secreted poisonous
substances. Contact with such poisons (i.e. endotoxins and exotoxins) can result in the onset of
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disease and infection.1 Therefore antibacterial agents are used to prevent the effects of their
parasitic intrusion that results in host morbidity and mortality.
1.1.5 Pathogenic Bacteria and Infectious Disease
Pathogenic bacteria are microorganisms that cause infection which sometimes result in
disease. Their degree of pathogenicity or virulence is often the result of their genetic,
biochemical, or structural features.1 Since pathogenic bacteria are parasitic microorganisms, the
degree of virulence is dependent on the strength of the host’s immune system, the resilience or
susceptibility of the bacteria, and the bacteria’s virulence factors.1 Pathogenic bacteria have two
main methods of inflicting disease: 1) invading tissues and colonizing and/or 2) producing
toxins.1 Invasiveness allows the bacteria to initially adhere to the tissue surface, grow, and
produce extracellular substances that debilitate host mechanisms.1 This usually occurs at sites
exposed to the external environment such as the urogenital tract, digestive tract, respiratory tract
and the eye. Bacteria that prey on these sites have special adherence mechanisms which allow
resistance to host defenses. There are two mechanisms (i.e. nonspecific adherence and specific
adherence) that facilitate bacteria cell adhesion, in which examples of bacterium-specific
adhesin-receptors per adhesion site are listed in Table 1.1.1 Nonspecific adherence to eukaryotic
cells uses various attractive forces and Brownian motion.1 However, a bacteria’s ability to
specifically adhere to a site relies on a receptor and ligand relationship. Receptors are commonly
peptides, proteins, or carbohydrates, on the surface of a eukaryotic cell.1 However, the bacterial
ligand is called an adhesin. Adhesins are polymeric cell surface proteins that control the
complimentary interaction between the bacteria and host cell receptor site. 1 This is a property of
the bacteria extracellular components, namely the pilli and fimbriae. More specifically, some
bacteria choose particular cells and tissue sites in which to colonize. Examples of histotropic
bacteria that use their invasiveness to inflict disease are Pseudomonas aeruginosa, Acinetobacter
5

baumanii, and Enterbacter cloacae, since they have an apparent tissue preference over others.
The methods in which these bacteria and some others adhere to cell receptors sites and the
resulting disease are highlighted in Table 1.1.
Table 1.1. Examples of adhesin-receptors per adhesion site by various bacteria.2

Bacterium

Adhesin

Receptor
N-acetylhexos-aminegalactose disaccharide

Streptococcus
pneumoniae

Cell-bound
protein

Staphylococcus
aureus

Cell-bound
protein

Enterotoxigenic
E. coli

Type-I
fimbriae

Uropathogenic
E. coli

Type I
fimbriae

Pseudomonas
aeruginosa

Type-I V
Pilli

Globobiose linked to
ceramide lipid
Species-specific
carbohydrate(s)

Klebsiella
pneumoniae

Type-I
fimbriae

Enterobacter
cloacae
Acinetobacter
baumanii

Attachment site Disease
Mucosal
epithelium

Pneumonia

Species-specific
carbohydrate(s)

Mucosal
epithelium

Various

Complex carbohydrate

Intestinal
epithelium

Diarrhea

Urethral
epithelium

Urethritis

Upper
respiratory tract

Pneumonia

Species-specific
carbohydrate(s)

Upper
respiratory tract

Pneumonia

Type – I
fimbriae

Species-specific
carbohydrate(s)

Mucosal
epithelium

Pneumonia

Cell-bound
protein

Species-specific
carbohydrate(s)

Mucosal
epithelium

Pneumonia

Amino terminus of
fibronectin

The other method, toxigenesis, is a method in which bacteria excretes either endotoxins or
exotoxins which can adversely affect the host. Endotoxins are cell-associated molecules that are
usually found within the outer membrane (i.e. lipopolysaccharide) of Gram-negative bacteria.1
These toxins are not secreted by cells, but rather are released when lysed by antibiotic therapy or
the host’s immune defenses.1 Bacteria that harvest endotoxins are Gram-negative pathogens such
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as Neisseria meningitides that causes meningococcal disease and Listeria monocytogenes that
causes listeriosis. By contrast, exotoxins are released from bacterial cells. Some exotoxins
behave differently on target cells and can be categorized by: (1) identification of toxin-producing
organism, (2) identification of organism susceptible to toxin, (3) target susceptibility to toxin, (4)
chemical structure or morphology, (5) resistance to environmental stressors, and (6)
chronological discovery-based nomenclature.2 Many exotoxins can be identified by several of
these categories. An example of an exotoxin is botulinum toxin produced by Clostridium
botulinum. Both endotoxins and exotoxins can be transported in circulation and result in
cytotoxic effects at localized and remote sites of invasion.1
1.2

Introduction to Antibacterial Drugs

1.2.1 History of Antibiotic Development
The emergence of antibiotic drug resistance among bacteria has become an increasing
health problem. Therefore, to better understand this dilemma it is useful to understand the
history and development of antibacterial drugs or antimicrobial agents. Antimicrobial agents
are generally classified into two categories: 1) antimicrobial drugs such as antibiotics amongst
other systemic drugs for infection treatment, and 2) antiseptics and disinfectants, used to
sterilize surfaces.1 Several types of antimicrobial drugs exist. Naturally occurring drugs
synthesized from microorganisms are defined as antibiotics. 1 Chemically synthesized drugs
that do not resemble the pharmacophoric groups of antibiotics are called synthetic drugs. 1 The
majority of antimicrobial drugs that have been developed are known as semi-synthetic drugs,
which are chemical derivatives of antibiotics. 1
Prior to modern day medicine, society relied on plant products to treat disease even
though their therapeutic properties were not clearly understood. These earlier medicines were
most effective on protozoan disease rather than bacterial infections. Early records show that both
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cinchona and ipecacuanha roots were effective treatments for malaria and dysentery,
respectively.3 Bacterial infections (i.e. syphilis) caused by Trepnema pallidum was treated with
guaiacum and heartsease and sometimes systemic mercury.3
The use of synthetic materials as antimicrobial agents serendipitously began with Paul
Ehrlich. He hypothesized that a “magic bullet” for the diagnosis and treatment of opportunistic
bacterial infections could come about a combinatorial based staining treatment that consisted of a
pathogen selective dye and a bactericidal toxin.4 In the midst of searching for a less toxic version
of the sleeping sickness cure Atoxyl, Ehrlich with Sahachiro Hata discovered that the
arsphenamine compound known as Salvarsan had anti-syphilitic activity.4 However, this
compound required the body to metabolize it into its active form even though still exploiting
patients to its idiosyncratic side effects. Sulfonamides or sulfa-drugs are credited to be the first
class of synthetic drugs. The antibacterial property of the first sulfonamide, trademarked as
Prontosil, was discovered by Gerhard Domagk.4 It had strong preferential antibacterial activity
for hemolytic streptococci rather than other Gram-positive cocci. Unfortunately, Prontosil did
not show antibacterial activity in vitro. Later it was revealed by Ernest Fourneau that when
Protosil is administered in vivo it is metabolized into two portions, an inactive dye and a
pharmacologically active sulfanilamide.4 This discovery led to the manipulation of the
sulfanilamide molecule as an effort to identify more broadly active, potent antimicrobials with
reduced cytotoxicity.
The idea to use microorganisms therapeutically is not new. Known formally as
antibiotics, this approach was used to describe any substance produced by one microorganism
that inhibited the growth of a secondary opportunistic microorganism.1 This definition excludes
naturally occurring substances lethal to microorganisms that were not produced by other
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microorganisms or chemically synthesized substances such as in the case of sulfonamides. 1
Native Americans relied on antibiotic therapy for many years. Early Native American documents
report the use of a “slimy” fungus to treat skin abscesses.3 In the 1890s, Rudolf Emmerich and
Oscar Low Coghill at the United States Department of Agriculture's Northern Regional Research
Laboratory in Illinois used mold from a cantaloupe to produce higher yields of penicillin.5
Throughout the 1940s and 1950s, substantial efforts were pursued to capitalize on the new found
ability to extract high yields of penicillin. Dorothy Crowfoot Hodgkin elucidated the 6aminopenicillanic acid (6-APA) chemical structure of penicillin in 1945.5
A variety of antibiotics surfaced after the discovery of penicillin, mostly those composed
of the 6-APA backbone. In 1948, Giuseppe Brotzu isolated a similar drug to penicillin known as
cephalosporin from Cephalosporium acremonium.5 It is documented to be one of the first
antibiotics effective against Salmonella typhi, which was resistant to other penicillin analogs.
Guy Newton, Edward Abraham, and Sir William Dunn isolated cephalosporin C, in which the 7aminocephalosporanic acid (7-ACA) backbone was determined.5 Cephalothin was the first
synthetic cephalosporin manufactured by Eli Lilly & Co. in 1964.1 Other antibiotics were
subsequently developed. For example, Selman Waksman and Albert Schatz are accredited for the
discovery of streptomycin and neomycin, later part of the antibiotic class of aminoglycosides.6
Likewise, Rene Dubos discovered the polypeptide-type antibiotic gramicidin from Bacillus
brevis in 1939.7 Shortly after, chlortetracycline and chloramphenicol were added to the growing
antibiotic arsenal.4, 8 In 1962, the synthesis of nalidixic acid led to another antibiotic class known
as fluoroquinolones.4
The drugs developed since the 1960s have been analogs of existing synthetic antibacterial
drugs. Resulting in more than 12,000 different active agents, structural modifications to the
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pharmacophoric skeletons of existing antibiotics have resulted in improved bactericidal potency,
broadened spectrum of activity, reduced toxicity, and attenuated adverse side effects.
Collectively, antibiotics have been the most important factor in extending the human lifespan.
1.2.2 Types of Antibacterial Drugs by Class
Infections caused by some bacteria pose a serious threat. Primarily, Gram-negative
bacteria are quite efficient in acquiring resistance which can limit antibiotic therapy. Aside from
deactivating various antibiotics, Gram-negative bacteria are able to release endotoxins from their
outer membranes which also makes antibiotic therapy a contraindicated treatment option as well.
Traditional synthetic approaches have yet to make a substantial contribution to any new
classes of antibacterial agents. Thus, clinicians have relied on a series of antibiotic analogs that
have reduced toxicities with increase spectrum and potent antibacterial activities. Though not
differing vastly in structural components, the pharmacophoric groups of these antibacterial
agents still face deactivation mechanisms already utilized by both Gram-negative and Grampositive bacteria. In this section, mechanisms of action for each antibiotic class and mechanisms
of antibiotic resistance are outlined.
1.2.2.1 Inhibitors of Cell-wall Synthesis
Beta-(β)-lactam antibiotics and inhibitors are among the most commonly prescribed
drugs, grouped together based upon the key pharmacophoric feature, the β-lactam ring, which
inhibits the activity of transpeptidase and causing the cell wall to become defective.1 The basic
structure of β-lactams consists of three parts: 1) a fused β-lactam ring, 2) a free carboxylic acid
group, and 3) a substituted amino acid group.1 Structural variation around the β-lactam ring has
yielded other drugs within this class such as penicillins, cephalosporins, carbapenems, and
monobactams with added greater antimicrobial potency against broader spectra of
microorganisms (Figure 1.3). Most advances in antibacterial therapy have been effective on
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Gram-positive bacteria, but recently approved β-lactam antibiotics such as ertapenem and
doripenem have shown useful against Pseudomonas aeruginosa. Since some β-lactam antibiotics
have lost potency against various species of Gram-negative bacteria, they are often combined
with β-lactamase inhibitors.1 Inhibitors prevent enzymatic degradation of β-lactam drugs caused
by β-lactamase (penicillinase) enzymes. Currently, there are three β-lactamase inhibitors
available (i.e. sulbactam, tazobactam, and clavulanic acid).1 Due to the emergence of resistance
to both β-lactam drugs and β-lactamase inhibitors, particularly by Gram-negative bacteria, these
agents are losing usefulness in treating nosocomial infections.

Figure 1.3. General structure of the five classes of β-lactam antibiotics.
Other examples of antibiotics that attack the cell wall are within the class of
glycopeptides. Glycopeptides are composed of either a glycosylated cyclic or polycyclic
nonribosomal peptide which makes these molecules very large compared to other cell wall
inhibitors (Figure 1.4). These antibiotics deactivate Gram-positive bacteria by binding to the

11

acyl-D-alanyl-D-alanine units that prevents the formation of new additions to the peptidoglycan
cell wall.1 Due to their large sizes, these molecules are often excluded from Gram-negative
bacteria and were commonly used to treat Gram-positive bacterial infections. Additionally, they
are bacteriostatic against most species but are lethal to Enterococci species. However,
vancomycin-resistance towards both Staphylococci and Enterococci species and toxicity has
limited its clinical use.

Figure 1.4. Two examples of glycopeptide antibiotics.
1.2.2.2 Inhibitors of Protein and Nucleic Acid Synthesis
Other conventional antibiotics belong to classes that attack protein synthesis or inhibit nucleic
acid synthesis. Examples of these types of antibiotics are shown in Figure 1.5. Antibiotics that
target the protein synthetic pathways selectively target bacterial ribosomes. Known as
aminoglycosides, these molecules consist of amino-modified sugars and enter the bacterial cell
through active transport to subsequently bind to the ribosomal subunit.1 With over 14 analogs,
these molecules selectively target different ribosomal subunits within the cell.1 For instance,
streptomycins target the 30S ribosomal subunit; whereas, kanamycins and neomycins bind to
both 30S and 50S subunits but in different locations than streptomycins.1 In addition to protein
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inhibition, these molecules are also capable of disrupting the cell membrane by creating fissures
and causing the intracellular components to leak. This antibiotic is typically administered to treat
Gram-negative bacterial infections; however, modification to ribosomal proteins, alteration to
cellular membranes or degradation of this antibiotic has led to increased bacterial resistance.1

Figure 1.5. Examples of three types of antibiotics that inhibit protein and nucleic acid syntheses.
Chloramphenicol is a broad-spectrum antibiotic that also inhibits protein synthesis by targeting
the 70S ribosomes.1 This molecule is active against resistant Gram-positive bacteria and some
Gram-negative bacteria. For example, this drug is not an effective treatment for infections
caused by Pseudomonas aeruginosa or Enterobacter species. This antibiotic has been replaced
by more recent, inexpensive alternatives but still remains the ideal treatment for meningitis and
infections in those with penicillin allergy. Unfortunately, therapeutic use of this antibiotic has
resulted in several adverse reactions such as aplastic anemia, leukemia, and Gray Baby
Syndrome.1 Resistance to chloramphenicol has also been reported. Enzymatic degradation of
chloramphenicol by chloramphenicol acetyl-transferase prevents its binding to the bacterial
ribosome.1 Similar to other large molecules, changes in the outer membrane permeability in
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Gram-negative bacteria also inhibits the entrance of the bacteriostatic drug. Lastly, tetracyclines
target protein synthesis by binding to the 30S subunit and deactivating aminoacyl tRNA.
Tetracyclines are cationic broad-spectrum antibiotics consisting of four fused rings.1 Resistance
also limits the clinical use of this type of antibiotic in that it is easily removed by efflux pumps,
proteins have modified its target ribosomal binding subunit, or it is enzymatically inactivated.1

Figure 1.6. Examples of DNA- and RNA-targeting antibiotics.

Some antibiotics that inhibit nucleic acid synthesis also stop folate synthesis.
Representative DNA and RNA targeting antibiotics are shown in Figure 1.6. Folate is a
coenzyme used to produce DNA and RNA in bacteria and is the target of sulfonamides and
diaminopyrimidines.1 Limited to sulfur allergies, sulfonamides are commonly not used unless
used in combination with a diaminopyrimidine as in the formulation of trimethoprimsulfamethoxazole.1 The inefficacy of sulfonamide drugs results from the over-production of paminobenzoic acid or production of dihydropteroate synthetase while the over-production of
dihydrofolate reductase or production of a drug resistant version collectively limits the activity of
diaminopyrimidines.1 Quinolones also inhibit bacteria growth by acting on enzymes in DNA
synthesis. Its broad spectrum activity results from its ability to target primary DNA in Gramnegative bacteria and topoisomerase IV in Gram-positive bacteria.1Quinolone resistance results
from decreased expression of membrane porins which enables its activity on DNA.1 However,
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modifications in efflux pumps and alterations in target enzymes also prevent this antibiotic from
being effective.
A new class of antibiotics, known as glycylcyclines, has broad-spectrum antibacterial
action for both drug-susceptible and resistant Gram-positive and Gram-negative microorganisms
(Figure 1.7). Similar to tetracycline and aminoglycoside antibiotics, glycylcyclines antibiotics
block protein synthesis by binding to the 30S ribosomal unit in the bacterial cell.1The most
recent advancement, Tigecycline, was approved in 2005 by the United State Food and Drug
Administration (FDA) as a treatment for skin and wound infections.1 Unfortunately, this
antibiotic’s utility is limited due to its inability to overcome the resistant efflux pump
mechanism, specifically MexXY, in P. aeruginosa bacterial cells.1Another recently developed
antibiotic that exhibits good antimicrobial activity against Enterobacteriaceae is fosfomycin
tromethamine.1 Although it has better pharmacokinetic properties, it also shows limited activity
against P. aeruginosa. Both tigecycline and fosfomycin are the better antibiotic options available
to treat infections caused by Gram-negative bacteria; however, concerns about resistance still
prevail

Figure 1.7. Structures of Tigecycline and Fosfomycin antibiotics.
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1.2.2.3 Antimicrobial Peptides
Antimicrobial peptides are a unique and diverse class of biologically available molecules
that have broad spectrum activity against a wide variety of microorganisms, including drugresistant bacteria. Composed generally of 12 – 50 amino acids, these peptides consist mostly of
positively charged amino acids (i.e. arginine, lysine, or histadine) and hydrophobic residues.1
Similar to other proteins, these antimicrobial agents can possess α-helical, β-stranded, β-hairpin,
or extended configurations.1 Because of its amphipathicity, these agents are able to partition into
biological membranes by folding and inserting through the lipid bilayers forming pores. Their
major mechanism of action involves membrane permeation, but these agents are able to target
various sites within the bacterial cell making them highly effective.1 An example of a potent
antimicrobial peptide is Polymyxin B, the most promising new additions to this class being
ceraginins and the NAB-series of polymyxins.1 Often considered as a last resort, these agents
have suffered from induced cytotoxicity and narrow spectrum activity against Gram-positive
bacteria.
1.2.2.4 Anti-Toxigenesis and Invasiveness Inhibitors
An indirect approach to treating infections caused by Gram-negative bacteria is to
interfere with the virulence factors and efflux pump regulation in the cells instead of targeting
bacteria viability.1 This approach prevents the process of infection because the bacteria cell is
unable to recognize host signals thereby limiting its pathogenic effect on the host. This results in
limited colonization in histological morbidity and improved host immune response. Main antivirulence target approaches include inhibitors of toxins and adhesins, organism specific virulence
gene expression, and organisms specific cell-to-cell signaling.2 Controlling the activity of efflux
pumps is another viable method to improve the efficacy of antibiotics on these organisms. Since
Gram-negative bacteria rely heavily on efflux pumps to prevent the intrusion of antibiotics, this
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is a sensible target when using combination drug therapy. Though useful in improving activity
against multi-drug resistant (MDR) bacteria, these agents are limited and few have been
approved for clinical use.
1.2.3 Mechanisms of Antibiotic Action and Resistance
Antibiotics are often grouped by their antibacterial action and spectrum of activity against
a range of microorganisms. Targeting different regions of the bacterial cell allow for a variety of
antibiotics to be used alternatively to ineffective antibiotics. The inability for an antibiotic to
detrimentally impact the survival of bacteria in which it once was effective is known as antibiotic
resistance.1 Sometimes an innate feature of a bacterial species, antibiotic resistance is often an
adaptation in which the bacterium modifies its cellular structure to resist the treatment of a
familiar class of antibiotics.
Antibiotic resistance can be categorized into two types, intrinsic or acquired. Intrinsic
resistance is an inherited trait within a bacterial species that prevents the bacterium from being
negatively affected by a class of antibiotics.1 This particular type of resistance requires no
alterations to the DNA of the microorganism. Usually, antibiotics are ineffective on this type of
species because the microbe either lacks an antibiotic target or has a barrier in which the
antibiotic is unable to permeate. A classic example is the intrinsic resistance of mycoplasmas to
β-lactam antibiotics, since they lack the peptidoglycan cell wall that these drugs target.1 The
second example is the impermeable outer membrane present in Enterobacteriaecae.1 Acquired
resistance can also occur through genetic mutation.1 This type of resistance happens when an
organism that is slowly exposed to an antibiotic adapts so it can tolerate further exposure to a
particular class of antibiotics. Bacteria with acquired resistance are also able to structurally
modify and deactivate an antibiotic, alter a drug’s accessibility to its target, or inhibit the drug’s
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uptake.1 A summary regarding each class of antibiotic, mechanism of action, and mechanism of
resistance is outlined in Table 1.2.
1.3

Introduction to Antiseptics and Disinfectants
Antiseptics and disinfectants have been indispensable in controlling infections in hospital

settings and maintaining food safety and quality. Although the terms antiseptic and disinfectant
are commonly used interchangeably, the two can be distinguished by their roles. By definition,
antiseptics are defined as broad-spectrum antimicrobials that destroy or inhibit the growth of
microorganisms on living tissues, while disinfectants inhibit bacterial existence on inanimate
objects or surfaces.1 Both agents have an essential role in controlling microbial growth as either
an agent in sterilization or preservation.1 Sterilization uses the chemical nature of an
antimicrobial agent to remove the presence of microorganisms from a surface.1 For instance,
physicians sterilize their hands using surgical scrubs prior to surgery to eliminate the presence of
any bacteria that could be transmitted or cause an infection. On the other hand, preservation uses
the chemical nature of an antimicrobial to inhibit the growth of bacteria in a consumer product
such as in food packaging or cosmetic applique.9 Whichever the type of antimicrobial agent or
application, its mechanism of action can be summarized by four key functions: 1) its electrostatic
attraction to the bacterium cell, 2) interaction of the agent with the cellular surface, 3)
permeation of the cell structure, and 4) action at the target site9. In spite of the vast number and
types of biocides available and their more detailed independent mechanisms of action, only
quaternary ammonium and bisbiguanidinium compounds and their interactions with different
types of bacteria will be discussed in further detail, as these are the biocides used in the research
presented in this dissertation. However, Table 1.3 categorically lists other examples of anti-
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Table 1.2. Summary of antibiotic classes, activities, and current mechanisms of action, and resistances.
Antibiotic Class
Mechanism of Action
Mechanism of Resistance
β-lactam

Glycopeptides

Binds to penicillin binding
proteins (PBPs), inhibiting
peptidoglycan cross-linking in
the cell wall.
Binds to acyl-D-alanyl-Dalanine in the peptidoglycan
cell wall
Binds to the 30S and/or 50S
ribosomal subunit

Aminoglycosides
&
Chloramphenicol
Inhibits protein synthesis by
Tetracyclines
binding to 30S subunit in the
ribosomal interfering with
binding of aminoacyl tRNA.
Promotes dissociation of
Macrolides
tRNA from the ribosome
inhibiting ribosome assembly
and preventing protein
elongation by inhibiting
peptide bond formation
Interfere with nucleic acid
Sulfonamides
synthesis by inhibiting folate
synthesis
Target DNA gyrase and
Quinolones
topoisomerase IV

β-lactamase enzymes hydrolyze the β-lactam ring making it unable to inhibit
peptidoglycan crosslinking

Enzymes use D-alanyl-D-lactate to construct peptidoglycan cell wall instead
of acyl-D-alanyl-D-alanine
Protein structure modification in the ribosome inhibits binding; Changes in
cell membrane that causes a reduction in antibiotic active transport ;
Antibiotic is enzymatically hydrolyzed causing structural modification
Bacteria efflux pumps prevent drug from entering; “Protection” proteins
prevent binding to the ribosome target; Antibiotic is enzymatically hydrolyzed
causing structural modification
Bacteria efflux pumps prevent drug from entering; Site mutation of the
ribosome allosterically prevents antibiotic binding

Overproduction in dihydrofolate reductase or alterations is dihydropteroate
synthetase enzymes prevent antibiotic interference
Decreased expression of membrane porins; Bacteria efflux pumps prevent
drug from entering; Mutations in protein targets that reduce antibiotic binding
affinity
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Table 1.3. Chemical structures and use of select antiseptics and disinfectants against non-sporulating bacteria (Adapted from G.
McDonnell and A. D. Russell (1999), with permission from the American Society for Microbiology).
Chemical
Example
Structure
Biocidal
Mechanism of Action
Class
Class
Alcohols
Ethanol
Sterilization Results in bacterial cell lysis via
Disinfection membrane damage, protein
Preservation denaturation, and interference
with metabolism
Aldehydes Glutaraldehyde
Sterilization Binds strongly to unprotonated
Disinfection amines on cell surfaces inhibiting
Preservation transport and enzymatic systems
Biguanides Chlorhexidine
Antisepsis
Results in cell lysis by acting on
Antiplaque
membrane, precipitating proteins,
Deodorant
and leaking intracellular materials
Preservation

Halogenreleasing
Agents
Heavy
Metal

Iodine

Peroxygens

Hydrogen
Peroxide

Quaternary
Ammonium
Compounds

Benzalkonium
chloride

Disinfection
Antisepsis
Cleaning
Disinfection
Preservation
Antisepsis
Disinfection
Preservation

Silver

Disinfection
Antisepsis
Preservation
Cleaning
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Targets free-sulfur amino acids
cysteine and methionine,
nucleotides, and fatty acids
Inactivates enzymes and protein
function
Produces active hydroxyl free
radicals that attack lipids,
proteins, and DNA
Distorts membrane integrity and
results in intracellular material
leakage

-septics and disinfectants by its application and chemical class to illustrate the similarities and
differences between the types.
1.3.1 Quaternary Ammonium Compounds
Quaternary ammonium compounds (QAC)s represent a small fraction of surface-active
agents that possess antibacterial properties widely used in disinfection. Other surface active
agents with antimicrobial activities may lack a charge (i.e. nonionic) or have multiple charges
(i.e. cationic, anionic, zwitterionic, or amphoteric). Most positively charged molecules with
antimicrobial activity are QACs, although there are some molecules with negative charges.
Structurally, these molecules consist of a charged “water-loving” head group and an aliphathic
“water-fearing” tail group (Figure 1.8). This imbalance between its hydrophilic and hydrophobic
regions helps its surface-active properties to be conducive in its antimicrobial activity.10

Hydrophobic Region
“Water Fearing”

Hydrophilic Region
“Water Loving”

Figure 1.8. Structure of cetyltrimethylammonium bromide as a representative cationic
quaternary ammonium compound.
The primary mechanism of action for QACs lies primarily in its membrane activity.
Figure 1.9 illustrates the events that have been postulated to lead to bacteria cell death after
exposure to a QAC: a) the QAC is adsorbed on to the cellular surface; b) the QAC penetrates the
cellular wall in Gram-positive bacteria or the outer membrane in Gram-negative bacteria; c) the
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inner membrane is imbalanced by the QAC perturbing the organization of the lipid bilayer; d)
cellular structure begins to collapse allowing intracellular materials to leak; e) proteins and
nucleic acids are degraded; and f) the cell wall is destroyed by autolytic enzymes.11, 12

Figure 1.9. Hypothesized mechanism of action for quaternary ammonium biocides where a-f
show progressive adsorption of the quaternary headgroup to acidic phospholipids in the
membrane with increasing QAC exposure/concentration. A decreased fluidity of the bilayers and
the creation of hydrophilic voids are formed in the membrane causing protein activity to be
disrupted, cell lysis, and solubilization of membrane components into micelles (Adapted from P.
Gilbert and L.E. Moore (2005), with permission from John Wiley and Sons).
In summary, examination of the literature suggests that QACs cause structural
deformities and damage the cytoplasmic membrane within bacterial cells.12, 13
22

1.3.2 Chlorhexidine and Bisbiguanidines
Molecules containing a bisbiguanide structure, e.g. polyhexamethylene biguanides
(PHMB), are heavily used in antiseptic oral products and surgical scrubs. Originally synthesized
in the early 20th century, these molecules have shown exceptional pharmacological activities. An
example of a PHMB molecule with profound antimicrobial activity is the dicationic salt
chlorhexidine

(1,1’-hexamethylenebis(5-chlorophenyl)biguanide).

This

molecule

is

symmetrically balanced by two chlorophenyl moieties appended to a charged guanidine group
linked together by a hexylmethylene-chain (Figure 1.10). Chlorhexidine is strongly basic and is
stabilized when made into a salt.14 This structural modification effects the physical properties of
chlorhexidine in that its relative hydrophobicity, solubility, and bioavailability is changed when
dihydrochloride, diacetate, or digluconate are introduced to the chlorhexidine base.14 Regardless
of the type of chlorhexidine formulated, the antibacterial activities remain unchanged.14
Collectively, bisbiguanide molecules have broad-spectrum activity as a membrane active agent
against both sporulating and non-sporulating bacteria, mycobacteria, yeasts, protozoa, and lipidenveloped viruses.9 Chlorhexidine antimicrobial activity is concentration dependent. At low
concentrations, chlorhexidine predominantly affects membrane integrity; whereas at high
concentrations it is capable of precipitating cytoplasmic materials.9 There are a few external
factors that can diminish chlorhexidine antibacterial activity. Mainly, the presence of anionic
substances (i.e. pus, lecithin, sodium dodecyl sulfate, and sodium carboxymethylcellulose),
variable pH, or the high abundance of protein or sera has been reported to interfere with
chlorhexidine antibacterial activity in vivo.9, 13, 14 On the other hand, chlorhexidine has shown
compatibility with various anionic antibiotics like sulfonamides, β-lactams, tetracyclines, and
chloramphenicol in which its antimicrobial efficacy is not suppressed.15, 16
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Figure 1.10. Structure of chlorhexidine base.
The potent antimicrobial activity of chlorhexidine salts made these molecules of
particular interest in the medical field. Thus, a variety of consumer products were developed
specifically for topical applications. Its potent activity against hemolytic streptococci made
chlorhexidine optimal for treating wound infections and preventing sepsis.9,

13, 14

However,

further evaluation of bisbiguanides was required to qualify its use to treat systemic infections or
to use as an antiseptic. It was also shown that handwashing with chlorhexidine was able to
reduce skin flora as much as 90%.9 Its post-antimicrobial activity (i.e. approximately 6 hours) on
skin is another attractive feature for the prevention of skin sepsis and drug-resistant S. aureus or
Enteroccoci outbreaks.17-19 Additionally, chlorhexidine provided in the nasal cavity in
combination with mupirocin helped reduce the incidence of methicillin-resistant S. aureus
among patients in intensive-care.20 This bisbiguanide has also been effective in reducing catheter
colonization and oropharynx infections.21
For decades, chlorhexidine has been widely approved as a skin and mucous membrane
antiseptic. Its use intravenously was prohibited after in vivo testing in mice, calves, and rabbits
revealed an 81-fold reduction in therapeutic index.22 As a result, chlorhexidine salts were
24

restricted to topical and oral applications where acute toxicity was less. Research suggests its
nontoxicity in topical or oral applications to result from its poor absorption.23 Although trace
percutaneous absorption occurs, it was also noted that chlorhexidine was safe to use in obstetrics,
ocular infections, and wound care since it did not induce birth defects, skin sensitivity (<2%
w/v), or eye irritation (<0.2% w/v).14 It is not recommended for use in pre-operative sterility
involving the central nervous system since it has occasionally shown ability to degenerate
nerves.14 However, insufficient clinical data does not conclusively prohibit its use as a skin
preparative before lumbar puncture, epidural catheter placement, or neurosurgical procedures.
Since, chlorhexidine has been provided commercially at concentrations ranging between 0.5% 4%, with and without co-solvents.
Chlorhexidine has been applied in both clinical and domestic settings for more than 50
years. Since that time few reports have indicated the development of resistance or significant loss
in antimicrobial activity. Although a five-fold difference in antimicrobial activity was noted by
Kropinski et al., this difference was attributed to structural changes in the bacterial cell.24 Of its
broad spectrum antibacterial activity, chlorhexidine is particularly ineffective against some
nonfermenting Gram-negative bacteria such as Pseudomonas species; however, if used with a
chelating agent it has been shown to be effective against this bacterium.17 Few assumptions
imply that current plasmid-mediated resistance, currently observed against QACs, will
negatively alter chlorhexidine efficacy.
1.3.3 Structural Differences between QACs and Chlorhexidine and Their Antibacterial
Mechanism of Activity
The differences between QAC and chlorhexidine structures directly explain their
dissimilarity in antimicrobial activity. Typically, long alkyl chains between 12- 16 carbons are
required for QACs to inflict damage on bacterial cells.9, 10,
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13, 25

Still great difficulty arises in

achieving optimal chain lengths required to permeate the cell without becoming solubilized by
the hydrophobic core of the bacteria.13 Since QACs interact fully with the membrane, they are
susceptible to efflux pump resistance mechanisms.9, 13 This is not the case with chlorhexidine
since the inflexible six-carbon chain length is fixed and does not result in the bacteria dissolving
or inactivating it.13 This is because bisbiguanides interact solely with the surface of the lipid
bilayer through cation displacement and head-group bridging via oblique insertion unlike QACs
which interdigitates into the bilayer. Figure 1.11 describes chlorhexidine’s mechanism of action.

Figure 1.11. Hypothesized mechanism of action for the interaction of chlorhexidine with the
bacterial cytomplasmic membrane. Diagram shows progressive decreases in fluidity of the outer
leaflet with increasing exposure to the bisbiguanide (Adapted from P. Gilbert and L.E. Moore
(2005), with permission from John Wiley and Sons).
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The charged guanidinium groups present in chlorhexidine facilitates cell membrane adsorption
which places it optimally at the cell surface so that chlorhexidine can bridge between bilayer
phospholipids and displace its associated divalent cations.13 This results from the similar length
of the hexamethylene linker to the distance between phospholipid head groups that aids in
chlorhexidine binding, oblique insertion into lipid bilayer or cell wall, and antimicrobial
activity.26,
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Research indicates that increasing or decreasing the hexamethylene linker length

detrimentally interferes with its binding ability and membrane disruption.13, 28 Chlorhexidine is
able to overcome osmosregulation provided by multi-drug efflux pumps, detrimentally affecting
many functions related to cell viability like inhibiting respiration, solubilizing membranes, or
destroying metabolic function.13,
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For the said reasons, there are more reports indicating

resistance to QACs than to chlorhexidine salts.
1.4

Combination Antibacterial Drug Therapy (CAT)
Since antibiotic-resistant bacteria have dominated the arsenal of antimicrobial drugs

currently available, there is a growing need to optimize the use of old and new antibiotics to treat
infections. Combination antibiotic therapy (CAT) has been a promising strategy to combat
bacterial resistance. Combination antibiotic therapy is a polytherapeutic approach that requires
the use of more than one antibiotic to remove an infection, mainly resistant infections.29 This
approach relies on four principal modes of action for improved antibacterial activity to be
observed using two or more compounds. Pokrovskaya and Baasov summarized the role of the
second drug in the four methods as follows: i) its use to prevent the degradation or modification
of the primary drug, ii)

inhibits the efflux pumps so that Drug A can be retained until

concentrations capable of bacteriolysis are accumulated, iii) impairs the tolerance mechanism of
the microorganism, and iv) targets the pathway that drug A inhibited so that it could deactivate

27

the bacterium.30 For CAT to be successful, the two drugs’ mechanisms must differ and not
interfere with each other and the target bacteria must be phenotypically susceptible to
treatment.31 The overall goal of CAT is to achieve synergy, or a drug combination that results in
better antibacterial activity than either antibiotic when used individually. Desirable synergistic
combinations allow for lower concentrations of drugs within combination to be implemented and
toxic dose-related responses to be reduced.32 Although a useful approach in treating MDR
Mycobacterium tuberculosis, HIV, Alzheimer’s disease, and a variety of different cancers among
other chronic and infectious disease, only CAT applied to bacterial infections will be henceforth
described.33-37
Preliminary successful antimicrobial combinations arose from the use of β-lactam drugs
with beta-lactamase inhibitors or aminoglycoside antibiotics. Examples of current CAT
containing β-lactam drugs with beta-lactamase inhibitors are Co-Amoxiclav (Amoxicillin +
Clavulanate), Timentin (Ticarcillin + Clavulanate), Unasyn (Ampicillin + Sulbactam), and Zosyn
(Piperacillin + Tazobactam).29,

31, 38

However, some antibiotic combinations do not result in

improvement or affect the organisms’ vitality (additivity) while other combinations interfere
with the antibacterial activity of each antibiotic (antagonism). This has led to a number of
combination drug therapies that have become the staple in treating resistant infections, while
several pharmaceutical companies seek to discover improved dual-mode-of-action compounds.
Therefore, the use of multiple drugs in tandem is gaining momentum as a systematic approach to
treat infectious disease.
Many studies have evaluated the effects of combining multiple antibiotics in vitro;
however, clinical studies often contradict superior in vitro antibacterial combinations. Since the
late 1950s, creative CAT has expanded the types of antimicrobials used to treat arduous
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infections but the optimization for CAT for a variety of bacterial infections has been a struggle.
A direct result of the antibiotic susceptibility of bacteria and its unique dependence upon
bacterial species, host tolerance, and dosing regimen often makes CAT a hit-or-miss approach.31
Therefore, correlating in vitro laboratory results with in vivo clinical treatments for bacterial
infections has so far been challenging. Since some successful combinations have arisen in the
past, scientists are still motivated to find better combined drug systems. Thus, the pursuit has
been mainly focused on particular types of bacterial infections.
In recent years, experimental CAT has focused on Gram-negative bacterial infections
since β-lactam/penicillinase inhibitor combinations have been very successful against resistant
Gram-positive bacteria. Some CAT treatments included experiments using Gram-negative
bacteria without complex resistant mechanisms. For example, synergetic antibacterial activity
was observed in the treatment of pathogenic E. coli using combinations that consisted of
aminocoumarin, novobiocin, and tetracycline; however antagonism was seen with novobiocin
combinations with chloramphenicol, erythromycin, and lincomycin.39 Successful antibiotic
combinations were often subsequently investigated against difficult Gram-negative bacteria such
as Pseudomonas species. Thus, the successful CAT consisting of novobiocin and tetracycline
also show superior efficacy against six Pseudomonas species.40 Other combinations containing
β-lactam antibiotics with aminoglycosides have also been evaluated as a CAT treatment option
for Gram-negative infections. Dalton et al. reported the mean susceptibility of thirty
Pseudomonas isolates to in vitro carbenicillin and gentamicin combinations.41 However, clinical
evaluation of 66 patients receiving gentamicin alone or in combination with penicillin,
ampicillin, chloramphenicol, or streptomycin showed contradictory in vitro antibacterial
activity.42 Only dual aminoglycoside + aminoglycide CAT (e.g. kanamycin + gentamicin) were
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synergetic in the treatment for the different Pseudomonal infections.42 Aminoglycoside
antibiotics have also been effective in combination with select tetracyclines.43 For instance, the
ability of oxytetracycline to suppress the production of acid in combination with neomycin was
synergetic against six enteropathogenic Gram-negative bacteria.44 Although β-lactam +
aminoglycoside CAT are effective against a broad panel of Gram-negative bacteria, they
sometimes cause kidney failure or worsen the current condition of a patient.45 For example, βlactam + aminoglycosides CAT in febrile neutropenic patients is reported to be effective yet
dangerous to the survival of these patients. DeJace et al. found that response rates of dual βlactam + β-lactam CAT is similar to β-lactam + aminoglycosides CAT against most
Enterobacteriaceae, excluding Pseudomonas species.38 These results were contradicted in vivo
after evaluating 7,600 patients and comparing the response observed for β-lactam monotherapy
and β-lactam + aminoglycoside CAT diagnosed with Pseudomonas aeruginosa infections
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.

Silbiger et al. concluded that the use of β-lactam + aminoglycoside CAT resulted in unchanged
fatality rates and increased the incidence of nephrotoxicity.46 More than 148 cases suggest that
there is no clinical benefit for the use of β-lactam + aminoglycoside CAT for treating febrile
neutropenia, pneumonia, abdominal/urinary tract infections, sepsis/bacteremia, endocarditis, or
bronchitis.45 As an alternative, hospitalized febrile neutropenic patients with Pseudomonal
infections that were currently not receiving fluoroquinolone therapy was able to be administered
β-lactam + ciprofloxacin CAT with a lower incidence of kidney failure.47
Resistant Gram-negative rods harboring extended spectrum β-lactamases (ESBL),
Klebsiella pneumoniae carbapenemases (KPC), and the New Delhi metallo-β-lactamases (NDM1, NDM-2) have been the most recent targets for CAT. Still in its infancy, successful CAT
against bacteria containing multiple-resistant mechanisms has only been performed in vitro. For
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example, the use of polymyxins combined with fluoroquinolones or glycylcyclines have resulted
in additive and synergetic interaction indices when used to treat NDM-1 producing
Enterobacteriaceae.48 Similarly, combined tigecycline and high-dose meropenem concentrations
and colistin + meropenem CAT were effective against KPC isolates.49, 50 Combination studies
with tigecycline + imipenem, tigecycline + amikacin, and tigecycline + ciprofloxacin yielded
synergy against MDR

Klebsiella species and E. coli.51 Ultimately, combinations under

investigation include mixtures of all antibiotic classes to improve the efficacy of current
antimicrobials against drug-resistant bacteria.52,

53

Mixtures of antibiotics with nonantibiotics

have shown to be a useful approach to also extend therapy against MDR bacteria.54
Since 1975, natural plant products have yielded synergetic responses with a variety of
antibiotic classes against both Gram-positive and Gram-negative bacteria. Most of the research
supports this CAT approach as an effective treatment against Methicillin-resistant S. aureus and
Vancomycin-Resistant Enterococcus species. A review by Hemaiswarya et al. lists the following
examples of effective natural products used with β-lactam drugs: carnosol epigallocatechin
gallate (EGCg), tea catechin, green tea extract, Corilagin, Baicalin, Tellimagrandin I, Rugosin B,
pomegranate extract, myricetin, sophoraflavanone, and novoimanin.55 The use of green tea
extract

with

levofloxacin,

myricetin

with

β-lactam/β-lactamase

inhibitors,

and

butylatedhydroxyaniosole with vancomycin was successful against E. coli O157:H7, ESBL-K.
pneumoniae, and non-susceptible E. coli, respectively.55 Although the most latest approach, Ejim
et al. investigated the utility of 1,057 FDA approved nonantibiotic materials in potentiating the
antibacterial activity of tetracycline drugs against opportunistic pathogens P. aeruginosa (PA01),
E. coli (BW25113), and S. aureus (ATCC 29213). The most notable finding was the observed
synergy in the use of nonantibiotic loperamide (trade name: Imodium) with antibiotic
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minocycline both in vitro and in vivo.54 These finding suggest the use of nonantibiotic +
antibiotic CAT as potential treatments for MDR bacterial infections with minimal adverse effects
on normal bacterial flora or host health.
Examination of recent literature clearly supports the use of CAT to treat difficult
infections. Although this polytherapy can allow a patient the convenience of fewer dose
regimens with potent antimicrobial activity and broadened activity spectrum, several problems
associated with polytherapy still exist. Sometimes the selections of particular antibiotic mixtures
are clinically contraindicated because either drug elicits unwanted side effects.32, 38, 39, 42 Aside
from higher costs and uncontrollable drug responses with narrow therapeutic windows, each
aforementioned CAT formulation is limited to the serendipitous chance that each drug will arrive
and deactivate a bacterial cell at the same time without causing adverse or idiosyncratic reactions
to the host or generating MDR organisms.56
1.4.1 Hybrid Antibiotics
The development of hybrid antibiotics is a recent approach to CAT. More specifically, it
consists of two covalently linked antibiotics, as opposed to consisting of two unreactive salts in a
mixture, that inhibit dissimilar targets in a bacterial cell. This alternative to CAT was
hypothesized to control the pharmacokinetic properties of antibiotics within combinations and
prevent adverse host responses. However, hybrid antibiotics are not effective in treating bacterial
infections caused by MDR strains. For that reason, most hybrid antibiotics consist of the drug
classes that have the least antibiotic resistance mechanisms developed against them. In addition
to the controlled phamacokinetic properties, other advantages include improvements in
antibacterial activity (potentiation), enhanced receptor binding affinity, increased spectrum of
microorganisms’ susceptibility against mono-resistant strains, and reduced host toxicity.
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Hybrid antibiotics are a blend between conventional CAT and prodrug antibiotics. Their
differences are illustrated in Figure 1.12. More specifically, this antibiotic combination consists
of a linker between the antibiotic pair. This important feature is an adaptation from prodrug
systems and is used to facilitate delivery of the two agents in tandem. Although not the main
focus of the research presented in this dissertation, the mechanism behind prodrug activity is
highlighted as it pertains to hybrid antibiotics. Most hybrid antibiotics are tethered together using
a covalent bond. However, several sub-types of covalent links can be used to deliver the
antimicrobial agents to the bacterial cell target. Covalent-bound hybrid antibiotics require the use
of a labile covalent bond between the two antibiotic components so it can undergo chemical
hydrolysis, enzymatic cleavage, or are environmentally responsive so that tethered-antibiotics
can be released to the bacterial cell target synchronously. Similar to CAT, synergetic,
antagonistic, and additive effects can be observed in hybrid antibiotic systems; this concept will
be discussed in the next section titled “Loewe’s Additivity Model”. Therefore, the antibiotic
components must be judiciously chosen to yield the greatest antimicrobial activity. Similarly, the
most appropriate length and type of linker must be identified that will facilitate the best
bactericidal behavior.
Most hybrid antibiotics reviewed to date consists of either fluoroquinolone or
aminoglycoside antibiotics. An example lies in the potent fluoroquinolone-oxazolidinone hybrid
known as MCB-3681 which contains a 4-hydroxy-piperidine linker. This patented antibiotic
hybrid has shown antibacterial activity against Bacillus anthracis as well as other drug resistant
Gram-positive and Gram-negative bacteria.57 A phosphate ester derivative of the MCB-3681
prodrug has since progressed into human clinical trials.58 Likewise, fluoroquinoloneanilinouracil hybrids have potent DNA polymerase and growth inhibitive properties. The best

33

representative of this antibiotic hybrid is the 251D fluoroquinolone-anilinouracil hybrid. This
hybrid has shown enhanced antibacterial activities, as compared to its precursor antibiotics, when
investigating its use on fluoroquinolone-resistant bacteria.59 Yu and co-workers reported the
development of aminoglycoside hybrids consisting of chloramphenicol or oxazolidinone to have
broad-spectrum activity against Gram-positive and Gram-negative bacterial strains. These
hybrids possess enhanced affinities to bind specifically to RNAs with lower dissociation
constants than the neomycin B aminoglycoside antibiotic.57,

60-62

In spite of their improved

binding affinities to RNA, their antimicrobial activities do not correlate well with their
dissociation constants and have been reportedly lower than the neomycin B aminoglycoside
when used alone.30 Thus, this hybrid has not been investigated for use in human trials. In some
instances the antibacterial activity of antibiotic hybrids are not greater than the precursor
antibiotics. However, they have found use to treat resistant infections. Aminoglycosidefluoroquinolone antibiotic hybrids were able to overcome some of the most prevalent
aminoglycoside resistance enzymes while still effectively inhibiting bacterial protein synthesis,
DNA gyrase, and topoisomerase IV activities.63 In summary, most hybrid systems reported to
date have been more effective in targeting active sites than the stoichiometric mixture of the
antibiotic precursor components despite fickle in vitro antibacterial activities. As a result, it is a
common hypothesis that there is a lower propensity to develop bacterial resistance to hybrid
antibiotics. However, this type of antibiotic therapy is not the main focus of this dissertation and
will not be described in great detail. Accordingly, an extensive review of the hybrid antibiotic
systems can be found by Pokrovskaya and Baasov.30
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Hybrid Antibiotics
Covalent linker

Combination Antibiotic Therapy
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Drug B

OR
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Figure 1.12. Schematic representating the differences between conventional combination
antibiotic therapy and hybrid antibiotic therapy.
1.4.2 Loewe’s Additivity Model
Studies at the forefront of pre-clinical drug development have continued to be a recent
topic of frequent and growing interest among pharmacologists. For instance, the ability to
quantify various interactions of drugs on the physiology of the body accurately is of utmost
importance in the study of combination drug therapy. In conventional combination studies,
interest centers on whether the drug combination creates an enhanced, worsened, or nullified
effect as compared to that expected from the activities of the individual components.
Strategic and empirical models are necessary to premise the rationale of combination
drug therapy and several have since been developed to calculate the “interaction index” between
the components in a mixture. As a result, many statistical techniques have surfaced to assess
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drug interactions when two or more compounds are mixed, namely Bliss Independence (1939),
64-67

the Additivity Envelope (1979), 68 and Loewe’s Additivity models (1926).31, 32, 38, 69-73 To be

more specific, the Bliss independence model suggests that the interaction between two drugs is
equal to the multiplication product of the activities of the agents when used individually.
Accordingly, this implies that two drugs do not pharmacologically or physiologically interact
with each other for the enhanced effect to be observed. The augmented therapeutic effect is often
caused by independent modes and/or differing sites of activity for each compound in a mixture.
Linear drug concentration-effect relationships are only supported by Bliss Independence model
and not for nonlinear drug concentration-effect relationship such as the commonly observed
sigmoidal curve seen in Loewe’s Additivity model.70 Hence, this model has limited applicability.
Secondly, the additivity envelope model is used only to describe the log-linear cell survival
relationship observed in radiation studies and cannot be applied to cytotoxic agents. 74 Therefore,
the appropriate mathematical model used throughout this dissertation research is Loewe’s
Additivity Model which considers the commonly observed sigmoidal shape of the concentrationeffect relationship for combination cytotoxic agents.70
Loewe’s Additivity Model is often illustrated graphically along a 3-dimensional surface
with two horizontal lines that indicate the concentrations of the two drugs in combination and a
vertical line that indicates the response respective to the fixed concentration of combined
drugs.69, 70 This 3-dimensional iso-effect curve that represents the set of all drug combinations
and their respective drug-like response is called an isobologram.71 Isobolograms were introduced
by Fraser (c.a. 1870) as an area relationship between survival and drug combinations of toxic
drug (atropine) and antidote (physostigmine) mixtures to illustrate interaction antagonisms. 74
Subsequently, Loewe used a similar relationship to define the synergetic reactions between two
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drugs in a mixture and has since been refined by various investigators.71 Loewe used a straight
line isobole to denote a zero (additive) interaction when the combined drugs caused in a similar
dose-response relationship to the individual drugs as indicated in Figure 1.13. He also
emphasized that the isobole would be curved concave upward or downward when the drug
mixtures had dissimilar dose-response relationships from the parent drugs and this would denote
either synergy or antagonism, respectively.

D

Normalized ED50 of Drug 2

1

0

A

E

A

B

Normalized ED50 of Drug 1

1

Figure 1.13. Representative concentration-response isobologram attributed to the activity of two
drugs in combination, where (a) is the line of additivity, (b & c) indicate synergetic combinations
and (d & e) indicate antagonistic mixtures.

Based on this model, the interaction index (I) between components in a mixture can be
described numerically as either (1) synergetic, when their combined effects are greater than the
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sum of their individual effects (I < 1), (2) additive or neutral, when the combined effect is equal
to their individual activities (1 ≤ I ≥ 3), or (3) antagonistic, when the effect is smaller than one of
the drugs itself or the presence of one drug nullifies the activity of the other (I < 3).75-77
The general equation (Eq. 1.1) of the Loewe additivity is defined as,

(Eq. 1.1)

where d1 and d2 are doses of each drug in the mixture that yield an equal effect to drug 1 (D1)
and drug 2 (D2) when used alone. This relationship was modified in this research to
accommodate the interaction index of the novel API-ILs and GUMBOS as (Eq. 1.2.):

I GUMBOS/API ILs 

[% Cation  IL]100% [% Anion  IL]100%

[Cation ]100%
[Anion]100%

(Eq. 1.2)

Here, the concentration of drug 1 and 2 in the GUMBOS are calculated using the percent
abundance of cation or anion responsible for the antibacterial activity within either GUMBOS or
API-ILs and is multiplied by its minimum inhibitory concentrations (MIC) prior to dividing by
the MIC of the precursor antibacterial agent when used alone. Interaction indices gauge how well
the components in the GUMBOS interact as it compares to the stoichiometric mixture of the
GUMBOS parent materials so the utility of these materials as potential pharmaceutics can be
compared to established combination antibiotic therapies. The standard checkerboard titration of
multiple drugs tested against bacteria in tandem will be explained further in the Antibacterial
Techniques and Characterization section.
1.5

Ionic Liquids
Ionic liquids (ILs) are a class of tunable ionic compounds that melt below 100 °C. These

salts can be divided into two types (i.e. room-temperature ILs with Mp < 25°C and frozen IL
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with Mp between 25 – 100°C) despite their similar chemical and physical properties.78 These
salts typically contain organic ions with differing sizes that allow changes in the usual physical
properties observed in high-melting inorganic salts into the rare physical properties unique to
ILs. Structurally, ILs have asymmetrical, bulky cations and anions that do not allow an ordered
packing lattice structure which inhibits efficient crystallization and requires lower energy to melt
these materials.78 Other physical properties unique to ILs are its nonvolatile, negligible vapor
pressure, nonflammable, and recyclable nature. In general, ILs are much more conductive,
viscous, and dense than conventional organic solvents. Its high solvating power comes from its
ability to behave as both a hydrogen bond acceptor (anion) and donor (cation) with molecules
bearing both donor and acceptor sites.78 As a result, two classes of ILs have been categorized
based on their aqueous miscibility. In summary, all of the physical features explain their
attractive thermal and chemical stability, and wide electrochemical window that attribute to their
“green” identity.79 To date, three generations of ILs have been reported in which first generation
ILs have been applied to systems that would benefit from their physical and chemical property
sets. Examples of cations and anions commonly used in first-generation ILs are shown in Figure
1.14.

The cations usually consist of substituted heterocyclic amines and quaternary

phosphonium groups, such as various alkylated imidazoliums, pyridinium, pyrrolidinium, and
phosphonium ions. Typically, halides are the anions used in first-generation ILs. Applications
that benefit from the customizable chemical and physical properties of first-generation ILs are
often found in non-biologically related industries that do not require air stable, nontoxic lowmelting materials.
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Cation
+

Anion
Task-specific Ionic Liquids and GUMBOS

Generation 1

Generation 2

Environmentally friendly
cation-anion pairs (not
consisting of halides) with
targeted physical properties
combined with physical
properties

Cation-anion pairs
with unique tunable
physical properties

Generation 3

Biologically active cationanion pairs with targeted
biological properties
combined with chosen
chemical and physical
properties

Figure 1.14. Representative cations and anions that compose first-, second-, and third generation
ionic liquids (ILs) and groups of uniform materials based on organic salts (GUMBOS).
Since the most desirable feature of ILs is the ability to manipulate ion pairs to design
task-specific molecules, researchers have begun investigating applied ILs by incorporating the
applications into either ion. This has led to the development of second- and third generation ILs
for applications that require more features than those related to its chemical and physical
properties. In particular, second- and third-generation ILs take advantage of the limitless number
of applied salts that melt below 100°C. Second-generation ILs, composed of halogen-free ions,
were developed to provide environmentally-friendly and stable molten salts for use in energetic
materials, synthesis, and chromatography. Most ILs consisting of tetrafluoroborate [BF4-],
hexafuorophosphate

[PF6-],

bis

(trifluoromethane)sulfonamide
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[NTf2-],

and

bis(perfluoroethylsulfonyl)imide [BETI-] are examples of second-generation ILs. Although a
safer alternative and more stable, these salts still possessed the features of conventional ILs such
as tunable solvent miscibility, ionic conductivity, selectivity, durability, resistance to thermal
degradation, and negligible vapor pressure. Third-generation ILs are the most task-specific group
of salts since they were especially synthesized to be application driven. For example, thirdgeneration ILs consider all salts that in addition to having environmentally-friendly chemical and
physical properties, they possess features that make them functional as primary active
components in the desirable application. These salts have steadily emerged in to applications that
once relied solely on organic or inorganic molecules. Although few in number, third-generation
ILs have shown to have chirality, spectroscopy, antimicrobial, and medicinal uses. The diverse
applications of ILs are numerous but can be limited by its defined thermal definition; thus, the
emergence of a Group of Uniform Materials Based on Organic Salts (GUMBOS) redefines the
useful limits of organic salts, thereby exponentially increasing the types of applied ions.
1.5.1 Groups of Uniform Materials Based on Organic Salts (GUMBOS)
The three generations of IL are not exclusive when the extended melting range provided
by GUMBOS is considered. Previously, the definition of ILs was limited by the types of taskspecific salts synthesized with melting points that exceeded 100°C. That is not the case with
GUMBOS, which have melting points between 25°C and 250°C and still possesses the features
of third-generation ILs. GUMBOS which are composed of organic and/or inorganic ions have a
unique architectural platform in that multi-modal properties innate to the desired application can
be incorporated into the salt via a judicious selection of the ions. To date, GUMBOS have
exemplified

the

feasibility

of

architecturally

modified

amorphous

nanomaterials

(nanoGUMBOS) with multi-modal functionalities for application in energy conversion,
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molecular sensing and extraction, biomolecular detection and imaging, and anticancer
therapeutics.78-88 Although most of the GUMBOS research has been published on the nanoscale,
the interesting properties observed in nanoGUMBOS remain expressed when used in the bulk
form as well. This new field of multi-modal salts is being extensively investigated in the Warner
Research Lab at Louisiana State University.
1.5.2 Antibacterial Ionic Liquids
Since ionic liquids (ILs) have offered promise as reagents that have the potential to
replace many hazardous volatile organic solvents, interest in the use of ionic liquids in
contamination control has reached a level sufficient to spur their commercialization as a green
alternative to volatile sterilants. Many approaches have been used to achieve a nontoxic and
biodegradable IL. More specifically, incorporating enzyme-hydrolyzing groups, short alkyl
chain, and non-halide containing stable anions has been sought to maintain the “green”
reputation of ILs in the ecosystem.89-92 In 2007, Docherty et al. observed that alkyl chains
between 6 and 10 carbons in pyridinium-based IL can be mineralized better than comparable
imidazolium-based ILs.93 Similarly, pyridinium-based ILs with pyridine or nicotinic acid side
groups were exceptionally biodegradable under aerobic conditions implemented by Harjani et
al.94 However, it was reported that some ILs are poorly biodegradable and should not be
considered “green” although it is suggested that these particular types of ILs may be useful in
antimicrobial applications since an inherent toxicity to bacteria was evident. 95 Supported by the
findings of Romero et al., the IL bactericidal activity is said to have resulted from the inability of
bacteria to use imidazolium salts as a carbon source. Quantitative-structure activity relationship
(QSAR) findings show the alkyl length of the cationic substituents and type of halide anion
detrimentally impact bacteria viability the most and govern the roles of IL in eco-toxicological
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toxicity.90, 91 However, conflicting issues about their general safety and rates of biodegradation
have been published.96-99 For instance, some IL cationic groups (i.e. imidazolium, pyridinium,
and pyrrolidinium) were not lethal to Zebra fish, but ammonium-based ILs were more fatal than
some organic solvents. Likewise, other IL eco-toxicological studies suggest significant toxicity
to Pseudokirchneriella supcapitata (algae) and Caenorhabditis elegans (multi-cellular soil
nematodes). Subsequent studies confirmed the “green”-prohibitive nature of these materials
resulting in a shift in their application towards antiseptics and disinfectants.98, 99
As previously mentioned, the potential to use ILs as antibacterial agents derived from
concerns about their biodegradability and persistent environmental use. Over the last decade,
most studies investigating the antimicrobial nature of ILs have been conducted on planktonic
bacteria. In 2003, Pernak and Chwala introduced the broad spectrum antibacterial activity of five
new groups of choline-derivative-based ILs.100 A total of 63 choline-based ILs consisting of
halides, non-nutritive sweeteners, and imides were synthesized and characterized for
antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi.100, 101 Other
studies with structurally modified imidazolium IL revealed that the presence of a long alkyl
chain led to superior antimicrobial activity.102, 103 Another quaternary amine, pyrrolidinium, was
found to be effective against bacterial rods, cocci, and fungi. Similar to the findings of Pernak et
al., enhanced antimicrobial activity was present in pyrrolidinium IL with alkyl chain lengths
ranging between 12- 16 carbons.104 Introducing multiple alkyl chains to conventional IL cations,
as that present in multi-geminal ILs, has led to improved antimicrobial activities as compared to
geminal monomer, QACs, or typical ILs.105 Additionally, QSAR studies reveal that undecane
incorporated in chiral ammonium-based ILs sufficiently inhibited the viability of bacteria and
fungi.106,

107

Biological properties of phosphonium-based ILs have also been evaluated.
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Cieniecka-Rosionkiewicz et al. reported potent bactericidal activity against Gram-positive cocci
with attenuated activity when the halide anion was replaced with a non-halide ion.108 Long alkyl
chain ILs consisting of azolate anions have also been reported to possess multi-functional
antimicrobial activity.109 However inconclusive findings suggest that the type of anion present in
the IL system generally does not affect the antibacterial activity of the salt, and in fact that the
cation is always responsible for IL antibacterial activity.110 Nevertheless three common findings
that remain undisputed among present literature about the general features of ILs with
antimicrobial activity are the presence of alkyl chain length, type of anion, and overall
lipophilicity.10, 111, 112
Few microbiological studies against nonplanktonic bacteria have been reported. The first
report of IL activity in preventing the formation of biofilms occurred in 2009 by Carson et al. In
this study, the antimicrobial activities a series of 1-alkyl-3-methylimidazolium chloride ILs have
been evaluated against both planktonic and nonplanktonic clinical pathogens.113 Similar to the
effects of ILs on planktonic bacteria, alkyl chain lengths greater than 10 carbons resulted in
potent biofilm eradication.113 Overall, it is concluded that biofilms caused by Gram-positive
bacteria and Candida species were more susceptible to 1-alkylmethylimidazolium ILs than
Gram-negative bacterial biofilms.113 To date, 1-alkylquinolinium bromide ILs are considered to
be the most potent antibiofilm ILs tested with superior toxicity to the previously synthesized
antifouling IL, 1-alkyl-3-methyimidazolium ILs.114
1.5.3 Active Pharmaceutical Ingredient Based Ionic Liquids
First-generation ILs have been used extensively in organic chemistry for the synthesis of
various biologically active compounds.115 However, the incorporation of active ingredients into
the IL structure has recently led to another sector of third-generation ILs called Active

44

Pharmaceutical Ingredient-based ILs (API-ILs). Active Pharmaceutical Ingredient-based ILs are
ionic salts that melt below 100°C in which either the cation or the anion contains a
pharmaceutical ingredient in its structure (Figure 1.15).116 Although these materials have been
coined API-ILs as of recently, literature shows that several existing pharmaceutical salts can also
be classified as ILs.117 For instance, most therapeutic salts come in the form of a first-generation
IL, even if the melting point exceeds 100°C. However, based on the definition of ILs, the APIILs with melting points exceeding 100°C are appropriately considered to be API-GUMBOS in
which most of the historical API-ILs fall into this category.
Conventional pharmaceutical salts typically contain an ion with a pharmacophoric group
and an inert biocompatible counter-ion.117 Some pharmaceutical ingredient counter-ions that are
generally regarded as safe by the Food and Drug Administration are sodium, potassium, sulfate,
nitrate, chloride, or phosphate. Converting the acid/base form of different pharmaceutics into a
salt-form consisting of an inert counter-ion may provide desirable thermal stability,
bioavailability, and biocompatibility to the API.117 In this way, crystalline active solids with
approved mechanisms and properties can be monitored without interference from a secondary
active ion.
Unfortunately, many APIs such as barbituates, sulfonamides, and steroids undergo
polymorphic conversion and suffer from poor bioavailability which detrimentally affects their
performance.115 The development of API-IL has shown to be a viable method to incorporate
multiple functions into a salt while remedying pharmacological problems associated with API
solids. This is represented in a couple of historical examples of structurally similar thirdgeneration API-ILs, developed in 1951 and 1952, namely, phenazone gentisate (i.e. analgesic,
anti-inflammatory, antipyretic, Mp = 87–88°C) and diphenhydrammonium 8-chlorotheophylline
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or Dimenhydrinate (antihistaminic, anitvertigo, motion sickness treatment, Mp = 102-107°C),
respectively.117 Rantidine docusate is a recent example of an API-ILs that eliminated drug
polymorphism associated with Ranitidine hydrochloride.116 Additionally, API-ILs such as
lidocaine docusate and didecyldimethylammonium Ibuprofen are other examples in which
challenges associated with APIs are overcome. In these particular cases the biologically active
ions within the API-IL structures are anionic and/or cationic, possess the properties of its
precursor ion, and remedy solvation properties caused by API crystallinity.116,

118

The added

control of the ion diffusion from the higher energetics within API-IL is another enhancement that
these materials offer.

Ionic Liquids/ GUMBOS
+
Ionic linker

-

+
-

+

Figure 1.15. Schematic representing the activity of pharmaceutically active ionic liquids and
GUMBOS.
Overall, API-ILs are designed to possess ionic-synergetic efficacy for the intended
purpose, have controlled, yet tunable chemical, physical, and biological properties, improve
bioavailability and pharmacokinetic properties, and reduce toxicity.115, 119 API-ILs possess the
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advantages of both conventional combination antimicrobial therapy and hybrid antibiotic
prodrug systems, although still vastly unique. With the exponential amount of possible active ion
combinations, representative API-ILs or API-GUMBOS will be found in every sector of
pharmaceutics.
1.6
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CHAPTER 2 ANALYTICAL TECHNIQUES, MECHANISM OF ACTION
VALIDATION, AND ANTIMICROBIAL CHARACTERIZATION
The pharmacological techniques used to characterize the utility of ampicillin-based ionic
liquids and β-lactam based chlorhexidine GUMBOS in biomedical application are highlighted in
this section. More specifically, several studies that characterize the properties of the
antimicrobial agents based on their physical and chemical features are described in addition to
the absorbance and fluorescence methods used to validate their antimicrobial activity and
mammalian cytotoxicity.
2.1

Pharmacological Techniques and Characterization

2.1.1 Rate of Dissolution
Drug dissolution is an analytical parameter that assesses the release profile of drugs into
aqueous environments. By definition, dissolution involves the solubilization of the drug particles
into the surrounding aqueous medium. This property is very important for systemic delivery of
hydrophobic drugs. The kinetics of drug dissolution (DR) can be defined by the Noyes-Whitney
equation (Equation 2.1), which correlates surface area (A), diffusion coefficient (D), boundary
layer thickness (h), saturation solubility (Cs), and the amount of dissolved drug (Xd) in the
volume of dissolution media (V).

(Eq. 2.1)
The dissolution rate (DR) or time required for drug to dissolve depends on the cohesive
properties of the drug. More specifically, the physico-chemical properties of a drug and its
physical form dictate how quickly a drug dissolves and will be absorbed. Therefore, many drugs
are particularly formulated to control its rate of dissolution. Drugs are converted into a salt, free
acid or base, or even pulverized to minimize the particle size and increase its dissolution rate. In
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sum, more than 33% of drugs suffer from poor aqueous solubility and undergo chemical
modifications to increase its systemic delivery. Hence, the onset of drug levels will be governed
by the dissolution release kinetics of the drug.
2.1.2

Predictive Intestinal Permeability
Highly oral bioavailability is an attractive feature for novel antimicrobial drugs. It is

defined as “the characteristics of a drug that affects the process by which unchanged drugs
proceed from the site of administration to the site of measurement within the body”.
Predominantly, its ability to provide convenience, patient compliance, and practicality as
compared to conventional injections or suppositories makes this a valid characteristic for
therapeutics. However, poor intestinal permeability (absorption) can label candidate molecules
unsuitable regardless of their potent activity. This process can be affected by several
physiological factors such as how well the drug was formulated or the contents of the
gastrointestinal tract among other things. To overcome the potential physiological interferences
inhibiting passive intestinal permeability, effective therapeutic agents have an optimal balance of
lipophilicity/ hydrophilicity, hydrogen bonding, size, and charge since most drugs are passively
absorbed through the lipid-aqueous interface of the cell membrane (transcellular transport) or
water-filled tight junctions formed by the fusion of lipid membranes of adjacent cells
(paracellular transport). Transcellular transport is the route commonly taken by molecules that
are more lipophilic prior to becoming systemic. Thus, predicting drug oral bioavailability
through intestinal permeability is vital to the success of candidate antimicrobial agents.
Various in vitro assays have been developed to quantify the relative lipophilicity and
intestinal permeability of therapeutic agents. Yet, the Parallel Artificial Membrane Permeability
Assay (BD Gentest pre-coated PAMPA Plate System; BD Biosciences, MA) and logarithmic
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octanol-water partition coefficient assays were the techniques employed in this dissertation
research. In the PAMPA technique, a diffusion cell consisting of a donor and acceptor
compartment separated by a synthetic membrane was used to quantify the predictable intestinal
permeability of the candidate molecules developed in this research. More specifically, this
approach consists of a 96-well filter plate coated with a proprietary phospholipid membrane
separating the donor and acceptor wells. Known concentrations of test solutions (e.g. 100 – 200
µM in buffer) are added to the donor plate while only buffer is placed in the acceptor well.
Typically, rates of diffusion can be calculated by quantifying changes in drug concentrations in
the acceptor well. However, the assay is developed to measure the final drug concentration after
5 hours of incubation using UV-vis spectroscopy. Effective permeability coefficients (Pe) are
calculated based on initial millimolar concentration in donor well (Co), millimolar concentration
in donor well at 5 hours (CD), millimolar concentration in acceptor well at 5 hours (CA), volumes
of donor (VD) and acceptor wells (VA), well filter area (A, 0.3 cm2), and incubation time (t,
18000 s) as calculated using the relationship in Equation 2.2.

(Eq. 2.2)

Pharmacologists can assess the drug-likeness of a given therapeutic agent based on its
lipophilicity to various organic solvents or quantifying its partition coefficient. Specifically, the
logarithmic octanol – water partition coefficient (Log P) is used extensively to describe a drug’s
lipophilic properties and its preferential affinity to either octanol or water. It is a ratiometric
parameter based on the concentration of therapeutic in either phase of the two-phase system
when at equilibrium (Equation 2.3). It logarithmic denotation is commonly used to characterize
this value since it scales at least 12 orders of magnitude. Many studies have shown that Log P is
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a valuable parameter in correlating a drug’s transport process, its interactions with concomitant
biological molecules, and its potential toxicity. Though the acquisition of Log P values can be
logically simple, it can be irreproducible, time-consuming and expensive ultimately forging
difficulty in its use at the screening level. Likewise, this method is not accurate for determining
the partitioning nature of ionizable compounds because charged molecules do not partition into
lipophilic environments regardless of its chemical features. However, the most reliable approach
to date is the classical shake-flask method. To prevent minimal solvent miscibility, octanol is
saturated with deionized water and allowed to separate for 24 hours prior to its use.
Subsequently, a known concentration of candidate drug is added to the flask and allowed to mix
for 2 hours minimal. The sample is then left undisturbed for 24 hours to allow the two solvents to
separate and the analyte to partition into its desired phase. Both phases are quantified using
absorbance spectroscopy and used to approximate the drugs lipophilic nature.

(Eq. 2.3)

2.2

Antimicrobial Testing and Preparation
Antimicrobial susceptibility testing is important to identify levels of pathogen

susceptibility to specific antimicrobial agents and/or to detect the development of resistance in
individual bacterial isolates. Various techniques and methods are used to quantify the effects
antimicrobial agents have on bacteria and those techniques are described in this section.
2.2.1

Turbidity Standards for Inoculum Preparation
Although there are many standards available to standardize the inoculum density for a

susceptibility test, a BaSO4 turbidity standard equivalent to a 0.5 McFarland standard was used. A
0.5 McFarland standard was prepared as outlined by the Center for the Disease Control and
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Prevention where 500 µL of 1.175% BaCl2 • 2H2O is added to 99.5 mL of 1% v/v H2SO4 under
gentle stirring. Frequent stirring is necessary to maintain the suspension. The density of the 0.5
MacFarland turbidity standard as verified using a spectrophotometer with a 1-cm light path at 625
nm should range between 0.08 to 0.10. To appropriately match the MacFarland standard to the
bacterial inoculum, the standard is dispensed in to same size vials as the bacteria inoculum and
sealed and stored in the dark. The standard should be replaced every month as their densities may
change and large precipitate may form.
2.2.2

Broth Dilution Tests
National Committee for Clinical Laboratory Standards (NCCLS) criteria outline broth

dilution tests as a quantitative measure of the drug-bacteria response.1 In this method as depicted
in Figure 2.1, two-fold dilutions of antibiotics are prepared in a liquid growth medium and
dispensed in a 96-well microtiter plate. Stock concentrations of antimicrobial can be prepared in
methanol, acetone, dimethylsulfoxide or in the testing solvent. Up to 2% organic solvent does
not inhibit cell growth in aqueous medium. The antibiotic-containing wells are inoculated with a
0.5 MacFarland standardized bacterial suspension to match 107-108 CFU/mL. To prepare the
concentration of bacteria for testing, the bacterial suspension must be diluted 100-fold in growth
medium to a final concentration of 105-106 CFU/mL. Equivolume amounts of bacterial
suspension are dispensed to the antibiotic dilutions for testing. This gives a final concentration
testing range 5 x 104-5 x105 CFU/mL. Following overnight incubation at 37°C, the wells are
examined for visible bacterial growth as evidenced by turbidity. The lowest concentration of
antibiotic that prevents growth is the minimal inhibitory concentration (MIC). This highthroughput method allows for as many as 12 antibiotics to be tested across eight concentrations.
A high yield of precision within one or two dilutions from the MIC value, as typically caused by
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deviations in antibiotic dilutions, is expected with this approach. The key advantage of this
technique is that it quantifies the affect a range of antimicrobial agents have on the viability of a
microorganism despite its tedious preparation. Thus, the same plates used for the MIC test can be
used to identify the minimum bactericidal concentration (MBC). The MBC is the minimum
concentration that kills the entire culture. To determine this value, each well that shows no
turbidity is subcultured on to a fresh agar plate or sterile broth and incubated overnight at 37°C.
The lowest concentration of antimicrobial agent that maintains no growth after inoculation on an
agar plate or in broth is considered to be the MBC of the antimicrobial agent.
The checkerboard method, which is commonly used to measure the inhibitory properties
of drugs used in combination, was incorporated in this study to evaluate the synergetic responses
of precursor components at different concentrations. This approach combined with Loewe’s
Additivity Model (Section 1.8.2) allows the calculation of a fractional inhibitory concentration
(FIC) index in which the antibacterial potencies of agents can be assessed against a particular
microorganism. This approach is most suitable in identifying drug combinations that effectively
inhibit the growth of drug resistant bacteria that are not susceptible to one or more of the agents
used in combination. The experimental method to determine the FIC is similar to what one
performs to identify the MIC value. More specifically, serial dilutions of one drug is performed
traverse the 96-well microtiter plate from Columns 1 – 12 while another drug is serially diluted
from Rows A – H. This allows each well in the microtiter plate to contain a different ratio of
each drug and for multiple concentrations of Drug A to be tested with one concentration of Drug
B, and vice versa. Subsequently, a known suspension of bacterial inocula is added to the wells in
equivolume amounts and incubated for 18 – 24 hours at 37°C. Growth is identified by the
turbidity of the bacterial suspension in each well or the use of a dye that is responsive to the
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presence of viable cells. The lowest FIC values of both drugs used in combination identifies the
best agent to inhibit the drug resistant microorganism.

MIC

Growth

1:1 Serial dilutions
in growth medium 0.125 µM 0.25 µM 0.5 µM

1 µM

2 µM

No Growth

4 µM 8 µM 16 µM

Inoculation from MIC
cultures into sterile,
antimicrobial -free media

MBC

Figure 2.1. Example of broth dilution susceptibility testing and determination of minimum
inhibitory and minimum bactericidal concentrations.
2.2.3

Kirby-Bauer Disk Diffusion Test
The Kirby-Bauer disk diffusion test is a qualitative susceptibility test that is often used to

screen the efficacy of antimicrobial agents on specific microorganisms. This simple and practical
test is performed by spreading a 108 CFU/mL bacterial inoculum on to the surface of a large
Müeller-Hinton agar plate. Müeller-Hinton agar is prepared using a commercially available
dehydrated base according to the manufacturer's instructions. Antibiotic solutions are pipetted on
to sterile dry 10 mm paper disks and dried to remove the solvent. Paper disks containing
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dehydrated antibiotic are placed on the inoculated agar surface and incubated overnight at 37°C
to develop inhibition zones.
The growth of susceptible bacteria around the antibiotic disk is inhibited causing different
size “halos” to be formed (Figure 2.2). More specifically, the zones are formed by the diffusing
antimicrobial agent through the agar and its growth inhibitive properties on the microorganism.
Thus, the concentration of antimicrobial agent is highest closest to the disk and decreases
logarithmically towards the halo boundary. This rate of diffusion is governed by the physical and
chemical properties of the antibiotic. Its relative hydrophobicity, aqueous solubility, and
molecular weight dictate how rapidly it will diffuse through the agar. For instance, large
molecules diffuse more slowly than smaller molecules and hydrophilic molecules diffuse more
rapidly than hydrophobic molecules. This technique is not completely suitable for hydrophobic
drugs and this test may result in hydrophobic molecules being categorized as poor antimicrobial
agents. Overall, these factors contribute to the breakpoint zone that shows qualitatively how
susceptible bacteria are to that compound.
The major disadvantage of this method is that the bacteriostatic (growth inhibitive) or
bactericidal (lethal) concentrations cannot be quantified since a MIC value cannot be effectively
determined. This is because the amount of antimicrobial agent that adheres to the disk cannot be
quantitatively controlled. Likewise, the susceptibility of the drug as resistant, intermediate, or
susceptible is categorized based on zone diameter limits fit within National Committee for
Clinical Laboratory Standards (NCCLS) criteria.1
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Figure 2.2. Kirby-Bauer disk diffusion assay showing various zones of inhibition.
2.2.4

Mechanism of Action Studies
Mechanism of action studies can reveal the detrimental role these agents have on viable

organisms. Thus, lethal effects of the antimicrobial agents were evaluated in tandem using
spectroscopic based assays. More specifically, fluorescence-based assays were employed to
measure bactericidal rate, membrane permeation and depolarization, and ability to sequester
lipopolysaccharide endotoxin. Absorbance spectroscopy was used to study the interaction
between GUMBOS and penicillinase enzyme based on Michaelis-Menten kinetics using a βlactam chromophore in competition. Lastly, scanning electron microscopy was used to visualize
the detrimental effects the antimicrobial agents have on the bacterial cells.
2.3

Absorbance-based Techniques
Absorbance-based techniques have been used extensively in clinical experiments to

evaluate the viability of microorganisms. Ultraviolet-visible absorption spectroscopy is the
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formal name for the analytical technique that quantifies the amount of energy molecules absorb
when exposed to light. More specifically, this technique quantifies the percent transmittance
(%T) observed by the difference in incident light at a particular wavelength that was transmitted
to the sample (IT) and the remainder that passed through the sample (Io) to the detector.
Equations 2.4 and 2.5 show the relationship between %T and absorbance (A).

(Eq. 2.4)
(Eq. 2.5)

Since many clinical samples are in an aqueous medium, it is necessary for absorbance
detection to occur in electromagnetic regions where water is optically transparent. Water is
optically transparent across the entire electromagnetic spectrum between 190 - 700 nm which
makes this technique ideal.
A spectrophotometer consists of five linearly arranged basic components. The first
component is a stable light source which can either be a continuum or line based. Continuum
radiation sources provide a broad, featureless range of wavelengths. Depending on the
wavelength of interest, xenon, deuterium, hydrogen, or tungsten lamps are used in
spectrophotometers consisting of continuum light energy. In contrast, line-based sources produce
narrow bands at specific wavelengths. Examples of line sources are hollow cathode lamps and
lasers, and neither was used in the absorbance instrumentation employed in the dissertation
research. Thus, a 75W tungsten-halogen continuum lamp source was used to irradiate the third
component, the sample. The second component is a monochromator that selects the desired
wavelength for the study. It is the monochromatic light that passes through the third component,
the sample. To eliminate the loss of light, the sample is placed in an optically transparent sample
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holder made of glass, quartz, or plastic depending on the requirements of the experiment. The
transmitted light that passes through the sample is then detected by a photomultiplier tube or
photodiode-array.

Figure

2.3

shows

the

instrumental

configuration

of

absorbance

spectrophotometer.

IT

Light
Source

Io

Monochromator

Sample

Detector

Figure 2.3. Schematic of the instrumental configuration of conventional absorbance
spectrophotometers.
A 96-well microtiter plate reader was also used for absorbance measurements in this
dissertation research. The major difference in absorbance-based plate readers and
spectrophotometers is in the instrumental configuration (Figure 2.4). In this case, a specific
wavelength of excited light passes through the sample well and strikes a secondary mirror that
directs the transmitted light to the perpendicularly placed detector. Although conventional
absorbance spectrophotometers are arranged linearly to permit the detection of all transmitted
light, microplate readers achieve the same goal using mirrors. Likewise this optical arrangement
promotes flexibility in the implementation of fluorescence experiments as well. The highthroughput nature of plate readers is based on the ability to measure responses from multiple
sample wells incrementally. Instead of a cuvette as commonly used in spectrophotometers, an
optically transparent flat-bottom 96-well microtiter plate is used to contain the sample.

64

Emission
Monochromator

Excitation
Monochromator

Fiber
optic
PMT
Detector
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Figure 2.4. Instrumental configuration of a 96-well plate absorbance and emission plate reader.2
2.3.1

Michaelis-Menten Kinetics
Drug systems that monitor the activity between enzyme and substrates are best

represented by Michaelis-Menten kinetic models. Specifically, it models the substrate conversion
into product through a reversibly formed intermediate complex using an enzyme (Scheme 2.1).
Symbolically enzyme kinetics can be denoted as S (substrate), E (enzyme), ES (complex), and P
(product) using the following scheme:
⇔

⇔

(Scheme 2.1)

Understanding this relationship, the interaction between a substrate and enzyme can be
quantified. More precisely, several kinetic parameters can be investigated such as its rate of
reaction (Vmax), turnover number (Kcat), binding affinity (Km), and catalytic efficiency
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(Kcat/Km). Figure 2.5 illustrates the typical rate versus substrate concentration curve in which
the enzyme kinetic constants are elucidated. The rate of reaction is not necessarily important
when it comes to quantifying the effects an enzyme has on a substrate. In fact, Vmax is the value
in which all enzyme active sites are consumed by substrate and changes in this rate of reaction
can illustrate the types of substrate-enzyme interactions. The turnover number, Kcat, is a firstorder rate constant that quantifies the number of molecules that the enzyme actively converts into
product per unit of time. This comprehensive value considers all enzyme-substrate, enzymeintermediate, and enzyme-product complexes. A less complicated value is the Michaelis-Menten
constant, Km. Experimentally, this value is determined as the substrate concentration at half the
maximum velocity. This value mostly correlates the binding affinity between the substrate and
enzyme. For example, a drug with a large Km value is considered to bind poorly to the substrate
active site. The specificity constant (Kcat/Km) is the second-order rate constant that identifies
how well the enzyme detaches from the complex and converts the complex into product. For
some substrate-enzyme systems, the catalytic conversion from substrate to product might be
instantaneous (i.e. Kcat/Km = 108 – 109 M-1 s-1).3 However, enzymes with poor catalytic
efficiencies may have lower Kcat/Km values indicative of poor complex-product conversion or
irreversible substrate-enzyme binding.
In this research, Michaelis-Menten kinetics were used to monitor competition
experiments between a β-lactam chromogenic substrate, candidate β-lactam GUMBOS, and
penicillinase P-0389, type 1 (B. cereus 3/5/2/6) in an effort to identify the role the cation has in
the degradation of the β-lactam antibiotics. In this way, indirect participation in the catalysis of
the β-lactam anion in the GUMBOS can be investigated and changes in its specificity constant
can be compared to the sodium antibiotic.
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Figure 2.5. Representative rate versus substrate concentration plot obtained from MichaelisMenten kinetic experiments.
The chromophore used in these experiments, CENTA, is a chromogenic analog to the βlactam drug Cephalothin. Though not able to be used therapeutically, this agent has successfully
exploited the kinetic properties of various penicillinase enzymes. Variations in its absorbance at
either 260nm (decreasing; hydrolysis of the endocyclic amide bond) or 405 nm (increasing;
appearance of the expulsed chromophore) facilitates the monitoring of CENTA hydrolysis as
reported by Bebrone et al.4 However, CENTA is incapable of displaying penicillinase presence
and activity in agar colonies and therefore is limited to in vitro solution kinetic studies of viable
penicillinase-containing bacteria or pure and crude enzyme extracts. Michaelis-Menten kinetic
constants are interpreted using the aforementioned rate versus substrate concentration plot and
mathematical relationships.
2.3.2

Mammalian Cell Cytotoxicity
In vitro cytotoxicity tests are necessary to assess cellular damage that is inflicted by the

presence of different chemical agents. Likewise, the development of high throughput cell
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viability assays has been propelled by the requisite to categorize potential therapeutics from
poisons. This allows hypothetically toxic agents to be removed early in the drug discovery
process. As such, cell viability assays premised on the absorbance of tetrazolium-converted
formazan dyes has created the groundwork for many viability quantification studies.
There are several advantages to using in vitro cytotoxicity assays. Many assays have been
developed to facilitate a quick and easy method to repetitiously assess drug toxicity. It relies on
the sensitivity of an absorbance spectrophotometric plate reader and is able to be multiplexed to
other systems. It also allows signal stability for flexible analysis time and minimal difference
between sample plates. Sensitivity does depend on cell types, metabolic markers, incubation
time, and cell quantity. Most importantly, it does not implement radioactive probes to assess cell
viability. In contrast, it can be cost prohibitive and possible artifacts can come about that
complicate the precise quantification of cell viability. For example, cell growth patterns among
long term assay analysis studies can become problematic in that cells with high passage numbers
may not convert dyes equally as younger cells. Similarly, some test compounds can interfere
with the absorbance of the chromogenic probe.
The principle of tetrazolium-based assays relies upon the cellular metabolic activity of
viable cells. In this case, mitochondrial reductases present in healthy, respirating cells are able to
reduce the tetrazolium dye into formazan. When cellular damage has occurred by the presence of
potential poisons, a reduction in the cell’s metabolic activity occurs with a subsequent
attenuation in the tetrazolium salt conversion to the formazan molecule. Dead cells are not able
to reduce tetrazolium agents; thereby, creating a clear indicator of dead cells from living cells.
To eliminate the confusion in dead and dying cells, most cytotoxicity measurements are
performed either 24 hours or 48 hours after the addition of the novel therapeutic. That is because

68

apoptosis (programmed cell death) occurs within 30 minutes – 6 hours of drug exposure and
robust cells may rehabilitate from toxicant exposure. More importantly, an absorbance
measurement can be given by apoptotic cells (dying) and dying cells are not what is of interest in
the early stages of drug discovery.
The first popular assay for measuring cell viability in a microtiter plate came from
Mosmann in 1983, in which it was reported that viable cells reduce the yellow aqueous MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution into a purple insoluble
formazan crystal. Initially isopropanol was added as a cosolvent to dissolve the formazan solid.
Nonetheless, dimethylsulfoxide, sodium dodecyl sulfate/dimethylformamide solutions, and other
organic solvents have been used to also dissolve the formazan and make it readable using
absorbance spectroscopy. This two-step assay creates a homogeneous solution with color
intensity (λabs =570nm) that is directly related to cell population density. However, this assay has
several chemical interferences that can distort the absorbance reading. Additionally, the judicious
selection of a miscible co-solvent that will not destroy the microtiter plate is important as well.
Therefore, the one-step MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium) tetrazolium assay was developed to produce an aqueous soluble
formazan product (Figure 2.6). A major difference in this assay and the MTT assay is that a cosolvent is not necessary due to the creation of the negatively charged formazan water-soluble
molecule. Though less sensitive than MTT, this assay also has similar benefits to the MTT assay
but absorbs differently at 490nm.
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Figure 2.6. Conversion of MTS to soluble formazan by cellular dehydrogenase enzymes present
in viable cells.5
2.4

Fluorescent-based Techniques
Biomedical research relies heavily on fluorescence-based techniques to reveal

mechanisms at the cellular and molecular levels. The sensitivity and flexibility in fluorescence
spectroscopy makes this approach suitable to investigate the intracellular and extracellular
mechanisms of both eukaryotic and prokaryotic cells. Likewise, the ability to miniaturize this
approach in microtiter plates yields minimal analyte consumption.
In fluorescence, a fluorophore absorbs a photon from an excitation source promoting it to
a higher energy excited state in the same spin state. Highly absorbing fluorophores may become
excited to higher electronic states above the first singlet excited state (S1). In this case, the
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photon will undergo a non-radiative decay via internal conversion to S1. Internal conversion
may result from both vibrational and rotational losses such as collisions with solvent molecules
or with other concomitants in the sample. Fluorescence emission from the first excited singlet
state to ground state is a rapid process and occurs between 1x10-7 to 1x10-9 seconds.2 A least
probable radiative decay called phosphorescence occurs when an excited photon undergoes
intersystem crossing to the excited triplet state and causes a phosphorescent emission as it decays
to the ground triplet state. Phosphorescence has a longer radiative decay than fluorescence (e.g.
10-4 to 10 seconds) and as a result is usually the source used in glow-in-the-dark toys.2 Often
times a photon will decay to a higher vibrational level in the ground singlet state because it has
emitted less energy than it absorbed. This causes a change, namely Stokes shift, in the emission
spectrum to a longer wavelength (or lower energy state) relative to the excitation wavelength.
Many factors can contribute to a Stokes shift such solvent effects, energy transfer, and the
formation of complexes. The electronic transitions (i.e. non-radiative and radiative processes) of
a molecule are illustrated using a Jablonski diagram (Figure 2.7).2
Steady-state fluorescence instrumentation consists of a light source, two monochromators
(i.e. excitation and emission), a sample chamber, and a detector or photomultiplier tube (Figure
2.8). Many light sources are available for use in fluorescence spectroscopy, including lasers,
photodiodes, and lamps. Two monochromators are used to filter transmitted light before and
after passing through the sample. Differing from absorbance spectroscopy, the second
monochromator is positioned orthogonally from the excitation light path to reduce the detection
of incident radiation. Conventional fluorimeters use optically-transparent cuvettes (e.g. quartz,
glass, polystyrene) to the wavelength ranges of interest to maximize the transmission and receipt
of excited and emitted light, respectively.
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Figure 2.7. Jablonski diagram illustrating photophysical transitions of an excited molecule.
The optical pathway used in fluorescent plate readers is different than conventional
steady state fluorimeters. Fluorescent microplate readers use special optics to guide the direction
of the excited and emitted light to and from the sample well to the detector in an unconventional
orthogonal manner. More specifically, excited light passes through the first monochromator to a
mirror containing a hole that allows the excited light to be transmitted to the sample well.
Since the fluorescence occurs in all directions, the same mirror is used to direct the
emitted light through the second monochromator to the detector. Opaque black-walled microtiter
plates are used to minimize background fluorescence, scattering, and cross-talk between sample
wells. Microplate readers also use various types of light sources; however, a 75W tungstenhalogen lamp was used as the light source for all fluorescence microtiter plate experiments
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conducted in this dissertation. Tungsten-halogen lamps provide continuous light output from 250
to 700 nm making this approach useful for assaying fluorophores that emit from UV to near-IR
wavelengths.2 This high throughput approach uses an x-y scanning stage to continue automated
measurements from well to well. A schematic of the optical pathway used in microplate reader
was shown in Figure 2.4.

Light
Source

Monochromator
(Excitation
Filter)

Sample

Monochromator
(Emission Filter)

Detector

Figure 2.8. Instrumental configuration of a fluorescence spectrophotometer.
Both cuvette and microtiter plate steady-state fluorescence-based techniques were used in
this dissertation to investigate the interactions the antimicrobial agents have with bacteria and to
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elucidate their mechanisms of action. Several advantages and disadvantages are evident in the
use of fluorescent techniques applied to in vitro bacterial research. For instance, fluorescent
probes are able to be incorporated into intact cells without disrupting cellular membrane
integrity. Likewise, they can be used at all phases throughout their maturation (i.e. lag,
exponential, stationary, and death phases). Some probes can be used to distinguish viable and
nonviable bacterial cells as well as specific cellular components and their activities. Thus,
fluorescent probes were used in this research to examine the intracellular and extracellular
changes within the microbe and their corresponding techniques and are briefly described below.
2.4.1

1-N-Phenylnaphthylamine (NPN) Permeability Assay
To investigate the membrane damage inflicted by the antimicrobial agents used in this

research, an uncharged, lipophilic fluorophore called 1-N-Phenylnaphthylamine (NPN; λex =
350nm, λem = 420 nm) was used Figure 2.9. Its drastic change in fluorescence emission from
aqueous to lipophilic environments makes NPN a suitable probe to assess membrane damage.
More specifically, NPN fluoresces weakly in aqueous environments but more strongly in
hydrophobic environments similar to the interior of a bacterial membrane. NPN is not readily
absorbed by viable bacteria cells and requires a membrane active antimicrobial agent to permeate
the outer membrane for the fluorophore to interact with the lipophilic cellular constituents.
Therefore, changes in the intensity of NPN steady-state fluorescence in membrane disrupted
cells attributes this probe useful in elucidating antimicrobial agents and bacterial cell
interactions. As such, NPN fluorescence has been used extensively to measure changes in outer
membrane permeability of Gram-negative bacteria.6-17
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Figure 2.9. Structure of 1-N-phenylnaphthylamine (NPN) fluorophore used in membrane
permeability studies.
2.4.2

BacLight Live/Dead Assay
BacLight Live/Dead assay uses two DNA intercalating dyes green fluorescent SYTO 9

and red fluorescent propidium iodide to investigate membrane integrity and cell viability. SYTO
9 penetrates all membranes in which green fluorescence is maintained by intact membranes.
However propidium iodide, which can only penetrate permeabilized membranes due to its large
size and negative charge, produces a red fluorescence in membrane-damaged cells by displacing
SYTO 9 and quenching its fluorescence via Förster resonance energy transfer (FRET). FRET is a
mechanism that describes the transfer of energy between two fluorophores when the emission
band from a donor fluorophore overlaps with the excitation energy of an acceptor fluorophore.2
This transfer of energy causes the acceptor fluorophore to become excited and emit energy.
FRET efficiency is governed by the distance between acceptor and donor molecules, both SYTO
9 and propidium iodide must be in close proximity and the distance between donor – excitation
and acceptor emission overlapping bands (<10nm).2 The overlapping excitation/emission
wavelengths between SYTO 9 (488 nm/533 nm) and propidum iodide (530 nm/635 nm) allow
for propidium iodide to consume all of the emitted energy from SYTO 9 leading to its detection
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being quenched and consequent quantification of living and dead cells to be performed.
Representative spectra showing differences in percent live/dead cells are shown in Figure 2.10.

Figure 2.10. Structure of propidium iodide (A), SYTO 9 (B), and the spectra representing
percentages of live and dead cells (C).
2.4.3

BacLight Membrane Potential Assay
Membrane potential is an important property of many functioning cells that governs the

activity of biological processes. In theory, a voltage potential is generated when ions partition
between the cells and the suspending medium thereby generating an electric charge. This
difference in electrical potential between the interior and exterior of the cell can be quantified
using the Nernst equation (Equation 2.6).
(Eq. 2.6)
There are three factors that establish membrane potential: 1) intracellular and
extracellular ion concentrations; 2) membrane permeability to ions by ion channels and their
resulting ion conductance; and 3) the activity of electrogenic pumps that maintain the ion
concentrations across the membrane.15, 17, 18 Therefore, an efflux or influx of certain ions (e.g.
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potassium, sodium, chloride, hydrogen, magnesium, or calcium) into or from the cell in
concentrations exceeding potential thresholds will cause detrimental effects on the viability of
the organism or activity of the cellular process. The concentrations of select ions and the
direction of flux are illustrated in Figure 2.11.
There are two extremes in membrane potential. Hyperpolarization occurs when a cell’s
membrane potential becomes more negative as caused by an efflux in potassium or influx or
chloride. On the other hand, depolarization occurs when there is a net positive voltage in
membrane potential. An influx in sodium ions or other cationic molecules can result in
depolarization. When membrane active molecules permeate the cellular permeability barrier,
ions contained extracellularly are able to distort membrane voltage as they travel inward. Thus,
most membrane active molecules depolarize cells in addition to permeating the outer membrane.
Studies on the neuronal networks, muscle contraction, and energy metabolism in both eukaryotes
and prokaryotes have benefited from the use of voltage sensitive fluorescent probes. The ability
of fluorescent probes to sense small incremental changes in membrane polarization and quantify
differences in hyperpolarization or depolarization facilitates the impact various antibacterial
agents have on bacterial cells. Much advancement in the development of voltage-sensitive
probes and subsequent fluorescent based assays has been developed to overcome some
challenges. More specifically, improvements in voltage sensitivity, absence of photodynamic
damage, photobleaching, toxicity, and nonspecific binding have resulted in the success of
erhodamine and carbocyanine dyes.
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Figure 2.11. Direction of ion flux and their differences in intracellular and extracellular ionicity,
where the abundance of potassium K+ (red), sodium Na+ (yellow), and calcium Ca+2 (blue) are
highlighted and presented in an embedded table.
The fluorogenic dye used in this research is 3, 3′-diethyloxacarbocyanine iodide (DIOC2)
(Figure 2.12). This dye changes emission properties depending on the membrane potential
environment of the cell. More specifically, DIOC2 partitions into the cell and accumulates in the
cytosolic regions. It becomes red when the cell is intact and can aggregate and the membrane
potential is normal. However, red fluorescence (λex 488nm, λemRed 612nm) decreases when the
membrane potential is disrupted and the dye is released into the buffer medium. When the
fluorophore is released into the aqueous medium as a result of depolarization, the strong
fluorescence becomes green (λex 488nm, λemGreen 538nm).
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Figure 2.12. Chemical structure of DIOC2 membrane potential probe.

To determine if the novel compounds affect the membrane potential of bacterial
membranes, aliquots of log-phase inocula are treated with the antimicrobial agents as outlined in
the BacLightTM Bacterial Membrane Potential assay kit. The proton ionophore that destroys
membrane potential by eliminating the proton gradient but does not destroy membrane integrity,
carbonyl cyanide 3-chlorophenylhydrazone (CCCP), is used as a positive control; whereas, the
membrane permeant ethylenediaminetetraacetic acid (EDTA) was is as a negative control since it
does not detrimentally effect membrane potential. Valinomycin, a potassium ionophore, helps to
quantify the changes in membrane potential by translating fluorescence measurements into
voltage so that the Nernst equation can be applied. Endpoint fluorescence red/green ratiometric
values are used to quantify intracellular cytosolic potassium concentrations, its leakage, and
corresponding changes in Nernst membrane potential. The red – to – green fluorescence ratio
can distinguish the portion of bacteria with intact or hyperpolarized membranes (red
fluorescence) and depolarized membranes (green fluorescence) since the DiOC2 dye shifts from
red – to – green emission upon changes in membrane potential and membrane integrity.
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2.4.4

Lipopolysaccharide (LPS) Endotoxin Sequestration
Blood poisoning due to the release of lipopolysaccharides (LPS), or endotoxins, into the

blood stream post-antibiotic therapy of Gram-negative bacterial infections is a common and
serious problem. It plays a key role in the morbidity and mortality of critically ill patients since
there are no present therapeutic options available to nullify its traumatic effects. LPS consists of
two portions, a polysaccharide and a lipid (Lipid A). The polysaccharide moiety consists of
repeating oligosaccharide units in which the number of units is uniquely associated to the species
and genus among Gram-negative bacteria. The active and toxic portion of LPS is the hydrophilic
negatively charged bisphosphorylated diglucosamine Lipid A. Although LPS is considered
chemically inert, its systemic presence sets a cascade of exaggerated immune responses that lead
to the implications associated with blood poisoning. For example, endotoxemia (endotoxins in
blood) can seriously interfere with the proper function of the blood circulatory system and
ultimately result in multiple organ failure.
To date, several macromolecules have been investigated for their potential in attenuating
endotoxin-stimulated immunoinflammatory responses. More specifically, several polyclonal and
monoclonal antibodies have been investigated for their ability to complex Lipid A.
Unfortunately, both human and murine anti-Lipid A do not bind to LPS and thus show poor
neutralization ability. Likewise, the use of non-antibody LPS complexants as an approach to
prevent cellular recognition has been most recently pursued. Of this class, antimicrobial peptides
(i.e. polymyxin B) have been recognized for their ability to sequester LPS but polymyxin B is
too toxic for parenteral use. Hence, nontoxic analogs of polymyxin B with potent LPS
sequestrating abilities are in development. Since many potent drugs are not approved for
parenteral use, structural-activity relationships have been sought to identify the pharmacophoric
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regions within these molecules that allow successful binding and sequestration of LPS to further
incorporate these features into nontoxic alternatives. Therefore, polycationic hydrophobic
molecules with a clear demarcation of charged apolar regions are considered to be important.
Similarly, the intermolecular distance between cationic groups is suggested to be ~ 15Å apart to
match the distance between negative phosphate groups in the Lipid A structure.19-21 Several
cationic amphiphilic molecules already approved for therapeutic use have been screened for their
Lipid A binding and LPS neutralization activity. Among them were antimalarial, antipsychotic,
and antiseptics. The strongest binders among those tested were chlorhexidine which was able to
bind Lipid A with an affinity 80 times greater than monobiganidies. This confirmed that the
inter-cationic distance and basicity of the cationic groups in dicationic molecules are important
for strong LPS binding.
In this dissertation, chlorhexidine-based GUMBOS were investigated for their ability to
sequester LPS endotoxins in vitro using the high-throughput BODIPY-cadaverine displacement
assay.22 This assay uses the highly sensitive and robust BODIPY-TR Cadaverine (BC; λex
=580nm ,λem = 620nm) which has been shown to bind strongly to LPS. Using a displacement
type of assay, the addition of a stronger binder than BC causes the fluorophore to be released and
fluorescence emission to increase. This assay has been miniaturized and can be performed
reproducibly using a cuvette or 96-well plate. Secondary properties of chlorhexidine can also be
assessed when in the form of GUMBOS and the roles the various antibiotics have on its ability to
successfully sequester LPS.
2.5

Scanning Electron Microscopy
Scanning electron microscopy (SEM) is a power microscopic technique used to

characterize sub-micron materials and their morphologies. Its high spatial resolution capabilities
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(i.e. <5nm) befits this technique to non-biological nanomaterials. However, SEM can also be
used to characterize bacteria and visualize nanometer sized defects inflicted in its membrane.
The instrumental configuration of a SEM is illustrated in Figure 2.13. A divergent electron gun is
first used to generate a beam that is focused through condenser lenses to the sample. Scanning
coils are used to move the electron beam across the sample that is focused using an objective
lens. Electrons that collide with the sample become either backscattered or secondary electrons.
Secondary electrons are collected into a photomultiplier tube which amplifies the electron signal
and backscattered electrons are collected by a semiconductor array. Aberrations in the sample’s
surface deflect electrons with different intensities thereby causing the viewer to see an artificial
three-dimensional image of the sample. For example, surfaces that are closer to the
photomultiplier tube will result in the production of more backscattered electrons and a higher
signal and surfaces that are further away appear darker. Since SEM measure sample deflected
electrons, the sample must be prepared differently from that required of conventional
microscopes. More specifically, SEM samples must be conductive in order for electrons to be
deflected to the detector. If not, the sample will absorb the electrons and immediately become
decomposed. Therefore, SEM sample are contained on a metal stub using conductive tape and
are covered with a conductive coating (e.g. gold or platinum).
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Figure 2.13. Instrumental configuration of a scanning electron microscope.
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CHAPTER 3 DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF BETA (β)LACTAM ANTIBIOTIC-BASED IMIDAZOLIUM- AND PYRIDINIUM-TYPE
IONIC LIQUIDS1
3.1 Introduction
Data accumulated over the last decade show that there is an association between
antimicrobial resistance in Staphylococcus aureus, enterococci and Gram-negative bacilli and
increases in mortality, morbidity, length of hospitalization, and cost of healthcare. 1,

2

Patients

infected with antimicrobial-resistant organisms have higher associated treatment costs (US
$6,000–$30,000) than do patients with infections of antimicrobial-susceptible organisms.3
Consequently, many antibiotics, particularly β-lactam drugs, are becoming less effective
treatment options.1,

4-7

This challenge necessitates the development of more effective

antibacterial agents. The development of ionic liquids (ILs) composed of antibiotics fortified
with other antibacterial compounds was investigated in this study as a promising strategy to
address antibiotic resistance.
Many strategies have been proposed to extend the efficacy and antibacterial spectrum of
current antibiotics. As alternatives to de novo drug synthesis, methods that employ organized
media as potential delivery agents to improve the absorption of various pharmaceutical agents
have met with some clinical success.8-10 Examples include the use of QACs to improve the
absorption, transport, and efficacy of various drugs. Specifically, dihydropyridinium salt delivery
systems have successfully achieved targeted penicillin delivery to the central nervous system. 11
Other pyridinium salts have been used to selectively facilitate drug transport across the brainblood barrier and dermis via enzymatic hydrolysis.12-15 Cetyltrimethylammonium bromide and
related surfactants have enhanced drug absorption by various strains of Gram-negative and
1

Reprinted by permission of Chemical Biology and Drug Design.
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Gram-positive bacteria.16 These formulation strategies have been shown to facilitate the uptake
of various antibiotics and improve their treatment properties.
In this study, a new set of ampicillin salts with quaternary ammonium cations, such as 1butyl-3-methylimidazolium,

1-hexadecyl-3-methylimidazolium,

dimethylimidazolium, cetyltrimethylammonium,

1-hexadecyl-2,3-

and cetylpyridinium were synthesized and

found effective on Gram-negative bacteria Escherichia coli O157:H7 and Klebsiella
pneumoniae, as well as the Gram-positive Staphylococcus aureus and Enterococcus faecium. By
taking advantage of the antibacterial nature of both the cationic and anionic components of the
IL, we demonstrate the antibacterial utility of ILs for various biological and medical
applications.
3.2

Experimental

3.2.1 Materials and Methods
3.2.1.1 Reagents
1-Methylimidazole and 1,2-dimethylimidazole, 1-bromohexadecane, cetylpyridinium
bromide (CPB or [CP][Br]), cetyltrimethylammonium bromide (CTAB or [CTA][Br]), 1-butyl3-methyl-imidazolium chloride ([BmIm][Cl]), sodium ampicillin ([Na][Amp]), sterile disks,
brain heart infusion broth (BHI broth), Petri dishes (100 mm × 20 mm and 150 mm × 20 mm), 3(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), chloroform, and diethyl
ether were purchased from Sigma Aldrich (St. Louis, MO) and used without further purification;
isopropanol and acetone were purchased from Mallinckrodt Chemicals (Phillipsburg, NJ), and
ethanol was purchased from Pharmco-Aaper and Commercial Alcohols (Brookfield, CT). All
solvents purchased were of analytical grade. Agar technical grade was purchased from Becton,
Dickinson, and Company (Franklin Lakes, NJ).
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3.2.1.2 Culture Preparation
Test organisms used in this study, Escherichia coli O157:H7 (ATCC 43895), Escherichia
coli (ATCC 25922), Staphylococcus aureus (ATCC 6538), Streptococcus mutans (PCM 2502),
Enterococcus faecium (ATCC 49474), Listeria monocytogenes (NCTC 7973), Klebsiella
pneumoniae (ATCC 4352), Salmonella enterica serovar typhimurium (ATCC 14028) were
received as a gift from collaborator Dr. Marlene Janes.17
3.2.1.3 General Procedure for Quaternization Reactions
Equimolar amounts of 1-methylimidazole or 1,2-dimethylimidazole

and

1-

bromohexadecane were stirred in anhydrous ethanol under reflux for 48 h in an argon
atmosphere. Ethanol was removed and the product was washed with diethyl ether. A white solid
was obtained after filtration. The product was dried and purified in acetone using the
recrystallization method.
3.2.1.4 General Procedure for Anion Metathesis
A typical anion-metathesis reaction procedure is as follows: [CP][Br] (1 equiv.) was
dissolved in chloroform with the slow addition of aqueous [Na][Amp] (1.1 equiv.) into the
solution. The chloroform-water mixture (4:1 v/v) was stirred for 48 h at room temperature. The
upper aqueous solution was separated and washed with fresh chloroform to obtain all exchanged
product. The removal of chloroform in vacuo yielded the white product, [CP][Amp], which was
further freeze-dried on a lyophilizer. Other Amp-ILs (i.e. [Bmim][Amp], [C16M1Im][Amp], and
[C16M2Im][Amp]) were synthesized in the same manner.
3.2.1.5 Ionic Liquid Characterization
These compounds were characterized using 1H-NMR (Bruker Avance-250, 250MHz)
with DMSO-d6 as solvent. The elemental composition was determined using Leco 932 CHNS
Analyzer (Atlantic Microlab, Inc. Norcross, GA). The thermal properties including melting

87

points were determined using a differential scanning calorimetry (DSC Q100, TA Instruments,
Wilmington, DE).
3.2.1.6 Critical Micelle Concentration (CMC)
The critical micelle concentration of the Amp-ILs was determined by measuring the
surface tension with a Sigma 703 tensiometer at 298K. Several half-fold dilutions were made
from a 2mM stock solution of both QAC and Amp-ILs. This method used a DuNuoy ring with a
circumference of 5.992 cm.
3.2.1.7 Solubility
The solubility of Amp-ILs was determined using a Shimadzu UV-3101 PC scanning
spectrophotometer. Briefly, this included measuring the absorbance of half-fold dilution series
ranging up to 2 mg/mL of sodium ampicillin in water. Since sodium ampicillin has three
characteristic absorption bands (i.e. 257 nm, 262 nm, and 268 nm),18 these bands were used to
confirm and quantify the solubilities of the Amp-ILs via the construction of a calibration curve
(R=0.99). Two mg/mL of each Amp-IL was dissolved in water with one minute of high mixing
and thirty minutes of sonication at room temperature. The suspension was filtered with a 0.45
µm and the filtrate was measured for solubility. The Amp-IL acquired absorbance was converted
into concentration using a Beer’s Law relationship from the sodium ampicillin slope. It was
noted that the imidazolium bromide absorbs at lower energies and therefore does not interfere
with the absorbance intensities of the ampicillin anion.19-21 Also, no absorption was detected for
[CTA][Br] either. However, [CP][Br] does absorb within this same range. To compensate for the
cross-absorbance in [CP][Amp], the absorbance of [CP][Br] at equal concentrations of
[CP][Amp] were subtracted to only obtain the absorbance of the anionic portion of the Amp-IL.
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3.2.1.8 Antibacterial activity - Minimum Inhibitory Concentration (MIC) and Minimum
Bactericidal Concentration (MBC)
The minimal inhibitory concentration (MIC) values were determined in triplicate by the
broth dilution method in a 96-well microtiter plate using Müeller-Hinton Broth.22 The test
organisms were grown individually on brain heart infusion (BHI) agar for 24 h at 37˚C prior to
each antibacterial test. The growth was adjusted using colony plate counts. Bacteria of 105
CFU/mL concentrations were exposed to an Amp-IL concentration range of 0.8 μM to 0.2 mM.
The MIC for each Amp-IL was recorded as the lowest concentration that showed no turbidity
after 24 h of incubation at 37°C. Turbidity is an indication of microbial growth and if present, the
corresponding concentration of antibacterial agent is considered ineffective.

To determine

whether the Amp-ILs inhibited growth or killed the bacteria, twenty microliters of (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) or MTT (1 mg/mL) was added to the
non-turbid wells of the MIC assay plate and incubated for 2 h at 37 ˚C for the bacteriostatic/cidal status determination.23, 24 In the case of viable cells with inhibited growth, the tetrazolium
dye (i.e. yellow solution) would be metabolically reduced to aqueous soluble formazan crystals
(i.e. purple solution); however, a solution containing dead bacterial cells would remain yellow. 24
3.3

Results and Discussion

3.3.1 Physical Characterization of Amp-ILs
3.3.1.1 Synthesis and Characterization
The synthesis of 1-alkyl-3-methylimidazolium ILs involved the quaternization of 1methylimidazole or 1,2-dimethylimidazole with 1-bromohexadecane followed by anionexchange. Quaternization was carried out for 48 h under reflux in anhydrous ethanol under argon
atmosphere. Amp-ILs (Table 3.1) were synthesized by anion-exchange reactions between the
synthesized

imidazolium

bromides

[Im][Br]
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or

commercially

available

QAC

(e.g.

cetyltrimethylammonium [CTA][Br] and cetylpyridinium bromide [CP][Br]) and excess sodium
ampicillin [Na][Amp] in a chloroform-water (4:1 v/v) mixture. The resulting products, 1-butyl3-methylimidazolium ampicillin [BmIm][Amp], 1-hexadecyl-3-methylimidazolium ampicillin
[C16M1Im][Amp],

1-hexadecyl-2,3-dimethylimidazolium

ampicillin

[C16M2Im][Amp],

cetyltrimethylammonium ampicillin [CTA][Amp], and cetylpyridinium ampicillin [CP][Amp],
were isolated as solids at room temperature and purified by washing with anhydrous diethyl
ether. These salts have limited solubility in water, but are soluble in ethanol, isopropanol,
dimethylsulfoxide, and chloroform.
3.3.1.2 Ampicillin – ILs NMR Characterization
Amp-ILs were characterized using 1H-NMR (Figure 3.1) and elemental analysis. All
Amp-ILs contained the chemical shifts of the ampicillin anion and the respective cations. In the
case of [BmIm][Amp] and [C16M1Im][Amp], a singlet peak was observed with a chemical shift
at 9.29 ppm and 9.11 ppm which was attributed to the acidic proton in the C2 position of both
imidazolium cations. These peaks are also present in the di-substituted imidazolium halide salts.
However, this acidic peak was absent in the spectra for [C16M2Im][Amp] because of the methyl
group substituted on C2. In fact, a singlet at 3.73 ppm is evident of a methyl group substituted on
the C2 position of the imidazolium. There was a small upfield shift once the halogen was
exchanged for the less electron-donating ampicillin anion (not shown). In addition, the chemical
shifts between the hydrogens on the C4 and C5 positions of the imidazolium rings decreased
upon successful metathesis. A secondary set of multiplets ranging from 8.27 – 9.19 ppm present
in the 1H-NMR of [CP][Amp] are attributed to the more electron withdrawing nitrogen in the
pyridinium ring. The anion exchange from bromide to ampicillin anion was confirmed by
examining the multiplet ranging from 7.11 – 7.52 ppm that was directly contributed by the
benzyl group in the ampicillin structure. Proton peaks from the substituted methyls on the
90

quaternary ammonium group in [CTA][Amp] are also evident as a singlet at 1.25 ppm. Lastly, a
strong singlet at approximately 1.22 ppm validated the existence of the long alkyl chain in the
cation moiety for each Amp-IL.
The surface tension of Amp-ILs and the corresponding surfactant cation groups at
different concentrations was measured at 25°C to determine if the micellar properties of the
cation were maintained. Figure 3.2 shows a comparison between the critical micelle
concentrations (CMCs) between halide-QACs and Amp-ILs. The results show that in each case,
the Amp-ILs has lower surface tension than the parent QACs. Critical micelle concentrations
were determined from the plot of surface tension and concentration. The tensiometry
measurements for [Bmim][Cl] and [Bmim][Amp] demonstrated no discontinuity and that a CMC
could not be established. This correlates with previously reported data for [Bmim][Cl].25 Since
ampicillin does not have a surfactant-like structure, no enhanced micellization properties were
expected for [Bmim][Amp]. Thus, increasing CMCs for Amp-ILs occurs as [CP][Amp] ≤
[C16M1Im][Amp] < [C16M2Im][Amp] < [CTA][Amp]. This differs slightly from the order of the
halide-QAC CMC values, in which [C16M1Im][Br] ≤ [C16M2Im][Br] < [CP][Br] < [CTA][Br].
Substantial reductions in surfactant-like properties for Amp-ILs ranged between 5 – 29 times as
compared to halide-QAC, with the least and greatest change observed for [C16M2Im][Amp] and
[CP][Amp], respectively. Since the CMC is dependent upon the nature of the amphiphile, size of
the head group, and the length of the alkyl chain, this decrease in CMC is attributed mostly to the
larger ampicillin anion that is likely to prevent hydration within the micellar core. This
phenomenon was observed in CMC studies containing 1-dodecyl-3-methylimidazolium chloride
[DMIM][Cl], in which CMC values were halved once a larger bromide ion replaced the chloride
ion.25-27 Therefore, the metathesis of anions appears to modify the lipophilic/hydrophilic balance
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observed in surfactants. Thereby, it is apparent that Amp-ILs are more hydrophobic than the
starting materials used in this study.

A)

B)

C)

D)

E)

F)

Figure 3.1. Stacked proton nuclear magnetic spectra of various Amp-ILs synthesized in this
study, where A=[CP][Amp]; B= [CTA][Amp]; C =[C16M2Im][Amp]; D = [C16M1Im][Amp];
E = [BmIm][Amp]; and F = [Na][Amp].
3.3.1.2.1 Cetylpyridinium Ampicillin ([CP][Amp]),
Yellow solid, yield, 92%. Mp = 56˚C [CP][Amp]. CMC= 24 μM [CP][Amp]; 690 μM
CPB. Water solubility: 348 μg/mL. 1H NMR (250 MHz, DMSO) δ 8.73 (tt, 5H), 7.24 (m, 5H),
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2.09 (s, 14H), 1.91 (s, 4H), 1.49 (d, 6H), 1.24 (s, 20H), 0.86 (s, 2H). Anal. Cacld for
C37H56N4O4S: C, 68.06; H, 8.64; N, 8.58; S,4.91. Found: C,67.97; H, 8.57; N, 8.55S, 4.84.

3.3.1.2.2 1-Hexadecyl-3-methylimidazolium Ampicillin ([C16M1Im][Amp])
Off-white

solid,

yield,

91%.

Mp

=

55°C

[C16M1Im][Amp].CMC=

24μM

[C16M1Im][Amp]; 430μM [C16M1Im][Br]. Water solubility: 379 μg/mL. 1H NMR (250 MHz,
DMSO) δ 9.11 (s, 1H), 8.31 (s, 1H), 7.72 (d, 2H), 7.59 – 7.12 (m, 5H), 5.36 (s, 2H), 4.14 (t, 2H),
3.85 (s, 2H), 2.09 (s, 3H), 1.77 (t, 2H), 1.47 (dd, 10.0 Hz, 6H), 1.24 (s, 28H), 1.09 (s, 3H), 0.85
(d, 2H).Anal. Cald for C36H57N5O4S: C, 65.92; H, 8.76; N, 10.68; S, 4.89. Found: C, 65.79; H,
8.81; N, 10.42; S, 4.87.

3.3.1.2.3 1-Hexadecyl-2,3-dimethylimiedazolium Ampicillin ([C16M2Im][Amp])
Off-white

solid,

yield,

94%.

Mp

=65˚C

[C16M2Im][Amp].

CMC=

92

μM

[C16M2Im][Amp]; 450 μM [C16M2Im][Br]. Water solubility: 475 μg/mL. 1H NMR (250 MHz,
DMSO) δ 8.27 (s, 1H), 7.60 (dd, 2H), 7.53 – 6.95 (m,5H), 5.70 (s, 2H), 5.30 (d, 4H), 4.07 (t,
2H), 3.73 (s, 3H), 2.09 (s, 1H), 1.68 (s, 6H), 1.22 (s, 30H),0.83 (d, 3H).Anal. Cald for
C37H59N5O4S: C, 66.33; H, 8.88; N, 10.45; S, 4.79. Found: C, 66.21; H, 8.84; N, 10.44; S, 4.72.

3.3.1.2.4 Cetyltrimethylammonium Ampicillin ([CTA][Amp])
Off-white solid at 90% yield. Mp = 73.89-81.36˚C, CMC= 101 μM [CTA][Amp]; 923
μM [CTAB]. Water solubility: not determined. 1H NMR (250 MHz, DMSO) δ 9.03 (s, 1H), 7.80
– 6.99 (m, 5H), 5.69 (s, 2H), 5.31 (d, J = 25.7 Hz, 2H), 3.93 – 3.77 (m, 2H), 3.27 (dd, J = 18.0,
9.8 Hz, 2H), 3.03 (s, 9H), 1.66 (s, 2H), 1.63 – 1.36 (m, 26H), 1.25 (s, 6H),, 0.85 (d, J = 6.7 Hz,
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3H). Anal. Cald for C35H60N4O4S: C, 66.42; H, 9.55; N, 8.85; O, 10.11; S, 5.07. Found: C,66.17;
H, 9.53; N, 8.61; O, 10.58; S, 5.11.

3.3.1.2.5 1-Butyl-3-methylimidazolium Ampicillin ([Bmim][Amp])
Yellow viscous liquid in 91% yield. Mp = liquid at room-temperature. CMC= none
[Bmim][Amp]; none [Bmim][Cl]. Water solubility: not determined.

1

H NMR (400 MHz,

DMSO) δ 9.29 (s, 1H), 8.67 (s, 1H), 7.77 (d, J = 27.3 Hz, 2H), 7.52 – 7.11 (m, 3H), 5.35 (d, J =
3.8 Hz, 1H), 4.49 (d, J = 13.2 Hz, 1H), 4.18 (t, J = 7.2 Hz, 2H), 3.92 – 3.74 (m, 4H), 3.47 – 3.09
(m, 2H), 2.55 (d, J = 30.0 Hz, 1H), 2.09 (s, 1H), 1.86 – 1.71 (m, 2H), 1.54 (d, J = 11.2 Hz, 3H),
1.42 (d, J = 20.6 Hz, 3H), 1.32- 1.22 (m, 4H), 0.99 – 0.84 (t, 2H). Anal. Cald for C24H33N5O4S:
C, 59.12; H, 6.82; N, 14.36; O, 13.12; S, 6.58. Found: C, 59.01; H, 7.08; N, 14.22; O, 13.43; S,
6.26.

3.3.1.3 Solubility
The solubility of Amp-ILs in water was characterized using UV-vis spectroscopy. We
determined the solubility for select Amp-ILs are 475, 379, and 348 µg/mL for [C16M2Im][Amp],
[C16M1Im][Amp], [CP][Amp], respectively. A 100- to 150-fold reduction (R2=0.99) in the
aqueous solubility of ampicillin was observed once the sodium was replaced with a quaternary
ammonium group. Aqueous solubility for [BmIm][Amp] and [CTA][Amp] was not able to be
accurately quantified. A positive control consisting of Amp-ILs in isopropanol confirmed that
the anionic ampicillin was an intact part of the IL structure as evidenced by absorption bands at
257, 262, and 268 nm.
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Figure 3.2. Comparsion between critical micelle concentrations of imidazolium and pyridinium
halides and their corresponding Amp-ILs.
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Table 3.1. Synthesis and structures of five ampicillin-based ionic liquids by anion-exchange reactions.
Ampicillin – based IL
C16-Quaternary Ammonium with Ampicillin as Anion

C16-Quaternary Ammonium with Br- as Anion
Structure

Name and Abbreviation

Structure

Name and Abbreviation

Cetyltrimethyl
ammonium bromide

[CTA][Br]

Cetyltrimethyl
ammonium ampicillin

[CTA][Amp]

1-butyl-3methylimidazolium
chloride

[BmIm]
[Br]

1-butyl-3methylimidazolium
ampicillin

[BmIm]
[Amp]

1-hexadecyl-3methylimidazolium
bromide

[C16M1Im]
[Br]

1-hexadecyl-3methylimidazolium
ampicillin

[C16M1Im]
[Amp]

1-hexadecyl-2,3dimethylimidazolium
bromide

[C16M2Im]
[Br]

1-hexadecyl-2,3dimethylimidazolium
ampicillin

[C16M2Im]
[Amp]

cetylpyridinium
bromide

[CP][Br]

cetylpyridinium
ampicillin

[CP][Amp]
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3.3.2 Antibacterial MIC of ILs
3.3.2.1 Disk-Diffusion Results
The antimicrobial activity of Amp-ILs were qualitatively tested against reference strains
of

Gram-positive

(L.monocytogenes

7973

and

S.aureus

6538)

and

Gram-negative

(S.typhimurium 14028. and E. coli O157:H7 43895) bacteria. The antimicrobial efficacy of
Amp-ILs were qualitatively studied using the Kirby-Bauer Disk Diffusion method (NCCLS M7A7) against two Gram-positive and two Gram-negative bacteria prior to assessing the minimum
inhibitory concentrations (MICs). Zones of inhibition are summarized in Figure 3.3.
The propensity to diffuse and the antibacterial activity of Amp-ILs against select Grampositive and Gram-negative bacteria were evaluated by the disk-diffusion assay. According to
the zone diameter interpretive standard values (NCCLS M2-A4, 1983), the susceptibility zone of
Enterobacteriaceae and highly sensitive Gram-positive bacteria are above 14 mm and 29 mm for
10 μg ampicillin, respectively (Table 3.2).
Table 3.2. Diffusion zone ranges based on NCCLs diameter criterion for sodium ampicillin
disks against Gram-negative and Gram-positive bacteria.
Antibiotic and Bacterial Class
Disk
Inhibition zone diameter to nearest mm
potency
Ampicillin - Gram-negative rods and
enterococci

10 µg

Resistant
11

Ampicillin - Staphylococci and
highly penicillin-sensitive organisms

10 µg

20

Intermediate
12 – 13

Susceptible
14

21-28

29

By these zone standards both Amp-ILs and [Na][Amp] are considered ampicillin resistant
to Gram-positive bacteria. Therefore, interpretation of the results are based on Gram-negative
bacteria susceptibility to these agents. In the case of [Na][Amp], a large diameter indicating
Gram-negative susceptibility was observed. E. coli O157:H7 did not show susceptibility to any
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of the Amp-ILs tested. Interestingly, susceptibility to S. typhimurium 14028 was observed for all
Amp-ILs, except for the intermediate inhibition zone formed by [C16M1Im][Amp]. Overall,
Amp-ILs diffused poorly as compared to [Na][Amp], While diffusion was not completely
inhibited by combining the two salts, none of the Amp-IL compounds diffused as well as
[Na][Amp]. We attribute this result to greater hydrophobicity in Amp-IL.; thereby, causing
diffusion in aqueous-based agar to be limited. Due to the aforementioned limitation among
others caused by the physico-chemical properties of antimicrobial agents, inhibitive zones cannot
be used to completely qualify antibacterial activity. Thus, the antibacterial activities of these
compounds were tested in vitro using the broth-dilution MIC test.
3.3.2.2 Minimum Inhibitory Concentration Results
The antibacterial activity of ampicillin-type ammonium-, pyridinium-, and imidazoliumbased ILs were tested against eight bacteria (i.e. 4 Gram-positive and 4 Gram-negative). To
quantify their antibacterial activities, the minimum inhibitory concentrations (MICs) and
minimum bactericidal concentrations (MBC) were determined. As controls, the precursor ions of
the Amp-ILs were evaluated for antimicrobial activity to determine the difference in activity
between the molecular and IL form of the compounds. The MIC results demonstrate that each
Amp-IL exhibited variable activity against both Gram-positive and Gram-negative bacteria
(Table 3.3). In sum, the antibacterial activity against Gram-positive bacteria in order of higher
MIC value is [CP][Amp] < [CTA][Amp] < [C16M2Im][Amp] < C16M1Im][Amp] < [Na][Amp] <
[BmIm][Amp]. The antibacterial activity of Amp-ILs against Gram-negative bacteria follow a
similar trend as [CP][Amp]<[CTA][Amp]<[C16M2Im][Amp]<C16M1Im][Amp]<[Na][Amp] <
[BmIm][Amp]. Overall increases in activity ranged from 2-43 times compared to [Na][Amp].
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3.3.2.2.1 Ammonium – based Ampicillin Ionic Liquid
The ammonium-type ampicillin IL is composed of four parts: the head ammonium, the
C16-alkyl chain, three methyl groups, and the anion (bromide or ampicillin). The MICs of
[CTA][Br] against Gram-positive bacteria are comparable to [CTA][Amp], although ranging
from 2 – 30 µM. Considerable differences in antibacterial activity between [CTA][Br] and
[CTA][Amp] reveal concentration gaps from 3 to 13 times. Effective antibacterial activities
range from 5 to 30 µM for Gram-negative bacteria. Our results show that [CTA][Amp] was most
effective against E. coli O157:H7 43895 and S. mutans 2502 with equal preferential activity for
both classes of bacteria. Mediocre antibacterial activity was observed for remaining isolates with
no preference to cell morphology. The antimicrobial mechanism of this Amp-IL is still not
known in detail, but is thought to involve a general perturbation of the lipid bilayer in bacterial
membranes; however more studies are necessary to validate this hypothesis. Several studies have
reported that long alkyl QACs disrupt the outer membrane of Gram-negative bacteria more
extensively than shorter chain compounds with subsequent intracellular leakage and cell death.28
Not much literature has explained the roll of QACs on the antimicrobial mechanism of action in
Gram-positive systems. However, we attribute this activity to the presence of the cell wall
inhibitor, ampicillin.
3.3.2.2.2 Imidazolium – based Ampicillin Ionic Liquids
The antibacterial activity of imidazolium-type ampicillin salts were not only tested but
correlated to structure and activity relationships and spectrum of activity. Mainly, the
antibacterial activity of the C16-imidazolium ampicillin ILs will be discussed, since
[BmIm][Amp] only showed mediocre activity against the organisms tested. Therefore,
[C16M1Im][Amp] and [C16M2Im][Amp] are composed of three parts: the head imidazole, the
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C16-alkyl chain, and the anion (bromide or ampicillin). The MICs of [C16M1Im][Br] and
[C16M2Im][Br] against E. coli O157:H7 43895 and E. coli ATCC 25922 showed marginal
difference however, the former had greater activity (Table 3.4). In the case of K. pneumoniae
4352 and S. typhimurium 14028, [C16M1Im][Br] was more 4 times more effective. The
antimicrobial mechanism of these types of long alkyl imidazolium bromides against bacteria is
still not known in detail, but is thought to involve a general perturbation of the lipid bilayer in
bacterial membranes.29-31 Similar to ammonium-type QAC, Ahlström et al. previously reported
that QACs with a C16 hydrophobic chain affected the outer membrane of Gram-negative
bacteria more extensively than shorter chain compounds leading to leakage of cytoplasmic
material and eventual death of the bacterial cell.28 Previous studies have also demonstrated that
imidazolium halides with hydrophobic groups in the C1 and C3 positions of the imidazolium
ring demonstrated higher antibacterial activity than 1,2,3-trisubstituted imidazoles.29 This
demonstrates that the relative antibacterial activity of these types of compounds can be attributed
to the alkyl chain length and head group substitutions, but not the imidazole ring structure.
In the case of the Gram-positive bacterium E. faecium 49474, [C16M1Im][Br] required six
fewer moles than [C16M2Im][Br] to inhibit its growth (Table 3.4). S. aureus 6538, L.
monocytogenes 7973, and S. mutans 2502 were equally susceptible to [C16M1Im][Br] and
[C16M2Im][Br]. This result can be attributed to the lack of a lipopolysaccharide layer. In terms of
the cation, Gram-positive bacteria have shown higher susceptibility than Gram-negative bacteria
to permeation by the long alkyl chain present on the imidazolium ring. Thus, it is suggested that
monoalkyl QACs bind by ionic and hydrophobic interactions to microbial membrane surfaces
arranged with the hydrophobic tails inserted into the lipid bilayer, resulting in the rearrangement
of the membrane and subsequent leakage of intracellular contents.30 The innocuous bromide
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counter-ion does not add any antimicrobial benefit to the halide-QACs, thereby allowing the
mechanism of action to be solely attributed to the properties of the cation. It is important to note
that the S. aureus 6538 used in this study acquired resistance amidst this investigation as
determined by high MIC (e.g. 40 µM) and limited disk diffusion zone diameters (Figure 3.3).
After undergoing anion exchange from bromide to the antibiotic, ampicillin, our results
demonstrate a reduction in the amount of ampicillin required to inhibit the growth of the
challenge pathogens. Since literature has suggested that there are minimal effects on antibacterial
activity from the variation of the anion within imidazolium- and pyridinium-type ILs, any
changes in antibacterial activity for our Amp-ILs will be attributed to the antibiotic ampicillin.3133

Similar to the investigation conducted by Docherty et al.,34 we also investigated the

antibacterial activity of the halide salts, sodium bromide, potassium chloride, and sodium
chloride in which no antibacterial activity was observed within the concentration range studied in
this investigation (data not shown). When comparing the antibacterial activities of the ampicillin
imidazoliums to the halide imidazoliums, improvements in antibacterial activity were evident
(data not shown).
Antibacterial activity against Gram-negative bacteria for imidazolium-type Amp-ILs
show improved spectrum of activity between di- and tri-substituted imidazolium ampicillins.
Minimal changes to the antibacterial activity were observed for both E. coli isolates. Nearly 6fold improvement in MIC values were achieved for K. pneumoniae 4352 for [C16M2Im][Amp].
Equal antibacterial activity was observed among all Gram-negative isolates treated with
[C16M1Im][Amp]. These findings could be explained by the known activities of penicillin and its
analogs against Gram-negative bacteria. For example, the β-lactam must be able to penetrate the
outer LPS envelope and intrinsically bind to the different target proteins within the bacteria cell
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wall.35 However, the LPS barrier protects the cell from large, hydrophobic permeating agents
such as certain antibiotics, detergents,36 or in this case Amp-ILs. In addition, the large masses of
the Amp-ILs may inhibit the compound from passing through pores located in the LPS layer and
actively inhibit transpeptidase activity. Despite being specific to the types of bacteria, the pores
located in E. coli, for example, do not allow molecules with masses larger than 600Da to enter
the cell37 and our Amp-ILs have masses greater than 600 Da on average.

Therefore, the

antibacterial activity of Amp-ILs against these microorganisms may be result from the cationic
portion of the Amp-IL structure. This is further supported in the results outlined in Table 3.3
where it is evident that neither halide nor ampicillin imidazolium produced substantial changes
in antibacterial activity compared to [Na][Amp]. When comparing [C16M1Im][Amp] and
[C16M2Im][Amp] to [Na][Amp], MICs for Gram-negative bacteria were 4-times better for K.
pneumoniae 4352 but equally or worse treatments for the other microbes.
It is commonly recognized that penicillin and its analogs are more effective on Grampositive than Gram-negative bacteria due to the absence of the LPS in Gram-positive bacteria
and the readily accessible cellular wall.38 In Table 3.3, it can be seen that the antibacterial
activities for ampicillin imidazoliums significantly improved requiring between 2 - 30 μM and
0.8 – 30 μM for [C16M1Im][Amp] and [C16M2Im][Amp], respectively, to inhibit Gram-positive
bacteria compared to 8 – 140 μM required for [Na][Amp]. Similar activity is required to inhibit
S. aureus for both ampicillin-type imidazoliums. When compared to [Na][Amp], both Amp-ILs
required approximately 50% lower concentration to inhibit the growth of resistant S. aureus
6538. It is believed that the acquired resistance shown by S. aureus 6538 in this study could be
due to its development into a mucoid strain which is less susceptible to long-alkyl disinfectants.
If this is the case, we attribute the [C16M2Im][Amp]’s improvement in antibacterial activity to
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Amp-IL hydrophobicity and its likelihood to transport through the slime-layer of S. aureus 6538.
Additionally, 2.25 times fewer moles are required for bacteriostatic activity against E. faecium
49474, and equal MIC values are required to inhibit the growth of L. monocytogenes 7973 and S.
mutans 2502. Therefore, imidazolium-based Amp-ILs are equally effective against all candidate
Gram-negative pathogens tested in this study with preferential activity to Gram-positive bacteria,
namely, E. faecium 49474.
3.3.2.2.3 Pyridinium – based Ampicillin Ionic Liquids
The antibacterial activity of the pyridinium-type ampicillin IL was also investigated.
These compounds are also composed of three parts: the head pyridinium ring, the C16-alkyl
chain, and the anion (bromide or ampicillin). Similar to imidazolium halides, pyridinium halides
have been extensively investigated to determine the structural contributions to their disinfecting
properties.39 The addition of a long alkyl chain to C1 on the pyridinium ring results in increased
IL toxicity against Gram-negative planktonic bacteria.34 It has also been demonstrated that C16alkyl chains are the most effective portion of the ionic liquid structure when reducing the growth
of bacteria.29,

40

Therefore, it is suggested that the hydrophobic chain on the pyridinium ring

helps to perturb the cell wall. For the Amp-IL [CP][Amp], this cell wall permeation would
improve the access of the ampicillin anion to the cell wall.
The MICs of [CP][Amp] against Gram-negative microbes showed improvement in the
antibacterial activities when converted into an Amp-IL (Table 3.3). After exchange of the
bromide to the ampicillin anion, improvements were observed up to 16 times and 3 times for
Gram-negative and Gram-positive bacteria, respectively. These improvements are attributed to a
combination of the long-alkyl pyridinium and ampicillin moieties. In comparison to the
antibacterial activity of [Na][Amp], the MIC was most notably improved up to 163 times for
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Gram-positive bacteria. The greatest difference in antibacterial activity between [CP][Amp] and
[Na][Amp] was 7 times for Gram-negative microbes. The most significant improvement was
observed when [CP][Amp] was used to inhibit E. faecium 49474 and E. coli 25922.
As the MIC value was equal to MBC for each Amp-ILs, the antibacterial activities of
these compounds were considered to be bactericidal. Therefore, we hypothesize that the
antibacterial behavior of the investigated Amp-ILs are due to the combination of a cell wall
permeant with a transpeptidase inhibitor. Overall, [CP][Amp] was most effective on K.
pneumoniae 4352, E. coli 25922, S. aureus 6538, and E. faecium 49474 growth inhibition, with
more effective activity on Gram-positive bacteria. This finding may be a result from the synergy
between the membrane active cation and cell wall inhibiting anion. This will be further described
in Section 3.4.2.
3.3.3 Critical Micelle Concentration and Antibacterial Activity Relationship
Amp-ILs are active well below their CMCs. This could be explained by the fact that
below the CMC values, the ILs are free monomers and participate in antibacterial activity;
whereas, above the CMC value the ILs are engaged in micelles and unavailable to participate in
the disruption of the cell wall. In addition, this bactericidal activity depends upon their ability to
adsorb at the water/cell membrane interface, as determined by the CMC value. The CMCs of
[CTA][Amp], [C16M1Im][Amp],[C16M2Im][Amp], and [CP][Amp] were found to be 101, 24, 92,
and 24 µM, respectively. Average MIC are approximately 1-6 times less than the CMC values,
which clearly indicates that these compounds are probably not acting as detergents and are not
forming micelles as a mechanism of action. Moreover, the interaction between the QAC and
ampicillin as an Amp-IL is due to a change in the physical properties of the cation moiety. Since
the CMC values were decreased upon metathesis, it appears that the free monomeric Amp-ILs
are able to adsorb at the cell/water interface at dilute concentrations. Cell/wall adsorption can
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lead to increases in cell wall solubility and cell membrane permeability by the monomeric AmpIL and lead to enhanced antimicrobial activity.

Figure 3.3. Experimental zone diameters obtained using Kirby-Bauer disk diffusion assay. Top
panel (A) demonstrate zones of inhibition results, and thresholds for resistance (R), intermediate
(I), and susceptible (S) against E. coli O157:H7 and S. typhimurium. Bottom panel (B)
demonstrates experimental inhibition zones acquired for S. aureus and L. monocytogenes.
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Table 3.3. Minimum inhibitory concentrations (MIC, μM) of ammonium-, imidazolium-, and pyridinium-type ampicillin ionic
liquids. MIC values and minimum bactericidal concentrations were equivalent in this study.
E. coli
K.
E. coli
S.
S.
E.
S.
L.
O157:H7 pneumoniae
ATCC
typhimurium aureus faecium mutans monocytogenes
43895
4352
25922
14028
6538
49474
2502
7973
[CTA][Amp]
[C16M1Im][Amp]
[C16M2Im][Amp]

5
19
17

30
30
30

11
20
18

[CP][Amp]
17
19
6
[BmIm][Amp]
150
200
180
[Na][Amp]
20
130
10
[CTA][Br]
19
30
30
[C16M1Im][Br]
17
30
30
[C16M2Im][Br]
19
13
30
[CP][Br]
12
30
100
[BmIm][Cl]
NA
NA
NA
NA – no activity observed within concentration range tested.

6
30
19

25
30
25

2
1.8
0.8

12
20
20

30
30
30

30
20
0.8
80
30
120
30
NA

13
200
40
10
60
50
30
NA

0.8
170
130
11
30
18
2
NA

20
200
140
20
20
20
20
NA

30
50
8
30
30
30
30
NA

Table 3.4. Interaction indices for ammonium-, imidazolium-, and pyridinium-type ampicillin ionic liquids.*
E. coli
K.
E. coli
S.
S.
E.
S.
O157:H7 pneumoniae
ATCC
typhimurium
aureus
faecium
mutans
43895
4352
25922
14028
6538
49474
2502
[CTA][Amp]
0.13 (S)
0.12 (S)
0.55 (N)
3.75 (N)
0.31 (S) 0.01 (S) 0.04 (S)
[C16M1Im][Amp] 1.03 (N)
0.62 (N)
1.33 (N)
19.25 (A)
0.63 (N) 0.04 (S) 0.57 (S)

L.
monocytogenes
7973
1.88 (N)
2.38 (N)

[C16M2Im][Amp]

0.87 (N)

0.23 (S)

1.20 (N)

11.95 (A)

0.56 (N)

0.03 (S)

0.57 (N)

2.38 (N)

[CP][Amp]

0.50 (S)

0.39 (S)

0.33 (S)

19.25 (A)

0.38 (S)

0.20 (S)

0.57 (N)

2.38 (N)

*: Interaction indices could not be calculated for [BmIm][Amp] because no antimicrobial activity was observed for [BmIm][Cl].
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3.3.4 Effect of Ampicillin-content in ILs
The activity of the IL compounds is more clearly described by normalizing the
concentrations based on the percentage of ampicillin content within the Amp-ILs and [Na][Amp]
(Equation 3.1).

Mwampicillinoate
MwAmp  IL

 MIC

(Eq. 3.1)

For all Amp-ILs, it was observed that the reduced concentration of ampicillin anion in
Amp-ILs was required to inhibit bacterial growth compared to [Na][Amp] (Figure 3.4).
Depending on the bacterial species, the ampicillin content required for inhibition was in the
microbe susceptible range for ampicillin activity (i.e. 0.1 to 20 μg/mL), excluding
[BmIm][Amp].17 The average concentrations of ampicillin, in Amp-ILs, required to kill Gramnegative bacteria was were found to be 2.5, 4.5, 3.8, 3.3, and 34.1 μg/mL for [CTA][Amp],
[C16M1Im][Amp], [C16M2Im][Amp], [CP][Amp], and [BmIm][Amp], respectively. Likewise,
3.3, 3.7, 3.4, 2.9, and 38.4 μg/mL was required for bactericidal activity in Gram-positive
bacteria. As previously stated, the average ampicillin content evident in [BmIm][Amp] is higher
than the ampicillin-microbe susceptible range. The average MIC in terms of ampicillin content
for [Na][Amp] was found to be 13.2 and 26.0 μg/mL for Gram-negative and Gram-positive,
respectively. This is a four- to nine-fold improvement in ampicillin content required for
antibacterial activity when Amp-ILs are compared to [Na][Amp]. These results demonstrate that
lower concentrations of Amp-ILs are capable of bactericidal activity against the tested
inoculums. This demonstrates that lower dosage amounts of ampicillin could be implemented if
applied in pharmaceutical systems as an Amp-IL.
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Figure 3.4. Bar graph depicting active concentrations of ampicillin content within Amp-ILs from MIC (µM) for Gram-positive (A)
and Gram-negative bacteria (B).
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3.3.5

Antibacterial Activity of Combinations

3.3.5.1 Combinatorial Effect of QAC and Sodium Ampicillin Co-Activity
It has been reported that the effect of a pharmaceutical agent on both resistant and
sensitive bacterial strains can be enhanced with surfactants. For example, Suling and O’Leary
observed that the addition of CTAB increased the activity of penicillin G on E. coli, P. mirabilis,
K. pneumoniae, and various Staphylococci strains.41 However, this was not completely evident in
our study. We investigated this phenomena using imidazolium- and pyridinium-type Amp-ILs.
It was observed that the use of both QAC and [Na][Amp] tested in combination did not
outperform the antibacterial activities of the Amp-ILs. For example, in Figure 3.5 the
antibacterial activities of [C16M1Im][Br] + [Na][Amp] and [CP][Br] + [Na][Amp] were 30%
less, in comparison to [C16M1Im][Amp] and [CP][Amp] for E. coli O157:H7 43895. Similarly,
the antibacterial activity of [C16M2Im][Br]+[Na][Amp] was reduced by 80%, compared to the IL
form, when two components were combined against E. coli O157:H7. Our results demonstrate
that the use of either QAC, [C16M1Im][Br] + [Na][Amp], or [C16M1Im][Amp] could equally
inhibit the growth of E. faecium; whereas, both [CP][Amp] and [C16M2Im][Amp] required 73%
reduction in concentration compared to the starting materials (Fig. 3.5). As controls [Na][Br] was
added to each Amp-IL to understand the effect of the salt as a by-product in these studies, and it
was observed that it did not enhance the antibacterial activity of the Amp-ILs. In fact, the
antibacterial activities of Amp-IL were reduced with the addition of equal moles of [Na][Br]. It
is hypothesized that this result is related to the change in the isotonic environment of the bacteria
resulting in a reduction in bacteria size and steric inhibition of the molecule’s absorption.
Overall, the Amp-ILs have an increased antibacterial activity for the investigated
pathogens. In 83% of the experiments, we demonstrate that Amp-ILs are more effective
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antibacterial agents than each salt individually, or in combination, for the tested bacteria. Further
investigation of this behavior will be conducted in future studies.
3.3.6 Loewe’s Additivity Model
Table 3.4 illustrates the interaction indices of Amp-ILs as calculated according to the
Loewe’s Additivity Model. This model reveals that Amp-ILs demonstrate independent
interaction indices between cation and anion. In 38% of the antibacterial studies using Gramnegative bacteria and 50% using Gram-positive bacteria, synergy was observed by the Amp-ILs.
Additivity was observed in 44% and 50% of the Gram-negative and Gram-positive isolates.
However, antagonism was only observed in 19% of the Amp-IL treatments on Gram-negative
and none on Gram-positive microbes. These results show that [CP][Amp] and [CTA][Amp] are
the better Amp-ILs to obtain synergetic interactions in Gram-negative bacteria. Although
minimal, the probability of observing antagonism in Gram-negative bacteria in test systems is
20% likely. Systems containing Gram-positive bacteria show that in the worse instance,
additivity could be observed. Nonetheless, synergy is still equally as probable when considering
the use of the Amp-ILs alternative.
A closer look at a comparison study between the interaction indices between Amp-ILs
and the mixture of stoichiometric mixture reveal the benefit of using this approach. For instance,
the interaction indices determined for [CP][Amp] and its precursors in combination (red bars)
reveal that synergy was favorable for the Amp-IL against

both Gram-positive and Gram-

negative strains. Contrary to the previous result, the stoichiometric mixture revealed additivity
and antagonism for E. coli O157:H7 and E. faecium, respectively. Upon comparing the
differences in interaction indices between Amp-ILs and the precursor ion combination, a 2- and
33-fold favorable improvement was observed when treating E. coli O157:H7 and E. faecium,
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respectively with [CP][Amp]. Likewise, an unclean Amp-IL containing equimolar [Na][Br]
demonstrated that the presence of by-product antagonizes the activity of [CP][Amp] causing
results to become additive and antagonistic.
In a similar system containing an Amp-IL consisting of a C16-imidazolium cation, it is
apparent that the combination and presence of [Na][Br] also attenuates the synergetic behavior.
Although [C16M1Im][Amp] is marginally more synergetic than the precursor and unclean
combinations, each system is considered to be additive according to established interaction index
thresholds. Thus, additivity was observed for [C16M1Im][Amp], [C16M1Im][Br]+[Na][Amp],
and [C16M1Im][Amp]+[Na][Br] (blue bars) against E. coli O157:H7. When treating E. faecium,
[C16M1Im][Amp] demonstrated antagonism. We conclude that these results show that the coadministration

of

sodium

ampicillin

and

1-hexamethyl-3-methylimidazolium

bromide

([C16M1Im][Br]+[Na][Amp]) are neutral and do not improve the activity of the other and the
presence of [Na][Br] interferes with the synergetic activity of the Amp-IL.
We also investigated the change in interaction index upon the addition of a methyl group
to C-2 of the imidazolium structure and increase in hydrophobicity. Similar to the other AmpILs, [C16M2Im][Amp] (green bars) was a more synergetic ion pair than the combinations against
E. coli O157:H7 in spite of its moderate additive index. However, [C16M2Im][Amp] was 42
times more synergetic than the mixtures when treating E. faecium. Likewise, the combination
and presence of [Na][Br] with the Amp-IL antagonizes its activity causing a additive effect. In
sum, the interaction indices ranging in order of increasing synergy is [C16M1Im][Br] >
[C16M2Im][Amp] > [CP][Amp].

111

In each study, the differences in interaction indices are apparent. For E. coli O157:H7,
all Amp-ILs were more synergetic than either combination. Similarly, the more hydrophobic
Amp-ILs (i.e. [CP][Amp] and [C16M2Im][Amp]) showed substantial improvements in synergy.
Another common feature among the interaction indices calculated for systems containing AmpILs and [Na][Br] is the attenuated observed synergy. We attribute this reduction in synergy to the
relative hydrophilicity of the Amp-ILs. As the aqueous solubility is increased, there is a greater
probability of the ions to dissociate and re-associate with the precursor counter-ions. Thus, the
relative interaction indices obtained for the Amp-ILs demonstrates an apparent increase in
synergy with increasing hydrophobicity.
3.4

Conclusion
We have successfully demonstrated the synthesis and antibacterial application of a novel

class of antibiotic-based ILs composed of either ammonium, imidazolium. or pyridinium cations.
Improvements in the bactericidal activity of the ampicillin anion were obtained when the anion
was combined with a QAC as the cation. The results indicate that Amp-ILs may be effective
alternatives as antibacterial agents in lieu of the use of either individual ionic parent compounds
(i.e. [QAC] or [Na][Amp]) or the combination in solution (i.e. [QAC] + [Na][Amp]).
The advantages by use of antibiotic-based ILs are numerous. Aside from the possibility
of extending the clinical usage of antibacterial agents that are associated with bacterial
resistance, there is potential to improve the half-life, reduce dosage rates, tailor the
bioavailability of the drug, reduce costs associated with new drug testing and formulation, and
expand the therapeutic activity of the antibiotic by pairing it with other biological ions.
Although, these specific types of ampicillin ionic liquids may be considered toxic and not
cleared for systemic use, the potential to apply these antibacterial materials to biomedical
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sterilization, food processing, and wound care therapy is promising. Thus, Chapter 4 highlights
an extension of this work in which a potent antiseptic and various β-lactam antibiotics are
integrated for their potential use against pathogenic bacteria in disease prevention and
eradication of E. coli O157:H7 from the terminal recta of cattle.
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Figure 3.5. Interaction indices calculated for ampicillin-based ionic liquids. Each color
correlates to a specific Amp-IL, where red = [CP][Amp] and its combinations, blue =
[C16M1Im][Amp] and its combinations, and green = [C16M2Im][Amp] and its combinations.
Darker colors are measured by the left axis indicative of E. faecium results and the right axis
describes the interaction indices against E. coli O157:H7.
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4.1

CHAPTER 4 SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL
EVALUATION OF BETA (β)-LACTAM BASED CHLORHEXIDINE GUMBOS
AGAINST ENTEROHEMORRHAGIC ESCHERICHIA COLI
Introduction
Enterohemorrhagic Escherichia coli (EHEC) infections are associated with bloody

diarrhea, thrombotic thrombocytopenic purpura, hemorrhagic colitis, and hemolytic uremic
syndrome.1,

2

Although strains of EHEC are represented by several serotypes, the majority of

severe infections are caused by serotype O157.1, 3 Cattle and other ruminants are reservoirs of
infection and sources for fecal contamination in food and beverages; therefore, they are
associated with large outbreaks of disease caused by EHEC.4,

5

Aside from enforcing good

hygienic practices with all aspects of food handling, from harvest to preparation, EHEC
transmission might be better controlled by reducing fecal shedding from food-producing
animals.2 Several methods tested in attempts to control the colonization of pathogenic microbes
in food-producing animals included regulating the animal’s diet and with vaccination. Studies of
such control measures to reduce or eliminate fecal shedding of EHEC in cattle have been
inconclusive.4, 6-8
One current approach to reduce EHEC fecal shedding in a food-producing animal is the
use of antiseptics. Various compounds have demonstrated some efficacy in the reduction of
EHEC in a food-producing animal’s feces; however, many of these compounds are inherently
toxic and not approved for this use in animals. One such compound is the di-cationic biguanide,
chlorhexidine. Low et al. reported that chlorhexidine enemas eliminated high-level fecal
shedding and reduced low-level shedding by killing E. coli O157:H7 at the terminal rectum.8
However, the effective concentrations used for eliminating or reducing EHEC fecal shedding are
cytotoxic.9-12 Many antibiotics commonly used in animal feedlots selectively reduce fecal
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shedding of EHEC in ruminants.5 One such antibiotic used in cattle feedlots is ampicillin.
However, the rapid rise of antimicrobial resistance in Gram-negative bacteria, particularly in
those with extended spectrum β-lactamases (ESBL), severely curtails the widespread use of
antibiotics in the control of microbe colonization in food-producing animals.13 Other methods of
reducing EHEC fecal shedding have been explored using FDA approved ionophores as feed
additives. However, ionophores such as monensin, lasalocid, laidlomycin propionate, and
bambermycin are ineffective in reducing EHEC shedding in fecal samples, particularly those
isolated from sheep.14, 15
With the goal of developing a safe and effective compound that could be administered to
food-producing ruminants such as cattle, goats, and sheep to reduce fecal shedding of EHEC,
chlorhexidine and ampicillin were combined to form a unique GUMBOS, chlorhexidine diampicillin. These two compounds were chosen based primarily on their history of use in
veterinary practice. Other β-lactam antibiotics -lactam antibiotics were also included to see if
their differing degrees in antibacterial potency and spectrum of activity would positively or
negatively affect EHEC eradication. Integrating pharmaceutically active cations and anions into
entities known as Active Pharmaceutical Ingredient – based Ionic Liquids (API-ILs) is an
innovative approach to resolving issues associated with single or combination therapy using
individual cationic or anionic agents. For example, API-ILs can be synthesized using antibiotics,
analgesics, and anti-inflammatory drugs.16-20
ILs are arbitrarily defined as salts that melt below 100˚C but there are many ion
combinations that form salts with melting points less than 250˚C with interesting and useful
properties.21 These ILs belong to a new category of applied low melting salts called Group of
Uniform Material Based on Organic Salts (GUMBOS).22 Beta (β)-lactam chlorhexidine salts are
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API-ILs that can be considered as GUMBOS. The purpose of this study was to synthesize and
characterize GUMBOS composed of the antiseptic, chlorhexidine, and four β-lactam antibiotics
(i.e. ampicillin, carbenicillin, oxacillin, and cephalothin) and investigate their antibacterial
activities and mechanisms of action on several strains of EHEC. Cytotoxicity studies and
predictive intestinal permeabilities were studied in vitro to assess the GUMBOS feasibility in
removing EHEC from the terminal recta of ruminants.
4.2
4.2.1

Materials and Methods
Synthesis of Chlorhexidine di-ampicillin GUMBOS
An excess of sodium antibiotic was added to a chlorhexidine methanolic solution in

stoichiometric amounts to a round-bottom flask. The mixture was stirred for two days at room
temperature to ensure the complete formation of chlorhexidine di-ampicillin, chlorhexidine
carbenicillin, chlorhexidine di-oxacillin, and chlorhexidine di-cephalothin. After removing
methanol using rotary evaporation, the un-reacted and by-products were removed by washing
several times with deionized water. The products were finally dried under high vacuum
overnight. Identity and purity of the GUMBOS were confirmed by

1

H and

13

C NMR

spectroscopy and mass spectrometry. The structural components of the β-lactam based
chlorhexidine GUMBOS are shown in Figure 4.1.
4.2.2

Dissolution Profile Measurement
The dissolution rates for β-lactam based chlorhexidine GUMBOS were measured using

UV spectrophotometry at 260 nm in 18.2 mΩ deionized water. Here, 20 mg samples were placed
in a stirred, 100 ml Erlenmeyer flask containing 50 ml of 18.2 mΩ deionized water. Over time,
one milliliter aliquots were collected and filtered through a 0.1 µm pore size syringe filter
(Whatman). Dissolution profiles were measured in triplicate at room temperature until
absorbance plateau.
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4.2.3 In Vivo Prediction of Intestinal Permeability and Absorption
Intestinal permeability was approximated using the BD Gentest Pre-coated PAMPA Plate
System (BD Biosciences, MA, USA). The procedure required that 300 µL of 200 µM compound
solutions in PBS buffer (100mM, pH 7.4) be added to the wells in a donor plate while 200 µL of
PBS buffer were added to corresponding wells in an acceptor plate. After the acceptor plate was
coupled to the donor plate, the assembly was incubated for 5 hours at 20°C. The last 100 µL of
wells from the donor and acceptor plates were added to a UV transparent 96-well plate for
quantification using a plate reader. The final concentrations in each plate were determined using
calibration curves at 260 nm. Membrane permeability was calculated using formulas provided in
the assay and resultant predictive intestinal absorption values were determined using a Log Pe ≥6 threshold that indicates ≥75% intestinal absorption.
4.2.4 Antimicrobial Activity
Seven strains of E. coli O157:H7 were used in this study (Table 4.3). Each isolate was
grown individually on MacConkey Agar with sorbitol for 24 hours at 37°C. E. coli (ATCC
25922) was used as a non-pathogenic strain. All bacteria were obtained from the collection
maintained in the Food Safety/ Food Microbiology laboratory, Louisiana State University.
Minimal inhibitory concentrations (MIC) were determined in triplicate by micro-broth
dilution essentially as described by Motyl et al.23 Test inocula were prepared with colonies
suspended in saline (0.85% NaCl) to a 0.5 McFarland standard. Cation-adjusted Mueller-Hinton
broth (Difco, Detroit, MI) with 2% DMSO was used to serially dilute (1:1) GUMBOS, sodium
antibiotic, chlorhexidine diacetate, or the stoichiometric combination of the antibiotic and
chlorhexidine diacetate [2:1 v/v for chlorhexidine di-ampicillin, chlorhexidine di-cephalothin,
and chlorhexidine di-oxacillin or 1:1 v/v] for chlorhexidine carbenicillin). After inoculation,
plates were incubated 24 h at 37°C. Minimum bactericidal concentrations of GUMBOS were
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determined by plating the clear MIC wells from microtiter plates onto trypticase soy agar and
looking for colonies after 24 h incubation. Antibacterial activity was statistically analyzed using
SAS 9.2 (SAS Institute Inc., Cary, NC), p<0.05.
4.2.5 GUMBOS Interaction Indices
Loewe’s additivity model24-26 was used to evaluate the interaction index (I) of
chlorhexidine diacetate and sodium antibiotic used in combination compared to I calculated for
GUMBOS. An I value of <0.5 denotes synergy; the combined effects of two agents are greater
than the sum of their individual effects. If I is ≥0.5 but ≤ 4, the effect of two agents is said to be
additive (i.e., the combined effect is equal to individual activities). If I >4 then the two agents are
considered antagonistic, meaning the effect of the combined agents is smaller than one of the
agents alone.
Equation 4.1 (Eq.4.1) shows the Loewe’s additivity mathematical model used to calculate
I values for drug combinations, where X refers to a specific inhibition level (i.e. 99.9%), Ca and
Cb are the concentrations of drug A and B when used in combination, and CA and CB are the
concentrations of drug A and B administered separately and have the same level of inhibition 26.
C
C
I a  b
(Eq. 4.1)
C A CB
The model used to represent the mixture of chlorhexidine diacetate (CHXAc) and sodium
antibiotic (NaβL) in the stoichiometric equivalent concentrations for the β-lactam based
chlorhexidine GUMBOS is shown in Equation 4.2:

Icombo 

[CHXAc ]COMBO [ NaL]COMBO

[CHXAc ]100%
[ NaL]100%

(Eq. 4.2)

Models for the β-lactam based chlorhexidine GUMBOS are shown in Equations 4.3 and 4.4.

I GUMBOS 

0.33  [CHX  L2 ]
[CHX ][ Ac ]100%



0.66  [CHX  L2 ]
[ Na][L]100%
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(Eq. 4.3)

Equation 4.3 was used to calculate interaction indices for GUMBOS (i.e. chlorhexidine diampicillin, chlorhexidine di-cephalothin, and chlorhexidine di-oxacillin) which consists of a 1
chlorhexidine diacetate: 2 sodium antibiotic stoichiometric ratio.

I GUMBOS 

0.5  [CHX  L]
[CHX ][ Ac ]100%



0.5  [CHX  L]
[ Na 2 ][L]100%

(Eq. 4.4)

Equation 4.4 was used to calculate interaction indices for chlorhexidine carbenicillin GUMBOS
which consists of a 1 chlorhexidine diacetate: 1 disodium antibiotic stoichiometric ratio.
4.2.6 Time-Kill Kinetics of Chlorhexidine di-ampicillin
Since chlorhexidine di-ampicillin required the lowest concentration to kill EHEC isolates,
its time-kill kinetics were performed as a model in reference to the antiseptic chlorhexidine
diacetate. Time-kill kinetics of chlorhexidine di-ampicillin was assessed using the BacLight
Live/Dead Assay (Molecular Probes, Carlsbad, CA) as outlined in the protocol. More
specifically, E. coli O157:H7 strain 43895 suspensions were adjusted to 1 x 108 CFU/mL (~0.3
OD670) and treated with 7.3µM (MBC of chlorhexidine di-ampicillin) antimicrobial agent. At
different times, bacteria aliquots were stained with fluorescent probe mixture (SYTO 9 and
Propidium Iodide) and mixed thoroughly. Samples were incubated in the dark for 15 minutes
prior to fluorescence detection.
4.2.7

Mechanism of Action Studies

4.2.7.1 Membrane Perturbating Activity of GUMBOS on E. coli
Outer membrane permeation was evaluated using the 1-N-phenylnapthylamine (NPN)
fluorescent probe as described previously by Hugo and Denyer and Helander et al.27, 28Briefly, E.
coli O157:H7 strain 43895 grown into log-phase (λ630nm = 0.5 ± 0.5) was centrifuged (1,000 x
g, 15 mins, 25ºC) and resuspended in half volume of HEPES buffer (5mM, pH 7.2). The
hydrophobic probe, NPN (final concentration of 20 µM), was added to bacteria and dispensed
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100 µL/well to black 96-well microtiter plates containing 100 µL of serially diluted GUMBOS
or chlorhexidine diacetate ranging from 3 – 500 µM, buffer (negative control), or 500 µM EDTA
(positive control). To test the impact divalent cations (i.e. Mg+2) have on the membrane
permeating ability of GUMBOS as compared to known membrane permeating properties of
chlorhexidine diacetate, a separate microtiter plate containing 5mM MgCl2 was used to assess
the role divalent cations have on the membrane permeation of these compounds. Increases in
fluorescence (λex 355nm, λem 405nm) were monitored within 3 mins from three parallel wells per
sample and concentration, in triplicate.
4.2.7.2

Membrane Potential Effect of Chlorhexidine di-ampicillin on E. coli
BacLightTM Bacterial Membrane Potential assay (Molecular Probes, Carlsbad, CA) was

used as outlined in the protocol to determine if GUMBOS depolarizes EHEC bacterial
membranes. Here, 100 µL aliquots of log-phase growth 106 CFU/ml E. coli O157:H7 strain
43895 was treated with 100 µL of 3 – 250 µM chlorhexidine diacetate or GUMBOS. Extents of
depolarization were quantified according to a 5 µM valinomycin-potassium calibration curve (1
– 50 mM KCl). The proton ionophore, carbonyl cyanide 3-chlorophenylhydrazone (CCCP),
which destroys membrane potential by eliminating the proton gradient, was used as a positive
control. After 30 minutes of antimicrobial treatment, bacteria were stained with 30 µM DIOC2
(3, 3′-diethyloxacarbocyanine iodide). Fluorescence measurements (λex 488nm, λemGreen 538nm,
and λemRed 612nm) were obtained in a black 96-well fluorescence microtiter plate. Endpoint
fluorescence red/green ratiometric values were used to quantify intracellular cytosolic potassium
concentrations, its leakage, and corresponding changes in Nernst membrane potential. The red –
to – green fluorescence ratio identifies the portion of bacteria with intact membranes (red
fluorescence) and depolarized membranes (green fluorescence) since the DIOC2 dye shifts from
red – to – green emission upon changes in membrane potential and membrane integrity.
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Fluorescence measurements were performed in triplicate using a FluoStar 0403 microplate
reader (BMG Lab Tech GMbH, Ortenburg, Germany) within 10 minutes, from three parallel
wells per sample concentration).
4.2.7.3

Membrane Activity of Chlorhexidine di-ampicillin on E. coli
Membrane effects of chlorhexidine di-ampicillin as compared to the parent salts

individually were evaluated on log-phase cultures of EHEC isolates using SEM. EHEC cultures
were prepared from the logarithmic growth phase to a 108 CFU/ml starting concentration.
Mueller-Hinton broth containing EHEC inocula of 108 CFU/ml were treated with supra-MICs of
sodium ampicillin, chlorhexidine diacetate, chlorhexidine di-ampicillin, or the stoichiometric
mixture of parent ions for 1 hour at 37°C. Untreated controls were prepared in cation-adjusted
Mueller-Hinton growth medium. Samples were fixed on a 0.2 μm pore polycarbonate filter in
2.5% glutaraldehyde in 0.2 M cacodylate buffer pH 7.2 for 1h, then rinsed 5 times in 0.1 M
cacodylate buffer containing 0.02M glycine over 12 h period. Then the materials were rinsed in
water twice, dehydrated in ethanol series, dried with chemical hexamethyldisilazane (HMDS)
series, mounted on aluminum SEM stubs, coated with platinum in an EMS550X sputter coater,
and imaged with JSM-6610 High vacuum mode SEM (Peabody, MA).
4.2.8

HeLa, NIH/3T3, and EOMA Cell Viability Tests
To determine cell viability, the colorimetric MTS dye (CellTiter 96 ® AQueous One

Solution Cell Proliferation Assay, Promega, Madison, WI) assay was used as an indicator of cell
viability. HeLa (ATCC CCL-2), NIH/3T3 (ATCC CRL-1658), and EOMA (ATCC CRL-2586)
were cells grown in Dulbecco’s Modified Eagle Medium – Reduced Serum (DMEM-RS)
supplemented with 3% FBS were plated at a density of 1x104 cells/well into 96-well culture
plates (Falcon, Franklin Lakes, NJ). Varying concentrations (3 µM to 350 μM) of GUMBOS,
chlorhexidine diacetate, and sodium antibiotic were used to treat cells for 24 h at 37ºC + 5%
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CO2. Cells treated with medium only served as a negative control. After 24 h incubation, 40 µL
of MTS solution was added to each well and incubated for an additional 1 hour. The absorbance
intensity was measured using a Perkin Elmer Wallac Victor2 V Fluorescence/Luminescence
Plate Reader (Boston, MA) at 490 nm. All experiments were performed in quadruplicate and the
relative cell viability (%) was expressed as a percentage relative to the untreated control cells.
Cytotoxicity was statistically analyzed using SAS 9.2 (SAS Institute Inc., Cary, NC), p<0.05.

4.3

Results

4.3.1 Representative GUMBOS Structural Analysis: Chlorhexidine di-Ampicillin
The structural components for all β-lactam chlorhexidine based GUMBOS are illustrated
in Figure 4.1. Using chlorhexidine di-ampicillin as a representative, inspection of its
spectroscopic properties indicates that both chlorhexidine and ampicillin are present in the
GUMBOS structure. More specifically, characteristic shifts in the 1H-NMR and

13

C-NMR

demonstrate changes in the chemical microenvironments of the ionic pairs, while particular
photo-physical properties of respective ions were still observed using absorbance spectroscopies.
Representative 1H-NMR and

13

C-NMR obtained for chlorhexidine di-ampicillin are shown in

Figures 4.2 and 4.3. Since all GUMBOS in this class contain chlorhexidine as the cation and
various β-lactam antibiotic analogs as the anions, only the details regarding chlorhexidine diampicillin will be discussed. However, structural assignments for all β-lactam based
chlorhexidine GUMBOS are provided in Sections 4.3.1.1 – 4.3.1.4.
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Figure 4.1 Molecular structures of dicationic chlorhexidine (top) and X counterions (from left to
right) acetate, ampicillin, oxacillin, and cephalothin and Y counterion carbenicillin. GUMBOS
consisting of chlorhexidine X consists of two anionic molecules electrostatically tethered to one
chlorhexidine molecule, whereas chlorhexidine Y consist of one carbenicillin molecule ionically
bound to chlorhexidine.
Proton NMR of the ampicillin structure reveals that H-2 and H-3β are in the same plane;
whereas H-5 and H-3α are in close proximity (Figure 4.2). Upon ion exchange, ampicillin’s H3α and H-3β protons experience isolated changes in their respective microenvironments which
caused a 0.28 ppm shift upfield from 1.45 to 1.18 ppm for H-3β protons. We attribute this
change to the close proximity of H-3β to either aromatic regions of chlorhexidine and secondary
ampicillin in its new conformation. In addition to the downfield shifts observed for the aromatic
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protons in ampicillin, the NH2+ groups in the guanidine structure shifted downfield from 7.51 to
8.54 ppm after exchanging the acetate anions for ampicillin.
The

13

C-NMR spectra for chlorhexidine di-ampicillin also shows the presence of both

cation and anion constituents (Figure 4.3). Beginning with the ampicillin molecule, three peaks
(i.e. 173.4, 167.5 and 167.3 ppm) correspond to the carbonyl groups (i.e. C-2α, C-7, and C-9) in
the anionic structure. Additionally, several peaks ranging between 122 – 139 ppm correlate to the
phenyl groups within both cation and anion. Tertiary carbons in the thiazolidine ring of
ampicillin (C-2) were confirmed by two peaks at 76 and 184 ppm. Contributions from the
carbons adjacent to the secondary amine-functionalized carbamimidoyl group (C-11 and C-12)
in the chlorhexidine cation and the primary and tertiary amines (i.e. C-10 and C-5) in the
ampicillin anion were evident by peaks shown at 60, 61, 59 and 68 ppm, respectively. Lastly, the
carbon peaks near 27 ppm are indicative of ampicillin’s C-3α and C-3β methyl groups and C-10
in the hexamethyl linker in the chlorhexidine di-ampicillin structure, respectively.
The molecular mass of chlorhexidine di-ampicillin was determined using ESI-TOF in the
positive-ion mode (Figure 4.4). The spectra gave a base peak at m/z 1203.4, which is assigned
[M + H]

+

of C54H66Cl2N16O8S2 (calc. 1202.24). This molecular formula corresponds to one

chlorhexidine and two ampicillin molecules. Table 4.1 lists other m/z peaks which were found to
correspond to monomer or [ampicillin – Na]+, dimer or 2 [ampicillin – Na]+, and 1:1
chlorhexidine hydride: ampicillin. These results suggest that the reaction between one molecule
of chlorhexidine and two molecules of ampicillin were successful.
The optical profile of chlorhexidine di-ampicillin was evaluated using CD and UV-vis
spectrophotometry (Figure 4.5 and 4.6). The analyte absorbed strongly in the UV range of the
spectrum which is typical of aromatic chromophores. Therefore, this analytical technique was
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used to qualify the presence of each parent ion in chlorhexidine di-ampicillin. Three
characteristic bands were evident in the absorption profile. The strong bands with a maximum at
208 and 259 nm are due to n – σ* and π- π* transitions from the chlorhexidine cation; whereas,
the weak absorbance band at 208 nm and 230 nm is attributed to the π- π* and n – π* transitions
in the ampicillin anion, respectively.29-31 Therefore, the optical rotation of chlorhexidine diampicillin was monitored between 200 and 300 nm.
The molar ellipticity profile of sodium ampicillin consists of a strong Cotton band
maximizing at about 232 nm, which suggests the intact β-lactam ring in the anionic structure.32, 33
This agrees with Rasmussen and Higuchi,42 who proved that losses in β-lactam drug activity can
be observed by monitoring the distinct optical rotary differences for intact and open β-lactam
rings. As such, the optical rotation was investigated for combinations of chlorhexidine diacetate
and sodium ampicillin and the chlorhexidine di-ampicillin GUMBOS. The molar ellipticities of
two ratios (e.g. 1:1 and 1:2 cation:anion) of chlorhexidine diacetate and sodium ampicillin were
investigated. In terms of the 1:1 combination of precursor ions, the ampicillin component rotated
optically at 232 nm. This shows that the presence of chlorhexidine diacetate does not disturb the
structural integrity of the ampicillin β-lactam ring. Since ampicillin is known to readily form
dimers causing its molar ellipticity to shift towards lower energies, the stoichiometric mixture of
chlorhexidine diacetate and sodium ampicillin were investigated.34 Similarly, a five nanometer
bathochromic shift was observed for the 1:2 ratio of chlorhexidine diacetate: sodium ampicillin
with a Cotton band at 237 nm. When investigating the molar ellipticity of chlorhexidine diampicillin, a similar positive peak was observed at 222 nm which confirms that the anionic
component was intact and that ampicillin did not form a dimeric species while exchanged with
chlorhexidine. This ten nanometer hypsochromic shift suggests that a higher energy is required
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to rotate the ampicillin molecules in the GUMBOS structure. We hypothesize the observed
hypsochromatism to have occurred due to intermolecular hydrogen bonding and electrostatic
attractive forces that restrict the molecular rotation of the ampicillin molecules within the
GUMBOS structure. Supported by the Franck-Condon Principle, molecular vibrations observed
by interactions with noninterfering concomitant molecules or adjacent molecules and a
chromophore are known to modify its nuclear coordinates of a chromophore analogous to the
solvation coordinate concept. Thus, the presence of both chlorhexidine and β-lactam antibiotics
(e.g. ampicillin, carbenicillin, oxacillin, or cephalothin) were confirmed using spectroscopy.

4.3.1.1 Chlorhexidine di-Ampicillin [CHX][Amp]
Off-white solid, yield 98%. Water solubility: 126 μg/mL. Ksp: 4.63 x 10-12 M3. 1H
NMR (400 MHz, DMSO-d6) δ 8.56 - 8.36 (m, 2 H). 7.21 - 7.50 (m, 18 H), 5.08 (d, J=2.74 Hz, 2
H), 4.96 (s, 4 H), 3.69 (d, J=3.13 Hz, 2 H), 3.26 (br. s., 2 H), 3.07 (dt, J=7.04, 6.65 Hz, 4 H),
1.85 (s, 4 H), 1.57 (s, 6 H), 1.49 (br. s., 4 H), 1.46 (br. quin., 4 H), 1.44 (br. s., 4 H), 1.27 (br.
quin., 4 H), 1.17 (s, 6 H), 1.15 (br. s., 2 H) 13C NMR (101 MHz, DMSO) δ 180.88, 172.88,
172.36, 166.94, 166.76, 139.07, 128.24, 127.01 – 128.43, 121.90, 76.07, 68.38, 60.80, 60.01,
58.64, 27.38, 26.76, 25.97. Anal. Calcd for C54H68Cl2N16O8S2: C, 53.86; H, 5.69; Cl, 5.89; N,
18.61; O, 10.63; S, 5.33. Found: C, 53.22; H, 5.81; Cl, 5.56; N, 18.37; S, 5.16. HRMS (ESI) m/z
calcd for C54H68Cl2N16O8S2, [M+H+], 1203.4424; found, 1203.4136.
4.3.1.2

Chlorhexidine Carbenicillin [CHX][Carb]
Colorless solid, yield 93%. Mp = 178°C decomp. Water solubility: 52 μg/mL. Ksp: 3.53

x 10-9 M2. 1H NMR (400 MHz, DMSO-d6) δ 0.69 - 0.76 (m, 1 H) 0.96 (s, 1 H) 1.06 (br. s., 2 H)
1.15 (br. s., 4 H) 1.34 (br. s., 4 H) 1.40 - 1.54 (m, 5 H) 1.61 (s, 2 H) 2.96 (br. s., 4 H) 3.07 (s, 1
H) 3.16 - 3.34 (m, 3 H) 3.43 (d, J=5.14 Hz, 1 H) 3.47 - 3.51 (m, 1 H) 3.52 - 3.56 (m, 1 H) 3.92 -
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3.99 (m, 1 H) 4.18 - 4.27 (m, 1 H) 4.82 (br. s., 1 H) 6.96 - 7.20 (m, 9 H) 7.28 (br. s., 3 H) 7.36 7.68 (m, 2 H) 8.24 - 8.35 (m, 1 H).

13

C NMR (101 MHz, DMSO) δ 128.71, 122.65, 108.20,

40.40, 40.19, 26.42. Anal. Calcd for C39H48Cl2N12O6S : C, 53.00; H, 5.47; Cl, 8.02; N, 19.02; O,
10.86; S, 3.63. Found: C, 51.12; H, 5.68; Cl, 7.74; N, 18.34; S, 3.50. HRMS (ESI) m/z calcd for
C39H48Cl2N12O6S, [M+], 883.8462; found, 883.8457.

4.3.1.3

Chlorhexidine di-Cephalothin [CHX][Ceph]
Orange solid, yield 83%. Water solubility: 218 μg/mL. Ksp: 1.89 x 10-11 M3. 1H NMR

(400 MHz, DMSO-d6) δ 1.27 (br. s., 5 H) 1.45 (br. s., 6 H) 1.79 (d, J=3.42 Hz, 1 H) 2.01 (s, 6 H)
3.07 (br. s., 5 H) 3.17 (s, 3 H) 3.27(d, J=17.61 Hz, 3 H) 3.33 (br. s., 4 H) 3.50 (d, J=17.36 Hz, 3
H) 3.77 (d, J=2.93 Hz, 4 H) 4.79 (d, J=11.98 Hz, 2 H) 5.00 (d, J=4.65 Hz, 3 H) 5.03(s, 1 H) 5.53
(dd, J=8.31, 4.89 Hz, 2 H) 6.89 - 6.98 (m, 5 H) 7.29 (d, J=8.80 Hz, 6 H) 7.33 - 7.38 (m, 2 H)
7.44 (d, J=8.31 Hz, 13 H) 9.03 (d, J=8.31Hz, 2 H)13C NMR (101 MHz, DMSO) δ 170.97,
170.41, 165.77, 163.59, 137.47, 134.44, 128.71, 127.04, 126.69, 125.39, 122.47, 113.60, 64.77,
59.12, 57.67, 40.63, 40.42, 36.23, 26.42, 25.64, 21.17. Anal. Calcd for C54H62Cl2N14O12S4: C,
49.96; H, 4.81; Cl, 5.46; N, 15.10; O, 14.79; S, 9.88. Found: C, 48.61; H, 4.99; Cl, 5.31; N,
14.70; S, 9.61. HRMS (ESI) m/z calcd for C54H62Cl2N14O12S4, [M+], 1298.3227; found,
1298.3199.
4.3.1.4

Chlorhexidine di-Oxacillin [CHX][Oxa]
Colorless solid, yield 85%. Water solubility: 167 μg/mL. Ksp: 8.38 x 10-12 M3. 1H

NMR (400 MHz, DMSO-d6) δ 8.99 (d, J = 9.0 Hz, 4H), 7.90 – 7.85 (br. m, 2H), 7.76 (d, J=7.6
Hz, 4H), 7.71 – 7.64 (br. S, 1H), 7.60 – 7.52 (br. m, 2 H). 7.52 - 7.43 (m, 15H), 7.38 (t, J = 7.4
Hz, 2H), 7.28 (d, J = 8.4Hz), 4.96 (d, J=8.0 Hz, 2 H), 4.61 (t, J = 8.4 Hz, 2H), 3.67 (s, 8 H),
3.40 ( s., 1 H), 3.27 (br. s., 2H), 3.05 (s, 4 H), 1.55 (s, 6H), 1.43 (br. m., 4H), 1.25(br. m., 4H),
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1.19 (s, 6H), 13C NMR (101 MHz, DMSO) δ 173.07, 1708.51, 169.46, 161.59, 159.98, 138.94,
129.85, 128.77, 128.22, 127.87, 121,84, 112.43, 75.22, 65.84, 59.67, 57.77, 52.01, 27.83, 26.02,
11.81. Anal. Calcd for C60H68Cl2N16O10S2: C, 55.08; H, 5.24; Cl, 5.42; N, 17.13; O, 12.23; S,
4.90. Found: C, 53.61; H, 5.40; Cl, 5.27; N, 16.67; S, 4.77. HRMS (ESI) m/z calcd for
C60H68Cl2N16O10S2, [M+], 1308.3191; found, 1308.3062.
4.3.2 Pharmacokinetic Properties and Bioavailability of β-lactam-based Chlorhexidine
GUMBOS
Pharmacokinetic properties of β-lactam-based chlorhexidine GUMBOS reveal an
increase in hydrophobicity and a reduction in first-order dissolution rates when the anion is
changed from acetate to an antibiotic (Figure 4.7). Dissolution rates were found to be 0.133
min-1, 0.109 min-1, 0.044 min-1, and 0.038 min-1 for chlorhexidine di-ampicillin, chlorhexidine
carbenicillin,

chlorhexidine

di-cephalothin,

and

chlorhexidine

di-oxacillin

GUMBOS,

respectively. It was also observed that aqueous solubility increases with molecular weight and
chlorhexidine-anion stoichiometry in which the anions rank in this order:
carbenicillin < ampicillin < cephalothin < oxacillin
This suggests that tuning molecular weight and ionic stoichiometry can affect the relative
hydrophobicity and dissolution rates of the GUMBOS.
Table 4.1. Diffusion rates and predicted intestinal permeability acquired using PAMPA GenTest
assay.
Pe (cm/s)

Log Pe

Sodium ampicillin

1.81 x 10-5

-4.93

Chlorhexidine diacetate

9.39 x 10-7

-6.02

Chlorhexidine di-ampicillin

4.03 x 10-6

-5.39
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Figure 4.2. Proton (1H)-NMR of chlorhexidine di-ampicillin.
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Figure 4.3. Carbon ( C)-NMR of chlorhexidine di-ampicillin. The peaks indicative of either ion are labeled as CHX (chlorhexidine)
and AMP (ampicillin) in addition to their color coated structural assignments in the embedded picture.
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Figure 4.4. Mass spectra of chlorhexidine di-ampicillin GUMBOS in both negative-ion mode
(top) and positive-ion mode (bottom).
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Figure 4.5. Optical ellipticities of chlorhexidine di-ampicillin (solid) and sodium ampicillin
(dashed) in PBS (100mM, pH 7.4).
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Figure 4.6. Absorbance spectra of chlorhexidine di-ampicillin in methanol.
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Table 4.2. List of ions with structures detected in positive-ion and negative-ion mode.

Name

Theoretical
Mass –to-Charge

Structure

Experimental Mass –to-Charge
[M + H]+

[M - H]-

1203.4276

1201.4159

Chlorhexidine di-ampicillin

1202.4235

Chlorhexidine ampicillin hydride

853.3128

852.3061

Ampicillin dimer

698.2193

697.2105

Chlorhexidine acetate hydride

564.2243

563.2119

Chlorhexidine base

505.4466

505.2187

Chlorhexidine fragment

423.9457

424.1974

Chlorhexidine fragment

335.8351

336.1724

Ampicillin monomer

349.1046
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Figure 4.7. Release and first-order dissolution profiles of β-lactam based chlorhexidine GUMBOS in deionized water at 298 K.
MW
625.65
1202.4
1308.32
1298.32
883.85

T= 298K
Chlorhexidine diacetate
Chlorhexidine di-ampicillin
Chlorhexidine di-oxacillin
Chlorhexidine di-cephalothin
Chlorhexidine carbenicillin
na: not acquired due to high solubility
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K1 Rate/ min-1
(r2)
na
0.133 (0.99)
0.109 (0.97)
0.044 (0.97)
0.038 (0.98)

Solubility (µg/mL)
19000
125.8
166.3
150.32
52.5
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Bioavailabilities of β-lactam-based chlorhexidine GUMBOS show that antibioticchlorhexidine ionic pairs have better intestinal permeability than the acetate form (Table 4.2).
Human intestinal absorption (HIA) was found to range between 86 – 95% for β-lactam-based
chlorhexidine GUMBOS which is 20% better absorption over the use of chlorhexidine diacetate.
The mean effective permeability coefficients (Pe) for β-lactam-based chlorhexidine GUMBOS in
200µM PBS were found to be 9.39 (+/- 0.87) x 10-7 cm/s, 4.03 (+/- 1.03) x 10-6 cm/s, 3.67 (+/0.74) x 10-6 cm/s, 4.98 (+/- 0.087) x 10-6 cm/s, and 4.91 (+/- 0.17) x 10-6 cm/s for chlorhexidine
diacetate, chlorhexidine di-ampicillin, chlorhexidine carbenicillin, chlorhexidine di-cephalothin,
and chlorhexidine di-oxacillin, respectively. Statistical analysis showed that the intestinal
permeability of chlorhexidine diacetate was significantly increased by the use of antibiotics as
anions (p<0.05). However, there was no significant difference between Pe values for the
GUMBOS, indicating that the intestinal permeation was independent of the cationic moiety.
4.3.3

Anti-EHEC Activity

4.3.3.1

Representative Combination Antibacterial Activity with Chlorhexidine Diacetate
and Sodium Ampicillin
Different ratios of sodium ampicillin and chlorhexidine diacetate were found to have

varying antibacterial activities against 6 EHEC isolates and E. coli 25922 (Figure 4.8). The most
susceptible strain to either chlorhexidine diacetate, sodium ampicillin, or the various mixtures
was found to be E. coli O157:H7 strain 43895. Additionally, EHEC isolates from chicken 301
and human 43890 showed the greatest susceptibility to chlorhexidine diacetate alone.
Chlorhexidine diacetate antibacterial activity was less effective on EHEC pork 204P and beef
933 isolates and E. coli 25922. Sodium ampicillin was preferentially more active on two out of
the seven E. coli strains investigated although all MIC values were less than 10 µM (4µg/mL) as
shown in Figure 4.8. All isolates tested were susceptible to both chlorhexidine diacetate and
sodium ampicillin.
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Table 4.3. Sources of Escherichia coli Strains

Strain

Characteristics

Escherichia coli 25922*

Quality control strain, Clinical isolate (stx1-, stx2-)

Escherichia coli O157:H7 43895*

Hamburger isolate(stx1+, stx2+)

Escherichia coli O157:H7 43889*

Human isolate (stx1-, stx2+)

Escherichia coli O157:H7 43890*

Human isolate (stx1+, stx2-)

Escherichia coli O157:H7 301C**

Chicken isolate (stx1+, stx2+)

Escherichia coli O157:H7 204P**

Pork isolate (stx1+, stx2+)

Escherichia coli O157:H7 933 **

Beef isolate (stx1+, stx2+)

Escherichia coli O157:H7 C7929**

Apple cider isolate (stx1+, stx2+)

* American Type Culture Collection, Manassas, VA
** Michael P. Doyle, University of Georgia, GA
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Figure 4.8. Antibacterial activities of chlorhexidine diacetate and sodium ampicillin in combination against E. coli 25922 and E. coli
O157:H7 strains isolated from different sources.
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Figure 4.9. Antibacterial activities of three mixtures of chlorhexidine diacetate and sodium ampicillin against E. coli 25922 and E.
coli O157:H7 strains isolated from different sources.
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Figure 4.10. Interaction indices for mixtures of chlorhexidine diacetate and sodium ampicillin against E. coli 25922 and E. coli
O157:H7 strains isolated from different sources.
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When investigating the antibacterial activities of chlorhexidine diacetate and sodium
ampicillin in mixtures, it is apparent that EHEC inhibition varies among strains. Overall, MIC
values worsened as the abundance of sodium ampicillin increased to more than 50%, with
greatest antagonism observed in E. coli 25922. When specifically examining the stoichiometric
equivalent to the chlorhexidine di-ampicillin GUMBOS, the mixture is more effective against
EHEC isolates than E. coli 25922 (Figure 4.9). The most effective antibacterial combination
consisted of 66.6% chlorhexidine diacetate and 33.3% sodium ampicillin. Therefore, the
effective combinations of chlorhexidine diacetate and sodium ampicillin required a larger
abundance of chlorhexidine diacetate than sodium ampicillin.
Figure 4.10 reveals the interaction indices obtained for combinations of chlorhexidine
diacetate and sodium ampicillin in which majority of them were neutral. Increasing
concentrations of sodium ampicillin resulted in increasing antagonism within mixtures.
Synergetic responses are evident in concentrations greater than 50% chlorhexidine diacetate. As
percentages of chlorhexidine diacetate exceeded 75%, interactions with sodium ampicillin led to
antagonism and additivity.
4.3.3.2

Chlorhexidine di-Ampicillin
The antibacterial activities of the reacted chlorhexidine di-ampicillin GUMBOS were

compared to chlorhexidine diacetate and sodium ampicillin and the stoichiometric combination
of parent salts against EHEC (Table 4.4). Chlorhexidine di-ampicillin inhibited EHEC growth at
a concentration ranging from 0.05 to 0.10 µM with an average inhibition observed at 0.07 µM.
The average MICs for chlorhexidine diacetate and sodium ampicillin were 0.3 µM and 6.5 µM,
respectively. Average inhibitory concentrations for the mixed salts (1:2 chlorhexidine diacetate
and sodium ampicillin, v/v%) was determined to be 2.1 µM. Thus, chlorhexidine di-ampicillin
required 28 – 154 and 8 – 49 times lower concentration to inhibit the growth of EHEC isolates
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than sodium ampicillin and the combination of parent salts, respectively. Although comparable,
chlorhexidine di-ampicillin was 2-10 times more effective than chlorhexidine diacetate, with an
average 4-fold improvement in MIC. Growth observed 24h after plating non-turbid MIC wells
demonstrated that chlorhexidine di-ampicillin is bacteriostatic at lower concentrations, but
bactericidal at concentrations greater than 7.3 µM (103x chlorhexidine di-ampicillin MIC).
4.3.3.3

Chlorhexidine Carbenicillin
The antibacterial activities of the reacted chlorhexidine carbenicillin GUMBOS were

compared to chlorhexidine diacetate and disodium carbenicillin (Table 4.5). Chlorhexidine
carbenicillin inhibited EHEC strain 43895 growth with 0.11 µM. The average MICs for
chlorhexidine diacetate and disodium carbenicillin were 0.3 µM and 93.75 µM, respectively.
Chlorhexidine carbenicillin required 3 and 852 times lower concentration to inhibit the growth of
EHEC isolates than chlorhexidine diacetate and disodium carbenicillin, respectively. Similar to
chlorhexidine di-ampicillin, comparable antibacterial activity to chlorhexidine diacetate was
observed for chlorhexidine carbenicillin. Additionally, chlorhexidine carbenicillin is considered
to be bacteriostatic since its MBC (i.e. 3.3 µM) is greater than its MIC by nearly 30x.
4.3.3.4

Chlorhexidine di-Cephalothin
The antibacterial activity of chlorhexidine di-cephalothin was compared to chlorhexidine

diacetate and sodium cephalothin (Table 4.5). Chlorhexidine di-cephalothin inhibited EHEC
strain 43895 growth with 0.10 µM. The average MICs for chlorhexidine diacetate was 0.3 µM.
The antibacterial activity of sodium cephalothin was found to be 104 µM. Thus, chlorhexidine
di-cephalothin required 3 and 1040 times lower concentration to inhibit the growth of EHEC
isolates than chlorhexidine diacetate and sodium cephalothin, respectively. The MBC obtained
for chlorhexidine di-cephalothin was also 3.3 µM which exceeds its MIC by 33-fold.
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4.3.3.5

Chlorhexidine di-Oxacillin
The antibacterial activity of chlorhexidine di-oxacillin was compared to chlorhexidine

diacetate and sodium oxacillin (Table 4.5). Chlorhexidine di-cephalothin inhibited EHEC strain
43895 growth with 0.13 µM. The average MICs for chlorhexidine diacetate was 0.3 µM. The
antibacterial activity of sodium cephalothin was found to be 98 µM. Thus, chlorhexidine dicephalothin required 3 and 753 times lower concentration to inhibit the growth of EHEC isolates
than chlorhexidine diacetate and sodium oxacillin, respectively. The MBC obtained for
chlorhexidine di-cephalothin was also 3.3 µM which exceeds its MIC by 26-fold.
4.3.4 Interaction Indices
Interaction indices tabulated for GUMBOS were compared to the mixture of precursor
salts in Table 4.6. Synergy was observed for chlorhexidine di-ampicillin in all EHEC isolates
(Iavg = 0.28), whereas, both antagonism and additivity (Iavg = 3.3) were seen for the
stoichiometric mixture in 71% and 29% of the test organisms, respectively. Additivity was
observed for chlorhexidine di-ampicillin and the mixture against E. coli 25922.
Table 4.7 lists the interaction indices obtained for GUMBOS against E. coli O157:H7
strain 43895 and E. coli ATCC 25922. The results reveal that all β-lactam based chlorhexidine
GUMBOS were synergetic against E. coli O157:H7 strain 43895 with increased synergy by
anion type in the following order:
Ampicillin < Carbenicillin < Cephalothin < Oxacillin
Interaction indices for the GUMBOS follow a similar trend, despite chlorhexidine di-ampicillin
additivity, against E. coli ATCC 25922.
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Table 4.4. Minimum inhibitory concentrations (µM) of antibacterial agents against E. coli O157:H7 strains isolated from different
sources. Standard deviations are from three measurements.

E. coli

Chicken

Pork

Beef

25922

301C

204P

933

Chlorhexidine
diacetate

0.3 ± 0.1

0.6 ± 0.05

0.1 ± 0.02

Sodium
ampicillin

7±1

4 ± 0.5

5 ± 0.1

7 ± 0.1

Combination
1 Chlorhexidine
diaceate:2 Sodium
Ampicillin

0.8 ± 0.1

2 ± 0.3

0.4 ± 0.1

1 ± 0.3

Chlorhexidine
di-ampicillin

0.3 ± 0.1

0.06 ± 0.02

Apple
Cider
C7929

0.4 ± 0.06 0.3 ± 0.07

Human

43895

43889

Human
43890

0.2 ± 0.03

0.3 ± 0.05

0.2 ± 0.03

10 ± 0.3

2 ± 0.2

10 ± 0.1

7 ± 0.3

7±1

0.7 ± 0.1

2 ± 0.03

2 ± 0.06

0.08 ± 0.02

0.06 ± 0.02

0.07 ± 0.02

0.05 ± 0.01 0.08 ± 0.04 0.1 ± 0.04
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Hamburger

Table 4.5. Average minimum inhibitory concentrations (µM) of β-lactam-based chlorhexidine GUMBOS against E. coli ATCC 25922
and E. coli O157:H7 ATCC 43895. Standard deviations are from six measurements.
E. coli

E. coli

25922

43895

Chlorhexidine diacetate

0.28 ± 0.03

0.23 ± 0.02

Chlorhexidine di-ampicillin

0.26 ± 0.10

0.08 ± 0.04

Chlorhexidine carbenicillin

0.22 ± 0.06

0.11 ± 0.03

Chlorhexidine di-cephalothin

0.20 ± 0.07

0.10 ± 0.03

Chlorhexidine di-oxacillin

0.20 ± 0.06

0.13 ± 0.04
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Table 4.6. Calculated interaction indices (classification denoted in parentheses, where A = Antagonism, N = Neutral, and S =
Synergy) for chlorhexidine di-ampicillin GUMBOS and the combined parent salts according a modified Loewe's Additivity Model.

E. coli Chicken

Pork

Beef

25922

204 P

933

301 C

Apple
Cider
C7929

Hamburger

Human

Human

43895

43889

43890

10.1 (A)

1.5 (N)

2.0 (N)

5.1 (A)

0.5 (S)

0.3 (S)

0.2 (S)

0.3 (S)

Stoichiometric
Combination
1 Chlorhexidine
2.8 (N) 1.4 (N) 1.9 (N) 1.2 (N)
diaceate:2 Sodium
Ampicillin

GUMBOS
Chlorhexidine
di-Ampicillin

0.9 (N) 0.1 (S) 0.5 (S)

0.1 (S)
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Table 4.7. Calculated interaction indices (classification denoted in parentheses, where A = Antagonism, N = Neutral, and S =
Synergy) for β-lactam based chlorhexidine GUMBOS according a modified Loewe's Additivity Model.

E. coli

E. coli

25922

43895

Chlorhexidine di-ampicillin

0.88 (A)

0.28 (S)

Chlorhexidine carbenicillin

0.47 (S)

0.23 (S)

Chlorhexidine di-cephalothin

0.33 (S)

0.22 (S)

Chlorhexidine di-oxacillin

0.21 (S)

0.19 (S)
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Figure 4.11. Killing kinetics of E. coli O157:H7 ATCC 43895 at 7.3 µM chlorhexidine di-ampicillin (Δ) and chlorhexidine diacetate
(□) as compared to the control (◊). Error bars represent standard deviations from three measurements.
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4.3.5 Time-kill Activity of Chlorhexidine di-ampicillin on E. coli O157:H7 43895
Bactericidal rates for chlorhexidine di-ampicillin and chlorhexidine diacetate were
monitored at the MBC for chlorhexidine di-ampicillin against 106 CFU/ml, (Figure 4.11). A
minimum of five hours minimal was required to kill 106 CFU/mL bacteria at 7.3 µM for both
chlorhexidine salts.
4.3.6 Mechanism of Action Studies

Figure 4.12. Effect of GUMBOS on E.coli O157:H7 ATCC 43895 outer membranes in absence
(top) and presence (bottom) of 5mM magnesium ions. Results normalized to NPN membrane
fluorescence obtained by EDTA as negative control.
4.3.6.1

Effects of Divalent Cations on EHEC Susceptibility to GUMBOS
The effects of divalent cations on the antibacterial susceptibility of chlorhexidine salts to

E. coli O157:H7 strain 43895 was evaluated. The addition of 200 µM Ca2+ or Mg2+ antagonized
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the antibacterial activity of all β-lactam based chlorhexidine GUMBOS equally to chlorhexidine
diacetate (data not shown). This attenuation in antibacterial activity suggests that excess divalent
cations interfere with the membrane activity of these agents and that the ions play a vital role in
the GUMBOS mechanisms of action.
4.3.6.2

Effects of GUMBOS on Permeability of E. coli O157:H7 strain 43895 Outer
Membrane
To determine whether GUMBOS targeted the outer membranes of EHEC, we performed

the NPN assay. No fluorescence accumulation was evident when GUMBOS or starting materials
were added to the buffer containing NPN absent of cells. The addition of GUMBOS to EHEC
cells in the presence of NPN caused a time-dependent increase in fluorescence with fluorescence
stability occurring at 3 minutes. Equal membrane permeation for all salts at concentrations below
30 µM was observed (data not shown). At higher concentrations, the greatest damage in
membrane integrity was observed by chlorhexidine di-ampicillin in the absence of extraneous
magnesium ions (Figure 4.12). Enhanced membrane permeation, with respect to EDTA,
decreases in the following order: chlorhexidine di-cephalothin > chlorhexidine carbenicillin >
chlorhexidine di-oxacillin > chlorhexidine diacetate. As expected, EDTA also caused increases
in fluorescence intensity without subsequent cell death. At the largest concentration,
chlorhexidine di-cephalothin causes 10.5x more membrane damage than EDTA. Chlorhexidine
di-ampicillin permeates the outer membrane 6x more effectively than EDTA. Chlorhexidine dioxacillin, chlorhexidine carbenicillin, and chlorhexidine diacetate detrimentally impacts the
membrane 2.5, 2, and 0.8 times better than EDTA. At lower concentrations, the extent of damage
is attenuated and the GUMBOS membrane activity are equally 2 times better than EDTA
Normalized results demonstrate that six times less concentration of GUMBOS can permeate
bacteria cells more efficiently than 250 µM EDTA. To confirm disrupted action on the outer
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membrane via replacement of divalent cations with β-lactam based chlorhexidine GUMBOS, we
investigated whether the divalent cations inhibited the increase in NPN fluorescence. Similar to
EDTA, we found that the addition of either Ca2+ or Mg2+ inhibited the increase in NPN
fluorescence induced by all chlorhexidine salts. Thus, the membrane activities of GUMBOS and
chlorhexidine diacetate to the cellular outer membrane are antagonized by the presence of excess
magnesium or calcium (Figure 4.12B). This indicates that displacement of divalent ions is an
important feature for activity.
4.3.6.3

Effects of GUMBOS on E. coli O157:H7 strain 43895 Membrane Potential
Beta-lactam based chlorhexidine GUMBOS caused different extents of membrane

depolarization at concentrations above 4 µM. More specifically, greater depolarization was
achieved using chlorhexidine di-ampicillin as compared to the other chlorhexidine salts. Even
more so, all GUMBOS outperformed chlorhexidine diacetate (Figure 4.13). The GUMBOS’
ability to depolarize E. coli outer membranes decrease in the following order: chlorhexidine diampicillin, chlorhexidine di-cephalothin, chlorhexidine di-oxacillin, and chlorhexidine
carbenicillin. Our results show that chlorhexidine diacetate is unable to depolarize EHEC cellular
outer membranes as efficiently as GUMBOS.
4.3.6.4 GUMBOS Activity on LPS-Rich and Deficient E. coli
Antibacterial activity against wild-type and increased membrane permeable E. coli strains
show that chlorhexidine di-ampicillin GUMBOS were 17x more effective in inhibiting E. coli
imp4213 than wild-type E. coli (Figure 4.14). Likewise, chlorhexidine carbenicillin and
chlorhexidine di-oxacillin preferentially inhibited E. coli imp4213 by 9x and 8x, respectively.
This implies that β-lactam based chlorhexidine GUMBOS are able to cross the LPS-deficient
outer membrane of imp4213 more readily than the LPS-rich membrane that is present in wildtype E. coli. The MICs for chlorhexidine diacetate and GUMBOS were comparable in imp4213

154

A)

160

100
90

120

Δψ Membrane Potential

Red/Green Fluorescence

140

B)

100
80
60
40
20

80
70
60
50
40
30
20
10

0
0.0

50.0

100.0
150.0
200.0
GUMBOS Concentration (µM)

Chlorhexidine dicetate
Chlorhexidine Carbenicillin
Chlorhexidine di-Oxacillin

250.0

300.0

Chlorhexidine di-ampicillin
Chlorhexidine di-Cephalothin

0

0.0

50.0

100.0
150.0
200.0
GUMBOS Concentration (µM)

Chlorhexidine dicetate
Chlorhexidine Carbenicillin
Chlorhexidine di-Oxacillin

250.0

300.0

Chlorhexidine di-ampicillin
Chlorhexidine di-Cephalothin

Figure 4.13. Changes in Escherichia coli O157:H7 ATCC 43895 membrane potentials using DIOC2 stained cells treated with
increasing concentrations of GUMBOS. The Panel (A) show the red/green ratiometric fluorescence obtained for different
concentration of GUMBOS. Using the Nernst equation, results in Panel (A) are converted to membrane potential values as shown in
Panel (B). GUMBOS Error bars represent standard deviations from nine measurements.
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inhibition; whereas, variable differences in antibacterial activity were observed with GUMBOS
treatment on wild-type E. coli.
Antibacterial activity on wild-type E. coli occurred in the following order: chlorhexidine
di-ampicillin > chlorhexidine diacetate = chlorhexidine carbenicillin > chlorhexidine dioxacillin. We attribute this order to the already established mechanism of action for
chlorhexidine salts that contain a bio-inactive counter-ion (i.e. dihydrochloride, diacetate, or
digluconate).9-11, 35-39 Regardless of the anion, GUMBOS still interact with the outer membrane
of Gram-negative bacteria at divalent-cation-binding sites on LPS, displaces stabilizing divalent
cations, and causes outer membrane permeation similarly to other polycationic antibiotics.
Furthermore, β-lactam antibiotics do not interfere with the membrane activity when
chlorhexidine is used in the form of GUMBOS.

Figure 4.14. Antibacterial activity of β-lactam based chlorhexidine GUMBOS against wild-type
and imp4213 E. coli strains.
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4.3.6.5

Effects of GUMBOS on membrane integrity of E. coli O157:H7 strain 43895.
Scanning electron micrographs of post-treated EHEC revealed elongated cells following

exposure to sodium ampicillin (Figure 4.15B). The cell surface for both untreated (Figure 4.15A)
and sodium ampicillin treated EHEC present a smooth cell surface. Evaluation of imaged cells
showed that untreated and sodium ampicillin treated cells maintained ultra-structural integrity of
the outer membrane. Figures 4.15C and 4.15E illustrated that chlorhexidine diacetate and the
mixture of salts disrupted the outer membrane of EHEC, as indicated by the ruffled surface of
the cells. In addition to the ruffled cellular surface similar to chlorhexidine diacetate, there was
long, undivided cells which is a feature of ampicillin treatment (Figure 4.15E). Our results
demonstrate that > 90% of chlorhexidine di-ampicillin-exposed cells suffered from inner and
outer membrane perturbation, which caused the intracellular materials to leak (Figure 4.15D).

A

B

C

D

E

E

Figure 4.15. SEM images of A) untreated and antibacterial treated E. coli O157:H7 ATCC
43895 with B) 50 µM sodium ampicillin, C) 50 µM chlorhexidine diacetate, D) 50 µM
chlorhexidine di-ampicillin, and E) 50 µM stoichiometric mixture of parent salts.
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4.3.7 Cytotoxicity
Potential routes of administration were evaluated by monitoring acute mammalian
cytotoxicity using HeLa cervical cells, NIH/3T3 fibroblasts, and EOMA endothelial cellular
lines (Table 4.8). Overall, cytotoxicity of the investigated chlorhexidine salts and stoichiometric
molar drug combinations increases in this order, ampicillin <oxacillin <cephalothin <acetate
≤carbenicillin. Differences observed between cellular lines may indicate tunable therapeutic
indices amongst chlorhexidine salts and potential expansion in administration routes. The
impacts GUMBOS have on each cellular line tested are described in more detail in the
subsequent sections.
4.3.7.1

Cytotoxicity to HeLa Cervical Cells
Cytotoxicity using HeLa cells is shown in Table 4.8. The acute toxicities (LD

50)

of

GUMBOS were determined to range between 44 to 149 µM. More specifically, the toxicity of
chlorhexidine diacetate, sodium ampicillin, and combined chlorhexidine diacetate and sodium
ampicillin was 43, and >400, and 76 µM, respectively. Chlorhexidine di-ampicillin is less toxic
to cervical cells than starting materials and combined precursor ions with a LD50 of 149 µM. This
GUMBOS is able to attenuate cytotoxicity nearly 2 – 3.5 times in comparison to chlorhexidine
diacetate and the stoichiometrically combined chlorhexidine diacetate and sodium ampicillin
salts, respectively. Although not as statistically significant from the mixture of chlorhexidine and
antibiotic, both chlorhexidine di-cephalothin and chlorhexidine di-oxacillin had improved LD50
values from chlorhexidine diacetate. Chlorhexidine carbenicillin is the only GUMBOS that had a
LD50 value similar to chlorhexidine diacetate and worse than stoichiometric mixture of
chlorhexidine diacetate and disodium carbenicillin. Reduced toxicity to cervical cells validates
the use of some chlorhexidine salts systemically.
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4.3.7.2

Cytotoxicity to NIH/3T3 Fibroblast Cells
Cytotoxicity results to NIH/3T3 fibroblasts reveal that β-lactam based chlorhexidine

GUMBOS are as equally nontoxic as chlorhexidine diacetate. As expected, β-lactam antibiotics
were not toxic within the concentration range tested and cell viability did not significantly vary
between chlorhexidine diacetate, mixtures, and GUMBOS when investigating acute toxicity
against NIH/3T3 fibroblast cells. However, polytherapeutic mixtures containing chlorhexidine
and antibiotic are more cytotoxic than β-lactam based chlorhexidine GUMBOS. Since
chlorhexidine diacetate is commonly used non-systemically, or as a topical disinfectant, this
shows that the novel chlorhexidine salts can continually be used topically without inflicting
additional toxicity.
4.3.7.3

Cytotoxicity to EOMA Endothelial Cells
Similar to HeLa cells, GUMBOS treatment on EOMA endothelial cells show variable

cytotoxicity. For instance, chlorhexidine carbenicillin and chlorhexidine di-oxacillin are more
toxic to endothelial cells than chlorhexidine diacetate. On the other hand, chlorhexidine diampicillin and chlorhexidine di-cephalothin are less toxic, with the latter by nearly 2x
chlorhexidine diacetate. These differences in cytotoxicity show that some GUMBOS are safe to
use systemically when large concentrations are considered. However, the antibacterial activities
of these salts against EHEC are more than 1000x less than their respective EOMA LD50 values
which suggests their safe use systemically.
Acute toxicity for chlorhexidine diacetate, antibiotic, and GUMBOS was determined in
vitro using HeLa, NIH/3T3, and EOMA cells. The LD50 values against all cells were about 43
µM or 2.7% w/v for chlorhexidine diacetate which agrees with previously published values.
Such concentrations of chlorhexidine have caused mild to severe inflammatory responses as well
as induced apoptosis, necrosis, and over-expression of cellular stress indicators when used
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systemically.40-43 Reports indicate that cytotoxicity results in mild to severe discomfort when
increasing quantities of chlorhexidine are ingested, although it is poorly absorbed. Additionally,
its use intravenously has caused hypotonic-induced hemolysis.9 Since literatures supports that a
2% concentration of chlorhexidine may detrimentally affect host tissues, reducing the apparent
toxicity associated with chlorhexidine in the GUMBOS structure is priority. At the LD50 for
chlorhexidine diacetate, mammalian cells treated with GUMBOS resulted in better cell viability.
Thus, our results suggest that these cells were more sensitive to the toxic effects of chlorhexidine
diacetate and its use with antibiotics in stoichiometric combination at concentrations above 3
µM. Interestingly, the addition of antibiotic molecules to the chlorhexidine structure as a mixture
or GUMBOS was able to reduce the cytotoxic effects of chlorhexidine on mammalian cells. This
approach demonstrates that the reacted GUMBOS have potential to extend the antibacterial
efficacy of antibiotics while reducing toxicities associated with chlorhexidine diacetate.
In summary, GUMBOS toxicity to fibroblasts was similar as each salt but different with
HeLa and EOMA cells. Both HeLa and EOMA viabilities are similar in β-lactam based
chlorhexidine GUMBOS where ampicillin is the least toxic anion used and carbenicillin is the
most. We attribute this to the cation-anion stoichiometry and anion size among GUMBOS. More
specifically, a 3-fold increase in chlorhexidine carbenicillin toxicity to HeLa cells was observed
when compared to chlorhexidine di-ampicillin. We attribute this difference in toxicity to the
structural difference between the two antibiotics. It is apparent that modifying C-8 to a
carboxylate (i.e. carbenicillin) forms a dianionic species that has a 1:1 cation-anion stoichiometry
with chlorhexidine. This differs from the 1:2 stoichiometry of chlorhexidine di-ampicillin that
has a primary amine on C-8 instead of a carboxylate like in carbenicillin. When comparing all
GUMBOS to chlorhexidine carbenicillin, it is apparent that this molecular change most
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negatively affected the cell viability of mammalian cells. Furthermore, the differences in acute
toxicity infer that chlorhexidine di-ampicillin, chlorhexidine di-cephalothin, and chlorhexidine
di-oxacillin would be better GUMBOS to use during the treatment of a systemic infection since
they are less cytotoxic than the other chlorhexidine salts investigated. These results indicate that
β-lactam based chlorhexidine GUMBOS are safer alternatives to antibiotic-chlorhexidine drug
mixtures when used either topically or systemically.

Table 4.8. Acute cytotoxicity (LD50) of chlorhexidine di-ampicillin, chlorhexidine diacetate,
sodium ampicillin, and the stoichiometric equivalent on HeLa cells. Standard deviations from
four measurements.
Antimicrobial Agent

HeLA

NIH/3T3

EOMA

Chlorhexidine diacetate

43 ± 6

47 ± 2

80 ± 3

Chlorhexidine di-Ampicillin

149 ± 4

48 ± 3

109 ± 6

Chlorhexidine diacetate + Sodium Ampicillin

76 ± 9

43 ± 2

67 ± 11

Chlorhexidine Carbenicillin

44 ± 7

48 ± 7

73 ± 10

Chlorhexidine diacetate + Disodium
Carbenicillin

58 ± 13

51 ± 4

59 ± 4

Chlorhexidine di-Cephalothin

79 ± 12

52 ± 5

150 ± 13

Chlorhexidine diacetate + Sodium
Cephalothin

64 ± 9

52 ± 6

103 ± 14

Chlorhexidine di-Oxacillin

139 ± 6

48 ± 4

97 ± 16

Chlorhexidine diacetate + Sodium Oxacillin

102 ± 21

44 ± 4

92 ± 7
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4.4

Discussion
The broth dilution technique indicated that GUMBOS were effective in inhibiting

bacterial growth at 24 h when challenged with several EHEC isolates with MIC ranging between
0.05 – 0.15 µM. These concentrations were significantly better than the MIC values obtained for
mixtures of commercial chlorhexidine diacetate and antibiotic. This observation demonstrates
that the GUMBOS would be a more effective antibacterial agent than simply using the two
parent agents in combination on E. coli O157:H7. Likewise, interaction indices classify
GUMBOS to be a synergetic ionic pair in comparison to the additive nature of the parent salts in
mixture. Thus, our results indicate that the co-administration of antibiotic and chlorhexidine
diacetate will not achieve similar synergy as observed by the reacted GUMBOS. Additionally,
minimum bactericidal concentrations obtained for GUMBOS were comparable to the effective
concentration used to eradicate EHEC from cattle in a study by Naylor et al.8 Time-kill results
also show that GUMBOS are rapidly bactericidal as chlorhexidine diacetate. Such a quick
reduction in cell number has been previously reported for chlorhexidine salts.44,
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Overall,

GUMBOS are bacteriostatic at lower concentrations and bactericidal at higher concentrations.
This type of antibacterial activity is similar to chlorhexidine diacetate. At low concentrations,
chlorhexidine is bacteriostatic primarily disrupting the bacterium’s osmotic equilibrium and
causing the internal contents to leak; however, at higher concentrations of chlorhexidine, the
contents of the bacterial cell begins to precipitate out.46
Since β-lactam chlorhexidine GUMBOS is composed of two separate and distinct
antimicrobial agents, it is important to understand the underlying mechanism of their synergetic
behavior and how it differs from the mixture of the two parent salts as combination drug therapy.
Keeping the principle of combination antibiotic design in mind, investigating novel ion-pairs

162

with desirable synergistic combinations can allow lower concentrations of drugs within
combinations to be implemented.47 Thus, integrating the membrane active chlorhexidine cation
and cell wall targeting β-lactam antibiotic into a GUMBOS is hypothesized to deliver a lethal
impact with a novel mechanism to decontaminate E. coli O157:H7 from infected cattle. Within
this mechanism of action, we believe a hybridization of the independent activities and physical
and chemical properties are governing the enhanced membrane activity at a localized site on the
bacterial cell. Our results support that the mechanism of action for chlorhexidine is conserved
within the β-lactam based chlorhexidine GUMBOS and that the antibiotic compliments this
activity by modifying the physical and chemical properties of the antiseptic-antibiotic conjugate.
To achieve equal membrane disruption, the mixture of salts would require the unlikely
probability of antibiotic molecules and a chlorhexidine molecule arriving at the cell in a localized
lethal dose and it reacting to subsequently change the physico-chemical properties of
chlorhexidine. With this, the mechanism of action for GUMBOS must use attractive forces
between the cation (chlorhexidine) and anion (antibiotic) to contain the ionic pair and remain as
one unit while it inflicts antibacterial activity.
Supported by an approach commonly known as ion pair transport, reacting counter-ions
with active pharmaceutical agents has successfully been used to increase the lipophilicity,
physiological compatibility, and poor bioavailability of certain hydrophilic drugs.48, 49 Thus, this
method has shown effective in improving cellular uptake of hydrophilic drugs and to increase its
overall molecular lipophilicity at the site where activity is to take place. 50 Neubert and Dittrich
reported that the incorporation of various lipophilic counter-ions on ampicillin improved its
transport across cellular membranes.51 Therefore, the increased hydrophobicity of chlorhexidine
as a counter-ion was expected to improve the membrane transport of antibiotic and
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simultaneously maintain its antibacterial activity.52 Our results support that β-lactam based
chlorhexidine GUMBOS as ion-pair are more hydrophobic than the more soluble antibiotic and
chlorhexidine diacetate salts and can traverse membranes more efficiently. Lengsfeld et al. also
found that hydrophobic ion pairs cross cell membranes easier than hydrophilic ionizable drugs,
and the associated antibiotics show better minimum inhibitory concentrations than their parent
salts.50 Therefore, the greater lipophilicity of the GUMBOS is a more efficient membrane
permeant than other chlorhexidine salts (i.e. dihydrochloride, diacetate, or digluconate) with
biologically inactive counter-ions.9-11,

36, 37, 39

Therefore, improved MICs and enhanced

membrane permeation behavior observed in the GUMBOS system as compared to the free
ionizable mixture of salts or individual parent ions is attributed to the hydrophobic nature of the
novel GUMBOS.
More importantly, we see that the membrane activity of the chlorhexidine moiety is
apparent and enhanced in spite of the presence of the antibiotic in the GUMBOS form. This
contradicts previous findings that suggest the presence of other anionic salts and detergents
antagonize the antibacterial activity of chlorhexidine salt.53 The antibacterial activity of
stoichiometric mixtures containing chlorhexidine diacetate and sodium antibiotic demonstrates
that β-lactams do interfere with chlorhexidine activity when unreacted.44, 54 However, this is not
the case with reacted β-lactam based chlorhexidine GUMBOS since synergetic and increased
antimicrobial activity over the mixture was observed. Antibacterial activities observed in this
study show that β-lactam antibiotics do not interfere with chlorhexidine when reacted and
suggest that the two ions must be functional without inhibiting the activity of the other.
Since polycationic molecules are reported to preferentially interact with the outer
membranes of Gram-negative bacteria by acting to competitively displace divalent cations that
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cross-bridge adjacent lipopolysaccharide ((LPS) molecules, we sought to investigate if this was
true for β-lactam chlorhexidine GUMBOS. As such, the antibacterial activity of the novel
GUMBOS, a dicationic antiseptic containing two β-lactam antibiotics, was further investigated
using EHEC in the presence and absence of Ca2+ or Mg2+ , wild-type E. coli, E. coli imp4213, and
E. coli DH5a (pAMP) in pursuit of understanding its mechanism of action. It was found that
EHEC susceptibility to all chlorhexidine salts were attenuated by Ca2+ and Mg2+. These findings
suggest that the antibacterial mechanism of action involves the displacement of divalent cations.
Authors have shown that chlorhexidine salts (i.e. dihydrochloride, digluconate, and diacetate) are
capable of permeating the outer membrane of E. coli and that this action was antagonized by
divalent cations such as Mg2+ and Ca2+. 45 Upon addition of increasing concentrations of EDTA,
which disrupts divalent-cation cross-bridges by chelation, the bactericidal activity against EHEC
was restored in MIC studies containing Ca2+. Even more so, high concentrations of EDTA
improved the GUMBOS antibacterial activity although it was not effective against EHEC alone.
Harper and Epis also found that chlorhexidine antibacterial activity was improved in vitro when
EDTA or EDTA/Tris systems were implemented against Gram-negative bacteria.55 We
hypothesize that the presence of excess divalent cations may repel GUMBOS by inhibiting its
interaction with LPS disallowing effective cation displacement. Therefore, improvements in MIC
values with increasing EDTA show that the removal of divalent cations enables effective
bactericidal activity.
An enhancement of NPN fluorescence in intact EHEC cells upon exposure to increasing
GUMBOS concentration supports that the GUMBOS permeabilized the outer membrane of
EHEC cells. As expected, the addition of divalent cations inhibited their membrane activities, as
observed by equal NPN fluorescence quenching. This could also be explained by competition
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between GUMBOS and the divalent cations for a divalent-cation-binding site on the outer
membrane since excess divalent cations reduce the likelihood of the GUMBOS effectively
destabilizing the membrane. Both chlorhexidine diacetate and GUMBOS are sensitive to divalent
cations and are similarly inhibited by their presence. Membrane potential studies also reveal that
chlorhexidine di-ampicillin caused greater membrane damage to E. coli O157:H7 strain ATCC
43895, than parent ion or mixture, resulting in superior depolarization of membrane potentials.10,
35, 37, 39

In addition, our results further demonstrate that neither combination nor precursor ion

resulted in comparable disruption of bacteria cell outer membranes or potentials.
Antibacterial activities of chlorhexidine di-ampicillin (MIC = 0.16 µM) as a
representative agent against ampicillin resistant strain of Escherichia coli DH5a (pAMP
plasmid) shows that its antibacterial activity is 2.5x better than the combination (MIC = 0.36
µM), but equal to chlorhexidine diacetate (MIC = 0.16 µM). This implies that the presence of
free ampicillin within the drug combination acts as an antagonist to the antibacterial activity of
chlorhexidine against ampicillin resistant strains. Since the MIC values of chlorhexidine diampicillin are not equal to the drug mixture, ampicillin resistant E. coli DH5a cannot effectively
deactivates the GUMBOS in the same way as the antiseptic/antibiotic combination. Thus, we are
not certain if the antibiotic is degraded by penicillinase as a GUMBOS and future studies are
underway to confirm this. However, our results suggest that neither the presence nor absence of
ampicillin interferes with chlorhexidine antibacterial activity when reacted.
4.5

Conclusions
The results of this study suggest that β-lactam based chlorhexidine GUMBOS may be a

viable alternative to antiseptics and antibiotics in the prevention of E. coli O157:H7 colonization
from ruminant reservoirs of infection. More importantly, the levels of potency, reduced toxicity,
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and improved synergy observed in GUMBOS were not exceeded by the equivalent combination
of chlorhexidine diacetate and antibiotic. Examination of our data also indicates that GUMBOS
have bactericidal activity against EHEC by directly disrupting the outer membrane. This activity
is premised on the displacement of divalent cations from their binding sites on LPS on the outer
membrane. The direct action of GUMBOS may contribute to its bactericidal activity against
Gram-negative bacteria. Other applications beyond reducing fecal shedding of EHEC in cattle
might be found wherever chlorhexidine might be used; for example, in the prevention of
meningitis in neonates by the eradication of group B streptococci in the vaginas of pregnant
women or in the reduction of resistant infections associated with catheter-induced bacteremia.
Ultimately, the GUMBOS approach represents an alternative to traditional pharmaceutical drug
design and conventional combination drug therapy.
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CHAPTER 5 ANTIBACTERIAL EFFECTS OF BETA (β)-LACTAM ANTIBIOTICCHLORHEXIDINE HYBRID SALTS ON ANTIBIOTIC RESISTANT
MICROORGANISMS
5.1 Introduction
Multi-drug resistant (MDR) bacterial infections comprise more than 30% of
nosocomial infections in the United States. 1 Particularly, the associated morbidities from
Gram-negative opportunistic bacteria (GNB) account for nearly 80% of intensive care unit
infections including those specifically causing pneumonia, or infecting the urinary tract, blood
stream, and surgical sites. 2,3 Of the ten most common pathogens responsible for 84% of
nosocomial infections, thirty-three percent is contributed by GNB, in which 8% result from
MDR-GNB.4 These pathogens include ESBL producing Escherichia coli, ampicillin-resistant
Klebsiella species, Acinetobacter baumanii, and Salmonella species, and fluoroquinolone- or
carbapenem-resistant

Enterobacteriaceae,

Serratia

marcescens

and

Pseudomonas

aeruginosa.5-10 Infections arising from MDR-GNB primarily come from the microorganisms’
highly efficient innate drug resistance; however the lack of host resistant mechanisms,
resulting from compromised immune systems, allows for infection to set more readily. Those
elements (i.e. AmpC – β-lactamases, MBLs, ESBLs, oxacillinases, and KPC enzymes)
combined with the lack of novel antibiotic development has created a platform in which
infections due to antibiotic resistant bacteria have become superior. 11 Therefore, prompt and
appropriate pragmatic antimicrobial therapy is necessary to improve clinical prognosis in the
treatment of severe resistant infections. 11
Although the antibiotic arsenal is limited, very few effective treatment options for
infections caused by MDR bacteria still remain. Primarily, combination drug therapy has
become the principal approach used to treat skin and soft tissue infections caused by MDR172

GNB and DR-Gram-positive bacteria (GPB).9 The use of multiple drugs in tandem is gaining
momentum as a systematic approach to treat complex disease. This has led to a number of
combination drug therapies that have become staples in treating such infections, while several
pharmaceutical companies seek to discover improved dual-mode-of-action compounds. Common
antibacterial combination drugs consists of β-lactam drugs approved in the U.S. are CoAmoxiclav (Amoxicillin + Clavulanate), Timentin (Ticarcillin + Clavulanate), Unasyn
(Ampicillin + Sulbactam), and Zosyn (Piperacillin + Tazobactam). Since these drug
combinations are losing drug efficacy, other combinations such as mixtures of polymyxin B and
tigecycline, meropenem, cefepime, or amikacin or β-lactams with aminoglycosides are being
investigated.12,

13

Likewise, mixtures of antibiotics with nonantibiotics are beginning to be

considered as a useful approach to extend therapy against MDR bacteria.14
Although the use of drugs in tandem might allow a patient the convenience of fewer dose
regimens with potent antimicrobial activity, several problems associated with polytherapy exist.
Aside from higher costs and uncontrollable drug responses with narrow therapeutic windows,
each aforementioned combination drug formulation is limited to the serendipitous chance that
each drug will arrive and deactivate a bacterial cell at the same time without causing adverse or
idiosyncratic reactions to the host. However, neither of these treatment options is considered to
be dual-mode-of-action and has yet to address the potential to cause lipopolysacharride (LPS)
endotoxin blood poisoning. Therefore, extending drug mixtures to multi-modal ionic pairs that
allow potent antimicrobials to be used in formulation with controlled pharmacokinetic properties
and nontoxicity may be a viable alternative to combating MDR bacterial infections.
Recently, we reported the improved antibacterial activities of β-lactam based
chlorhexidine GUMBOS on several isolates of E. coli O157:H7 with the intent to control and
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prevent the transmission of disease resulting from EHEC contamination from cattle ruminants.
Since the GUMBOS display unparalleled antibacterial synergism, nontoxicity, and tunable
pharmacokinetic properties it is interesting to investigate these materials as applied to other
systems treated with combination drug therapy. Herein, we use β-lactam based chlorhexidine
GUMBOS as a modern approach to treat MDR infections caused by GNB and GPB in addition
to preventing subsequent blood poisoning. The major objectives of this study were to investigate
the antibacterial activity of β-lactam-based chlorhexidine GUMBOS against drug-susceptible
(DS) and MDR bacteria and to exploit chlorhexidine’s abilities to sequester LPS endotoxin in
vitro as a novel modern reacted ionic drug therapeutic treatment option.
5.2

Materials and Methods

5.2.1 Antimicrobial Activity
Table 5.1 lists the clinical isolates that were used in this study. The minimum inhibitory
concentration (MIC) values of the starting materials and GUMBOS and the fractional inhibitory
concentrations (FIC) of the stoichiometric mixture were determined in triplicate by broth dilution
method in 96-well micro-titer plates.15 Test inoculums were adjusted using saline (0.85% NaCl)
according to a 0.5 McFarland standard using colonies grown individually on tryptic soy agar
plates. Cation-adjusted Mueller-Hinton broth with 5% DMSO was used to serially dilute (1:1)
antibacterial agents from 0.012 µM to 200 µM and to adjust bacteria inoculums to 105 - 106
CFU/mL. Isolates were treated with GUMBOS, sodium antibiotic salt, chlorhexidine diacetate,
or combinations of sodium antibiotic salt and chlorhexidine diacetate in a checkerboard dilution
format. The MIC or FIC for each antimicrobial agent was recorded as the lowest concentration
that did not show visual turbidity after 24 h incubation at 37°C. Antibacterial activity was
statistically analyzed using SAS 9.2 2 (SAS Institute Inc., Cary, NC, USA), p<0.05.
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Table 5.1. Sources and characteristics of drug-susceptible and drug-resistant bacterial strains
Strain

Characteristic

Escherichia coli 25922+

Clinical isolate, Quality control organism

Escherichia coli O157:H7 43895+

EHEC, hamburger isolate (stx1+, stx2+)

Salmonella typhi++

Fluoroquinolone resistant

Acinetobacter baumanii 225T2++

Respiratory isolate, MDR*

Acinetobacter baumanii 250++

Skin isolate, MDR

Acinetobacter baumanii 252++

Catheter isolate, MDR

Acinetobacter baumanii 254++

Wound drain isolate, MDR

Enterbacter cloacae 210T2++

Pleural fluid isolate, MDR

Enterbacter aerogenes 221T2

++

Sputum, MDR

Klebsiella pneumoniae 10031

+

Quality control organism

Klebsiella pneumoniae 50T2

++

Klebsiella pneumoniae 86T2

++

Urine isolate, MDR
Pleural fluid isolate, MDR
++

Respiratory: Sputum isolate, β-lactam drug resistant

+

Blood isolate, Quality control organism

Pseudomonas aeruginosa 124T2
Pseudomonas aeruginosa 27853

Pseudomonas aeruginosa PSA3++

Urine Isolate, β-lactam drug resistant

Pseudomonas aeruginosa PSA4++

Sputum isolate, β-lactam, fluoroquinolone, carbapenem
drug resistant

Serratia marscescens++

Wound isolate, MDR

Staphylococcus aureus 25923+

Clinical isolate

Streptococcus mutans35668+

Quality control organism

Streptococcus facaelis 19433+

Quality control organism

Micrococcus luteus 4698+

Quality control organism

Streptococcus facaelis 9790+

Quality control organism

Bacillus cereus 1178+

Quality control organism

Methicillin-resistant

Wound isolate, vancomycin susceptible

Staphylococcus aureus 449++
Methicillin-resistant
Staphylococcus aureus KHR1

++

Prosthetic joint infection isolate, vancomycin
susceptible

*MDR= β-lactam, floroquinolone, carbapenem, aminoglycoside-resistant
+
Obtained from American Type Culture Collection, Manassas, VA
++
Obtained from Jeffrey A. Hobden, Louisiana State University Health Science Center, LA
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5.2.2

Lipopolysaccharide (LPS) Sequestration
Lipopolysaccharide (E. coli O111:B4) of the highest purity was obtained commercially from

Sigma Aldrich (St. Louis, MO, USA). (LPS) sequestration was investigated by competitively
displacing BODIPY-cadaverine (BC, Molecular Probes, Inc. Eugene, OR, USA) that is bound to
LPS using increasing concentrations of the chlorhexidine containing salts. More specifically, the
BC-LPS conjugate was prepared by mixing 1 µM BC solution (Tris-buffer, pH 7.4, 50 mM) with 5
mg/L of LPS. Then, small aliquots of chlorhexidine diacetate or GUMBOS were titrated into 3 mL
of BC-LPS solution contained into a quartz cuvette. Changes in fluorescence (λex = 580 nm, λem =
620 nm) was monitored with a 1 cm pathlength quartz cuvette (Starna Cells) using a Spex
Fluorolog – 3 spectrofluorimeter Model FL3-22TAU3 ( Jobin Yvon, Edison, NJ, USA) at roomtemperature. The percent BC displacement upon increasing concentration of chlorhexidine salts was
determined by comparing the fluorescence of LPS with and without BC, where BC solution without
LPS is the 100% displaced control sample.
5.3
5.3.1

Results and Discussion
Representative Antibacterial activities of Chlorhexidine diacetate and β-lactam
Antibiotics against S. aureus 29523 and K. pneumoniae 10031
Table 5.2 shows the MIC results for the starting material against representative Gram-

positive and Gram-negative bacteria. Effective MIC values for chlorhexidine diacetate treatment on
S. aureus 29523 and K. pneumoniae 10031 are 0.8 ± 0.6 µM and 15.6 ± 6.3 µM, respectively. The
MIC values obtained for chlorhexidine diacetate match the values obtained in other studies
conducted on the S. aureus 29523. However, a three-fold decrease in MIC values was observed
when K. pneumoniae 10031 were treated with chlorhexidine diacetate. Beta-lactam antibiotics
showed variable antibacterial activity on both Gram-positive and Gram-negative strains
investigated. Staphylococcus aureus 29523 were increasingly susceptible to antibiotics in this order:
sodium ampicillin < disodium carbenicillin < sodium cephalothin = sodium oxacillin. However,
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disodium carbenicillin and sodium cephalothin were equally efficient in preventing K. pneumoniae
10031 growth. Lack of antimicrobial activity was seen for sodium oxacillin and sodium ampicillin.
Table 5.2. Antibacterial activities (MIC, µM) of chlorhexidine diacetate, sodium ampicillin,
disodium carbenicillin, sodium cephalothin, and sodium oxacillin against representative
microorganisms S. aureus 29523 and K. pneumoniae 10031.

Chlorhexidine diacetate
Sodium Ampicillin
Disodium Carbenicillin
Sodium Cephalothin
Sodium Oxacillin
5.3.2

S. aureus 29523
0.8 ± 0.6
25
12.5 ± 3.3
1.6 ± 0.4
1.6 ± 0.2

K. pneumoniae 10031
15.6 ± 6.3
>50
12.5 ± 1.5
12.5 ± 5.8
>50

Comparative Antibacterial Activities of Chlorhexidine and β-lactam Antibiotics in
Combination and as GUMBOS
Using the checkerboard technique, the combined effects of chlorhexidine diacetate and

various β-lactam antibiotics against representative organisms S. aureus and K. pneumoniae are
presented in Figures 5.1 and 5.2. Staphylococcus aureus 29523 was variably susceptible to
combinations of chlorhexidine diacetate and β-lactam antibiotics. Carbenicillin was the most
synergetic antibiotic used with chlorhexidine diacetate to inhibit S. aureus 29523 growth. The most
synergetic FIC ratio observed against the Gram-positive isolate consisted of 0.39 µM chlorhexidine
diacetate and 1.56 µM carbenicillin disodium. Similarly, 1.56 µM sodium cephalothin compliments
0.20 µM chlorhexidine diacetate antibacterial activities against S. aureus 29523. Fewer synergetic
ratios between chlorhexidine diacetate and sodium ampicillin or sodium oxacillin were seen in S.
aureus 29523 growth inhibition studies. Predominantly, FIC ratios consisting of chlorhexidine
diacetate and either sodium ampicillin or sodium oxacillin reveal that 66% combinations tested
were additive for both.
In the FIC studies against K. pneumoniae 10031, fewer synergetic combinations were
observed. Interaction indices ranked from 0.5 – 5 for each antiseptic and antibiotic combination
tested. More specifically, interaction indices suggest that the presence of antibiotic greatly
antagonizes the activity of chlorhexidine diacetate. However, K. pneumoniae 10031 was the most
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susceptible to combinations of chlorhexidine diacetate and disodium carbenicillin. In this case, 6.25
µM chlorhexidine diacetate and 12.5 µM disodium carbenicillin efficiently inhibited K. pneumoniae
10031 growth. Lower concentrations of chlorhexidine diacetate and disodium carbenicillin
drastically become antagonistic and susceptibility to K. pneumoniae 10031are substantially
reduced. The remaining antibiotics, sodium ampicillin, sodium cephalothin, and sodium oxacillin,
showed increasing antagonism with the latter being the worst in combination with chlorhexidine
diacetate. Despite the increasing antagonism in concentrations less than 12.5 µM chlorhexidine
diacetate and 12.5 µM sodium ampicillin or sodium cephalothin, additivity is maintained in 80% of
the FIC values tested.
5.3.3

Antibacterial Activities of β-lactam-based Chlorhexidine GUMBOS

5.3.3.1 Drug Susceptible and Drug Resistant Gram-positive
The antibacterial activities of β-lactam based chlorhexidine GUMBOS were investigated
against 6 drug-susceptible GPB and two Methicillin-resistant S. aureus strains. Figure 5.3 shows
the results obtained for this study. Overall, it required less than 1.5 µM of the antibacterial agents to
inhibit the growth of both DS-GPB and MRSA. For each GPB, chlorhexidine diacetate performs
equally or worse than the GUMBOS. The antibacterial activities for the GUMBOS increase
proportionately with molecular weight. More specifically, one or more GUMBOS are better
inhibitors of GPB bacteria than chlorhexidine diacetate in 88% of isolates tested. It required 0.8 µM
± 0.6 µM chlorhexidine diacetate to inhibit both DS-GPB and MRSA. Chlorhexidine diacetate was
least effective against MRSA 449. When evaluating the activity of chlorhexidine di-ampicillin, B.
cereus 1178, S. mutans 35668, and S. facaelis 19433 were the most susceptible. Staphylococcus
aureus 25923 was least susceptible to chlorhexidine di-ampicillin. Both MRSA strains required 0.7
µM ± 0.1 µM chlorhexidine di-ampicillin for growth inhibition. The average MICs of GPB required
by chlorhexidine carbenicillin and chlorhexidine di-cephalothin were determined to be 0.5 µM ±
0.3µM. The most effective β-lactam chlorhexidine GUMBOS used to treat GPB was found to be
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chlorhexidine di-oxacillin. More specifically, the concentration required to inhibit GPB ranges
from 0.1 to 0.8 µM, with the latter the concentration to inhibit S. facaelis 9790. Likewise, both
MRSA strains required 0.1 µM for growth inhibition. In summary, antibacterial potency for the
novel β-lactam based chlorhexidine GUMBOS increases in the following order: chlorhexidine
diacetate < chlorhexidine di-ampicillin < chlorhexidine carbenicillin < chlorhexidine di-cephalothin
< chlorhexidine di-oxacillin.
5.3.3.2 β-lactam antibiotic Susceptible Gram-Negative Bacteria
The antibacterial activities of β-lactam based chlorhexidine GUMBOS were investigated against
antibiotic susceptible GNB. Figure 5.4 shows the results obtained for this study. Overall, less than
0.3 µM of the antibacterial agents were required to inhibit the growth of DS-GNB. For each DSGNB, chlorhexidine diacetate was outperformed by the GUMBOS. Escherichia coli 25922 required
0.25 µM ± 0.05 µM antibacterial agents to inhibit its growth. Therefore, E. coli 25922 is equally
susceptible to all chlorhexidine salts tested in this study. However, preferential antibacterial
activities toward Escherichia coli (EHEC) 43895 and ampicillin-resistant S. typhi were seen when
comparing the GUMBOS efficacy to quality control strain E. coli 25922. Escherichia coli 43895
required 0.11 µM ± 0.3 µM GUMBOS to inhibit its growth. This concentration is half the
concentration of chlorhexidine diacetate necessary to equally inhibit the growth of E. coli 25922.
Hence, either type of GUMBOS is sufficient to inhibit the growth of EHEC 43895. It was observed
that S. typhi was the most susceptible to GUMBOS investigated in this study. Interestingly,
antibacterial activity increases proportionately with increasing molecular weight. Chlorhexidine diampicillin was least effective in inhibiting S .typhi growth. The efficacy of the GUMBOS against S.
typhi increases in this order: chlorhexidine di-ampicillin < chlorhexidine carbenicillin <
chlorhexidine di-cephalothin < chlorhexidine di-oxacillin. Although worse, the antibacterial activity
of chlorhexidine di-ampicillin against S.typhi is not statistically different from chlorhexidine
diacetate.
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A)

C)

B)

D)

Figure 5.1. Interaction indices determined by fractional ihibitory concentrations (µM) of chlorhexidine diacetate and A) sodium
ampicillin, B) disodium carbenicillin, C) sodium cephalothin, or D) sodium oxacillin against S. aureus 25923.
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Figure 5.2. Interaction indices determined by fractional ihibitory concentrations (µM) of chlorhexidine diacetate and A) sodium ampicillin,
B) disodium carbenicillin, C) sodium cephalothin, or D) sodium oxacillin against K. pneumoniae 10031.
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Figure 5.3. Antibacterial activity of β-lactam-based chlorhexidine GUMBOS on drug-susceptible and drug-resistant Gram-positive
bacteria.
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Figure 5.4. Antibacterial activity of β-lactam-based Chlorhexidine GUMBOS on drug-susceptible and drug-resistant Gram-negative
bacteria.
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5.3.3.3 Multi-Drug Resistant Gram-Negative Bacteria
The antibacterial drug susceptibility of 14 ampicillin-resistant GNB was assayed by the 5
chlorhexidine salts. Twelve of the fourteen ampicillin-resistant GNB are considered MDR, in which
6 major bacterial genera responsible for MDR infections are represented. Overall, less than 35 µM
antibacterial agents were required to inhibit MDR-GNB growth. Chlorhexidine susceptibility for
the clinical isolates of A. baumanii ranked with chlorhexidine di-oxacillin = chlorhexidine
carbenicillin > chlorhexidine di-cephalothin > chlorhexidine di-ampicillin > chlorhexidine
diacetate. Similar to other classes of bacteria investigated, A. baumanii increases with increasing
molecular weight. However, it appears that this organism might be more susceptible to the
decreased ionic stoichiometry or the unique structural configuration of the chlorhexidine
carbenicillin GUMBOS. Both Enterobacter species were equally susceptible to the chlorhexidine
salts. The most effective growth inhibitor of both E. aerogenes 221T2 and E. cloacae 210T2 was
found to be chlorhexidine di-oxacillin; whereas, the least effective agent was chlorhexidine diampicillin. It required 10 – 20 µM of β-lactam based chlorhexidine GUMBOS to inhibit K.
pneumoniae isolates. Although K. pneumoniae 10031 is not a MDR-GNB, greater antimicrobial
susceptibility was only observed to chlorhexidine carbenicillin, chlorhexidine di-cephalothin, and
chlorhexidine di-oxacillin. Chlorhexidine diacetate was able to efficiently inhibit both ampicillinresistant and MDR-K. pneumoniae growth with approximately 5 µM.

Ampicillin-resistant P.

aeruginosa 27853 was more susceptible to the hydrophobic chlorhexidine di-oxacillin and
chlorhexidine di-cephalothin GUMBOS only requiring 3 µM for growth inhibition. Minimum
inhibitory concentrations between 10 – 16 µM were effective against MDR-P. aeruginosa.
Chlorhexidine carbenicillin was found to be least effective on MDR-P. aeruginosa. Overall, mean
antibacterial activities were found to be 11.2 µM, 14.7 µM, 15.4 µM, 15.6 µM, and 11.1 µM for
chlorhexidine diacetate, chlorhexidine di-ampicillin, chlorhexidine carbenicillin, chlorhexidine dicephalothin, and chlorhexidine di-oxacillin, respectively.
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5.3.4

Interaction Indices
Figure 5.5 shows all interaction indices acquired for β-lactam-based chlorhexidine

GUMBOS. It is apparent that different extents of synergy are observed for the GUMBOS for
MRSA, DS-GPB, DS-GNB, and MDR-GNB. Although FIC indices of the antibiotic and
chlorhexidine mixtures show ranges of additivity for all combinations against S. aureus 25923 and
K. pneumoniae 10031, synergy was observed in each case that the β-lactam-based chlorhexidine
GUMBOS was used. Interaction indices (I) was found to range between 0.3 and 1.5 for GUMBOS.
More specifically, decreasing synergy was observed for all isolates in this order: chlorhexidine dicephalothin > chlorhexidine di-ampicillin = chlorhexidine carbenicillin > chlorhexidine di-oxacillin.
Likewise, all GUMBOS were synergetic against GPB, E. coli 43890, and E. coli 25922. Interaction
indices obtained for S. typhi and K. pneumoniae 10031reveal the GUMBOS to be additive and that
neither chlorhexidine nor antibiotic are more effective than the other in the form of GUMBOS. For
all of the GUMBOS, synergy was solely found for 14% of the MDR-GNB isolates. When
considering synergy by type of GUMBOS, the combination of chlorhexidine and oxacillin in the
form of chlorhexidine di-oxacillin proved to be a successful combination for 57% of the MDRGNB isolates. In conclusion, GUMBOS were able to synergistically inhibit % of the bacteria tested
in this study.

Thus, the use of β-lactam antibiotics reacted with chlorhexidine yield better

synergetic salt pairs (i.e. β-lactam-based chlorhexidine GUMBOS) that show better interaction
indices than the combination of precursor salts on the same microorganisms.
5.3.5

Antibacterial activity in 10% Human Serum Albumin
The antibacterial activity of β-lactam based chlorhexidine GUMBOS were also assayed in

the presence of 10% Human Serum Albumin (HSA, Sigma Aldrich, St. Louis, MO, USA). It was
found that the antibacterial activities worsened variably for each chlorhexidine salt. Table 5.3
reveals the MIC values obtained for each GUMBOS in the presence of 10% HSA. Using EHEC
43895 as a representative microbe, it was observed that nearly 50-fold more chlorhexidine diacetate
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was needed to inhibit its growth. Likewise, the GUMBOS required 90 – 300 times more material to
inhibit the growth of E. coli O157:H7 43895, which was extremely susceptible to the GUMBOS in
the absence of HSA. This suggests that systemic administration of these GUMBOS may be
problematic in that the agents might interact strongly with albumin proteins causing their
antibacterial activity to be limited. Future studies will be required to investigate the in vivo
potential of these agents.
Table 5.3. Antibacterial activities (MIC, µM) of chlorhexidine diacetate, chlorhexidine diampicillin, chlorhexidine carbenicillin, chlorhexidine di- cephalothin, and chlorhexidine dioxacillin against representative microorganism E. coli O157:H7 43895 in the presence of 10%
human serum albumin.

5.3.6

Chlorhexidine diacetate

E. coli O157:H7
43895
11.7 ± 5.5

Chlorhexidine di-ampicillin

15.6 ± 4.3

Chlorhexidine carbenicillin

23.4 ± 11

Chlorhexidine di-cephalothin

31.3 ± 8.2

Chlorhexidine di-oxacillin

11.7± 5.5

Therapeutic Indices Chlorhexidine and Antibiotics in Combination and as GUMBOS
The therapeutic index (TI) is widely used to calculate the flexible dosing concentrations

between the effective antibacterial activities and lethal concentrations of antibacterial drugs.
Therefore, larger therapeutic indices indicate greater flexibility in the strength of concentrations
used to treat systemic infections. As mentioned before in Chapter 4, chlorhexidine diacetate is an
effective antimicrobial with poor intestinal bioavailability and higher systemic cytotoxicity; hence
its therapeutic index is lower. Changing the antibiotic component in the GUMBOS has greatly
expanded the therapeutic index of chlorhexidine when considering the different mammalian cell
lines (Figure 5.6).
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Ranges for GUMBOS TI (i.e. 100<TI <300) obtained by MRSA and DS-GPB. More
specifically, TI varied among GPB in the following order: chlorhexidine di-ampicillin >
chlorhexidine di-oxacillin > chlorhexidine di-cephalothin > chlorhexidine carbenicillin >
chlorhexidine diacetate for HeLa cells. The TI obtained for NIH/3T3 fibroblasts show indifference
among chlorhexidine salts. Endothelial cells also have variable TI; in which, the greatest and least
TI was found for chlorhexidine di-cephalothin and chlorhexidine carbenicillin, respectively. Drug
susceptible GNB consistently have the largest therapeutic index (i.e. 300<TI <900) for HeLa,
NIH/3T3 and EOMA cells. Of the three cellular lines, NIH/3T3 fibroblasts had the lowest
therapeutic index which suggests a discrete margin of GUMBOS treatment concentrations would be
available for wounds. However, the narrowest TI (i.e. 2<TI<10) was approximated for MDR-GNB.
Therapeutic ranges for treating MDR-GNB systemic infections were improved 10-fold for βlactam-based chlorhexidine GUMBOS compared to the 3-fold therapeutic index observed for
chlorhexidine diacetate.
5.3.7

Lipopolysaccharide (LPS) Sequestration
The dose-dependent displacement of BODIPY-cadaverine from LPS endotoxin shows that

each β-lactam GUMBOS can sequester LPS with differing affinities. Figure 5.7 illustrates that
equal LPS sequestration can be achieved by concentrations of chlorhexidine diacetate and
chlorhexidine di-ampicillin below 30 µM. However, greater concentrations of chlorhexidine diampicillin have 16% better sequestration from 30 to 62 µM. The ability to sequester LPS by the
remaining GUMBOS occurs slowly until 13 µM is reached. In which concentrations above 13 µM
significantly discriminates the LPS sequestering abilities of chlorhexidine di-cephalothin and
chlorhexidine di-oxacillin. At the maximum concentration of GUMBOS, 78 and 97% LPS was able
to be bound by chlorhexidine di-cephalothin and chlorhexidine di-oxacillin, respectively. However,
chlorhexidine carbenicillin was the worst LPS sequestering agent used in this study. Chlorhexidine
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Figure 5.5. Interaction indices on MDR- and MDS bacteria for chlorhexidine di-ampicillin, chlorhexidine carbenicillin, chlorhexidine dicephalothin, and chlorhexidine di-oxacillin.
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Figure 5.6. Therapeutic Indices using mean inhibitory concentrations per bacteria drug susceptibilities for β-lactam-based chlorhexidine
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Figure 5.7. Determination of BODIPY-cadaverine (BC) displacement from LPS (left) and remaining LPS concentration (right) by
chlorhexidine diacetate, chlorhexidine di-ampicillin, chlorhexidine di-cephalothin, chlorhexidine di-oxacillin, and chlorhexidine
carbenicillin. BODIPY-cadaverine was mixed with LPS and various concentrations of GUMBOS added. Displacement of BODIPYcadaverine from LPS was calculated as [1-(F − F0)/(Fmax− F0) ]* 100%, where F0 is the fluorescence intensity at LPS saturation with
BODIPY-cadaverine and Fmax is the fluorescence intensity without LPS.
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carbenicillin was only able to sequester 44% LPS. Further processing of this data using a
Scatchard interpretation reveals further details about the binding affinities between GUMBOS
and LPS. We found that the GUMBOS have very strong binding affinities to LPS. More
specifically, increasing binding affinities occur in the following order: chlorhexidine
carbenicillin < chlorhexidine di-cephalothin < chlorhexidine di-ampicillin < chlorhexidine
diacetate < chlorhexidine di-oxacillin.
Although not yet understood, the different abilities for GUMBOS to sequester LPS are
hypothesized to be driven by the GUMBOS hydrophobicity and unique structural configuration.
Our data shows that LPS sequestration increases with increasing hydrophobicity, where
chlorhexidine diacetate is the least and chlorhexidine di-oxacillin is the greatest, within the
GUMBOS consisting of two antibiotics. Therefore, this physical property is believed to facilitate
the GUMBOS adsorption into the hydrophobic alkyl appendages of the lipid A moiety of LPS.
This agrees with the findings of David et al. who have, to date, investigated the interaction of
several lipopolyamines with the lipid A moiety of LPS.16-20 Although chlorhexidine carbenicillin
is more hydrophobic than chlorhexidine diacetate, we believe that hydrophobicity alone is not
capable of successfully removing LPS in vitro. When comparing chlorhexidine carbenicillin and
chlorhexidine diacetate, the increased hydrophobicity of the GUMBOS has led to better
antibacterial activity. However, the difference in stoichiometry or structural configuration may
also contribute to the variances in LPS sequestering ability. Therefore, the intermolecular forces
that contain the LPS-binding GUMBOS are believed to promote a favorable conformation that
facilitates direct binding to the phosphate sites on the lipid A moiety of LPS. Since each
phosphate group is approximately 16 Å apart,19 it is believed that these GUMBOS have a
structural conformation that that allows the dicationic biguanidinium residues on the
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chlorhexidine backbone to bind favorably to the LPS phosphate groups. The one-to-one
stoichiometry between chlorhexidine and carbenicillin is thought to create a structural
conformation that is too acute to successfully bind to the phosphates. This electrostatically driven
process is hypothesized to occur in spite of the antibiotics since there are several hydrogen
bonding donor and acceptor groups between the two ions that are able to maintain the ionic pair
without the use of their charges. Further studies are required to confirm the hypotheses premised
on the unique LPS-GUMBOS interactions and their ability to sequester LPS endotoxin better
than chlorhexidine diacetate alone. However, this study suggests that the efficiency of these
compounds may be a result of the culmination of the ability to suppress cell activation in
addition to the antibacterial activities.
5.4 Michaelis-Menten Kinetics using CENTA as a Substrate against Type I Penicillinase
5.4.1 CENTA and Chlorhexidine
Kinetic studies demonstrate that each component of the GUMBOS structure impacts the
activity of penicillinase on CENTA degradation. Active ampicillin moieties within the
GUMBOS structure is believed to specifically promote binding of chlorhexidine di-ampicillin to
penicillin binding proteins (e.g. transpeptidase) as well as identify the GUMBOS role in
enzymatic degradation by Type 1 penicillinases to be understood. If ionic dissociation of the
GUMBOS occurs, than it is expected that the kinetics of CENTA with either mixture or
GUMBOS would be similar. Table 5.4 summarizes the kinetic results obtained for sodium
ampicillin, chlorhexidine diacetate, and chlorhexidine di-ampicillin in the presence of CENTA.
Using CENTA in combination with chlorhexidine diacetate suggests how the
stoichiometric mixture containing unreacted 1:2 chlorhexidine diacetate: sodium ampicillin (v/v
%) is impacted by enzyme hydrolysis. More importantly, the addition of chlorhexidine diacetate
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Table 5.4. Average kinetic parameters between Type 1 penicillinase and CENTA substrate in the presence of sodium ampicillin,
chlorhexidine diacetate, and chlorhexidine di-ampicillin secondary substrates. The Michaelis-Menten constants were calculated using
linear regions from the different rate saturation curves. Apparent values are an average with standard deviations from all kinetic
parameters acquired for each inhibitor concentration from four measurements.
Substrate

Km (µM)

Km, app
(µM)

Vmax
(mM/min)

Vmax app
(mM/min)

Kcat

Kcat/K m (108)

Ki (µM)

Chlorhexidine
diacetate

-

3.33 ± 0.76

-

0.38 ± 0.09

641 ± 158

2.09 ± 0.99

na

Chlorhexidine
di-ampicillin

-

42.3 ± 19.1

-

2.65 ± 0.87 4993 ± 1478

1.07 ± 0.22

59.3 ± 38.8

Sodium ampicillin

-

25.1 ± 13.5

-

1.60 ± 0.93

2715 ±1571

1.26 ± 0.39

25.0 ± 15.5

CENTA

28.3 ± 4.4

-

2.77 ± 0.36

-

4707 ± 261

1.66 ± 0.74

-

na: Inhibitor dissociation constant for chlorhexidine diacetate could not be calculated
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to increasing concentrations of CENTA revealed an uncompetitive-like inhibitive effect on the
substrate although resembling a rare inhibition type known as induced- substrate inhibition
(Figure 5.8). Since chlorhexidine diacetate does not structurally resemble the inhibitor it will not
interfere with the penicillinase active binding site.

Figure 5.8. Saturation curve with 0.5 units Type 1 penicillinase showing the relationship
between CENTA (substrate) concentration and its degradation rates in the presence of increasing
concentrations of chlorhexidine diacetate at 37°C.
In fact, it is electrostatically attracted to CENTA’s anionic carboxylate groups within the
enzyme-substrate complex, since penicillinase degradation would not compromise the chargedistribution of this molecule.21,

22

It was observed that even at low concentrations of

chlorhexidine diacetate, the degradative rate of CENTA (vmaxapp = 0.38 µM) was decreased
suggesting that the conversion of enzyme-inhibitor-substrate complex to product is reduced.
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Increasing CENTA concentrations were not able to overcome this inhibitive effect, so it is
concluded that the presence of CENTA is required to provide a site for chlorhexidine diacetate to
interfere with binding. Since this data does not follow conventional Michaelis-Menten kinetics,
the inhibitor dissociation constant (Ki) could not be calculated. In summary, the mixture of
precursor ions may prevent the degradation of ampicillin if the chlorhexidine diacetate and
sodium ampicillin arrive synchronously to the active site of penicillinase. However, the unlikely
probability of this occurring may not allow chlorhexidine to work synergistically with ampicillin.
5.4.2 CENTA and Chlorhexidine di-Ampicillin
As for chlorhexidine di-ampicillin, CENTA hydrolysis deviated substantially from
standard Michaelis-Menten kinetics, demonstrating induced-substrate inhibition at higher
substrate concentrations (Figure 5.9). This irreversible process behaves similarly to the system
consisting of the stoichiometric mixture. Since ampicillin is structurally similar to CENTA and is
electrostatically bound to the chlorhexidine molecule, initial competitive inhibition is observed at
low concentration of GUMBOS. In this case, the GUMBOS compete with CENTA to bind to the
free enzyme at the active site. At insufficient inhibitive concentrations, increasing the amount of
CENTA allows it to overcome inhibition since penicillinase is consumed in the enzyme-substrate
complex. However, if the individual rate saturation plots are evaluated in the presence of
increasing chlorhexidine di-ampicillin, it appears that an induced-substrate inhibitive effect
occurs upon increasing concentrations of CENTA substrate. Increasing the CENTA
concentration enables penicillinase to bind additional molecules at other inactive sites which, in
this case, may cause the chlorhexidine di-ampicillin’s physical and chemical properties to inflict
protein distortion disabling penicillinase hydrolytic activity.23 Subsequent binding of the second
substrate, chlorhexidine di-ampicillin, seems not to be productive and therefore reduces the
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catalytic activity at the first step. In addition, binding chlorhexidine di-ampicillin drastically
decreases the nucleophilic activity of water causing the deacylation step (i.e. conversion from
enzyme-substrate complex to product) to be inhibited. On average, adding the chlorhexidine diampicillin molecules had no effect on the overall substrate recognition and penicillinase active
processes, since it is clear that the inhibition of activity is largely, if not entirely, due to the
formation of the enzyme - GUMBOS complex. Although more studies are ongoing to investigate
the influence GUMBOS has on penicillinase activity, we believe that chlorhexidine di-ampicillin
will retain the binding affinity of the ampicillin moiety to the serine active site in the penicillin
binding protein, transpeptidase. Additionally, our preliminary results suggest chlorhexidine diampicillin irreversibly binds to these proteins detrimentally impacting the sequence of events
required to degrade the β-lactam drug.

Figure 5.9. Saturation curves with 0.5 units Type 1 penicillinase showing the relationship
between CENTA (substrate) concentration and its degradation rates in the presence of increasing
concentrations of chlorhexidine di-ampicillin at 37°C.
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Thus, chlorhexidine di-ampicillin shows potential to resist enzymatic hydrolysis by Type
1 penicillinase containing microorganisms as well as remain effective against ampicillin resistant
microorganisms. However innate resistance mechanisms to β-lactam drugs present in nonpenicillinase Gram-negative bacteria may require the antibacterial activity to rely solely on the
chlorhexidine molecule.
5.5

Conclusion
A trend among GUMBOS and their antibacterial activities, increasing molecular weights,

and relative hydrophobicities were found to gauge drug susceptibility. In general, GUMBOS
antibacterial activity was selective for drug-susceptible GNB over GPB, with both having better
drug susceptibilities than MDR-GNB. Overall, the growth inhibitive activity of antibiotic-based
GUMBOS on MDR-GNB occurred in this order: S. marscescens < E. cloacae < E. aerognes <
A. baumanii < K. pneumonia < P. aeruginosa, in which the least antibacterial activity was
observed on S. marscescens. In summary, 0.5 ± 0.2 µM 0.2 ± 0.07 µM, 14 ± 6 µM is required to
inhibit GPB, DS-GNB, and MDR-GNB, respectively. Since the MIC of GUMBOS (14 ± 6 µM)
is insignificantly different from the MIC of chlorhexidine diacetate (11± 8 µM), it is assumed
that the choice of antibiotic has a negligible impact on these particular microorganisms. Thus,
incorporating chlorhexidine and β-lactam antibiotics into salts appears to only alter the physical
properties of chlorhexidine resulting in better bacterial susceptibility. However, the abundance of
protein in vivo may limit the systemic use of the materials as anti-infective agents.
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To date, the ability to sequester LPS endotoxin as observed using fluorescence spectroscopic
studies reveals an added, yet unexpected benefit from the inclusion of the chlorhexidine
molecule into the GUMBOS structure. This work shows that the GUMBOS are able to neutralize
the immunostimulatory endotoxins of GNB that are released from bacteria once treated with
different bactericides. As implied by Zorko et al. the incorporation of bisbiguanides in
combination with antibiotics does not result in lower concentrations of antibiotics.24 In fact,
additivity is observed between the two components. However, improved antibacterial activities
of the GUMBOS and large therapeutic index suggest that they would be useful to treat topical
infections that result from DR- bacteria. In this case, the role of the chlorhexidine molecule in the
GUMBOS would be to neutralize the pro-inflammatory endotoxin constituents that are released
upon subsequent cell death at the same time as killing the microbe. Therefore, the LPS study
preliminarily shows that these GUMBOS are dual-mode-of-action compounds and that in
addition to eradicating an infection, at least 20% LPS endotoxin can be sequestered using the
lowest MDR-GNB inhibitory concentration of GUMBOS. Preliminary findings suggest that the
presence of the β-lactam anion in the GUMBOS still enables penicillin binding protein
recognition; however, an irreversible substrate-induced inhibitive activity was found on Type I
penicillinase suggesting the β-lactam drugs within the GUMBOS have an ability resist enzymatic
degradation. These results show that the GUMBOS are able to retain antibacterial activity
against drug-resistant bacteria that use penicillinase as its primary resistance mechanism. Future
work would be required to investigate the roles GUMBOS have on other types of bacterial
resistance mechanisms and its antibacterial activity. Ultimately, the broad spectrum antiinflammatory/ antibacterial activity observed by the β-lactam based chlorhexidine GUMBOS
shows that the properties of both ions are conserved as an ion-pair and that tunable therapeutic
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treatments against drug-susceptible and drug-resistant bacteria are available by implementing
this modular, ionic approach.
5.6

References

1.

Peleg, A.Y.; Hooper, D.C.; New England Journal of Medicine, 362, (19), 1804-1813.

2.

Bouza, E.; Cercenad, E.; Seminars in Respiratory Infections, 2002, 17, 215-230.

3.

Paterson, D.L.; American Journal of Medicine, 2006, 119, (6 Suppl 1), S20-28; discussion
S62-70.

4.

Hidron, A.I.; Edwards, J.R.; Patel, J.; Horan, T.C.; Sievert, D.M.; Pollock, D.A.; Fridkin,
S.K.; Infection Control and Hospital Epidemiology, 2008, 29, (11), 996-1011.

5.

Sleigh, J.D.; British Medical Journal, 1983, 287, 1651-1653.

6.

Mohamudha, P.R.; Srinivas, A.N.; Rahul, D.; Harish, B.N.; Parija, S.C.; International
Journal of Collaborative Research on Internal Medicine & Public Health, 2010, 2, (7),
226-237.

7.

Pessoa-Silva, C.L.; Meurer Moreira, B.; Câmara Almeida, V.; Flannery, B.; Almeida Lins,
M.C.; Mello Sampaio, J.L.; Martins Teixeira, L.; Vaz Miranda, L.E.; Riley, L.W.;
Gerberding, J.L.; Journal of Hospital Infection, 2003, 53, (3), 198-206.

8.

Arpin, C.; Dubois, V.; Coulange, L.; Andre, C.; Fischer, I.; Noury, P.; Grobost, F.; Brochet,
J.-P.; Jullin, J.; Dutilh, B.; Larribet, G.; Lagrange, I.; Quentin, C.; Antimicrobial Agents and
Chemotherapy, 2003, 47, (11), 3506-3514.

9.

Patterson, D.L.; American Journal of Infection Control, 2006, 34, (5, Supplement 1), S20S28.

10.

Rahal, J.J.; Clinical Infectious Diseases, 2009, 49, (Supplement 1), S4-S10.

11.

Paterson, D.L.; Bonomo, R.A.; Clinical Microbiology Revews, 2005, 18, (4), 657-686.

12.

Clock, S.A.; Whittier, S.; Weisenberg, S.A.; Kubin, C.J.; Schuetz, A.N.; Tabibi, S.; Alba,
L.; Jenkins, S.; Saiman, L.; In 48th Annual Meeting of the Infectious Disease Society of
America: Vancover, British Columbia, Canada, 2010.

13.

Bouza, E.; Cercenado, E.; Seminars in Respiratory Infections, 2002, 17, (3), 215-230.

14.

Ejim, L.; Farha, M.A.; Falconer, S.B.; Wildenhain, J.; Coombes, B.K.; Tyers, M.; Brown,
E.D.; Wright, G.D.; Nature Chemical Biology, 2011, 7, (6), 348-350.
199

15.

Motyl, M.; Dorso, K.; Barrett, J.; Giacobbe, R.; Basic Microbiological Techniques Used in
Antibacterial Drug Discovery. UNIT 13A.3 ed. John Wiley & Sons, Inc., 2006.

16.

David, S.A.; Sil, D.; Wang, X.; Quinn, P.J. Harris, J.R.; Biswas, B.B.; Quinn, P., Eds.;
Springer Netherlands; Vol. 53, pp 255-283.

17.

David, S.A.; Silverstein, R.; Amura, C.R.; Kielian, T.; Morrison, D.C.; Antimicrobial
Agents and Chemotherapy, 1999, 43, (4), 912-919.

18.

David, S.A.; John Wiley & Sons, Ltd., 2001; Vol. 14, pp 370-387.

19.

Burns, M.R.; Jenkins, S.A.; Wood, S.J.; Miller, K.; David, S.A.; Journal of Combinatorial
Chemistry, 2005, 8, (1), 32-43.

20.

Wood, S.J.; Miller, K.; David, S.A.; Combinatiorial Chemistry & High Throughput
Screening, 2006, 7, (3), 239-249.

21.

Bebrone, C.; Moali, C.; Mahy, F.; Rival, S.; Docquier, J.D.; Rossolini, G.M.; Fastrez, J.;
Pratt, R.F.; Frere, J.-M.; Galleni, M.; Antimicrobial Agents and Chemotherapy, 2001, 45,
(6), 1868-1871.

22.

Grenier, D.; Journal of Dental Research, 1993, 72, (3), 630-633.

23.

Hjeljord, L.G.; Rølla, G.; Bonesvoll, P.; Journal of Periodontal Research, 1973, 8, 11-16.

24.

Zorko, M.; Jerala, R.; Journal of Antimicrobial Chemotherapy, 2008, 62, 4, 730-737

200

6.1

CHAPTER 6 CONCLUSIONS AND FUTURE STUDIES
Concluding Remarks
Adequate antibiotic therapy and antiseptic use are the cornerstones of appropriately

managing all infectious disease. However, infections resulting from pathogenic bacteria, with
drug resistant bacteria of a higher concern, have become paradoxical due to the contraindications
surrounding the use of antibiotic therapy. Primarily, the fear of liberating endotoxins and the
emergence of multi-drug resistant organisms have limited clinicians to the number of effective
anti-infective agents available for treatment. Therefore, the synthesis and characterization of
novel antibiotic- and antiseptic- hybrid salts derived from API-ILs and GUMBOS as discussed in
this dissertation have shown to offer multiple advantages that allow for some antibiotics to be
reconsidered for infection treatment.
In Chapter 3, the development of ampicillin-based ILs using various antiseptic surfactants
as cations, have revealed a reduction in the antibiotic content required to inhibit the growth of
Gram-positive and Gram-negative bacteria. Although yielding additive interaction indices, their
efficacies against E. coli O157:H7, K. pneumoniae, S. aureus, and E. faecium revealed that
ampicillin-based ILs have outperformed the antibacterial activities of both quaternary
ammonium halide and sodium ampicillin.
In Chapter 4, the synergy found among four antibiotics and chlorhexidine combinations in
the form of GUMBOS have shown to possibly expand the armamentarium available for
combination antibiotic therapy. Larger therapeutic indices, improved bioavailability, and
enhanced pharmacokinetic properties of these materials exploit the plausibility for these
GUMBOS to be considered as modern forms of combinatorial drugs. Likewise, the reduction in
201

chlorhexidine toxicity observed in this study was also discussed. Potential for these novel
nontoxic anti-infective agents lies in their abilities to remove pathogenic E. coli O157:H7 from
the terminal recta of ruminants with unparalleled antibacterial activity and damage to the
bacterium. Thus, mechanism studies exposed the potentiated membrane active properties of
chlorhexidine upon the addition of β-lactam antibiotics as counter-ions.
In Chapter 5, the application of antibiotic-based chlorhexidine GUMBOS was discussed
for the prevention, control, and treatment of drug-resistant bacterial infections. Preliminary
results show that these hybrid salts more effectively killed both drug-susceptible and drugresistant bacteria as compared to the mixture of precursor salts. Exploring the ability to remove
lipopolysaccharide components in vitro using GUMBOS, revealed tunable endotoxin
sequestration with potential to reduce the onset of endotoxemia, bacteremia, and sepsis.
Penicillinase kinetics investigations revealed unusual GUMBOS-enzyme binding between
chlorhexidine di-ampicillin and penicillinase suggesting the potential to use chlorhexidine as an
inhibitor of β-lactam drug degradation when administered as a GUMBOS form. Developing
multi-modal therapeutic GUMBOS by means of anti-infective agents derived from hybridizing
antibiotics with antiseptics, as shown in this dissertation, show the ability potential to positively
reduce the emergence of multi-drug resistant infections and subsequent endotoxin septicemia.
6.2

Future Studies
Until now, various approaches have been used to treat pathogenic infections and prevent

transmission of disease such as, but not limited to, antibiotic development, vaccine
administration, antiseptic use, and combined antibiotics. However, the emergence and reemergence of resistant infectious disease implicates the paramount importance to continue the
pursuit of anti-infective agents. As such, the use of multi-functional anti-infective agents derived
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from GUMBOS offer ways to modernize the therapeutic approaches required to detect, identify,
and treat resistant infections. Incorporating other technologies into antimicrobial GUMBOS can
potentially serve as localized markers of disease and as vesicles for antimicrobial drug-delivery.
The need to rapidly treat surface- and deep-wounds often caused by, but not limited to,
methicillin-resistant Staphylococcus aureus or Acinetobacter baumanii makes these types of
multimodal GUMBOS developed in this research desirable. As such the development of
nanoparticles derived from GUMBOS, or nanoGUMBOS, may provide a more bioavailable,
nontoxic, and potent approach to treat disease systemically as compared to the bulk parent
material. Exploiting the properties often associated with the high surface area of nanoparticles
may find conceivable use in anti-infective therapy. For example, anti-infective nanoGUMBOS
can provide concentrated, localized therapy in a more bioavailable form.
To remedy the contraindications associated with endotoxemia induced by antibiotic
therapy, further studies investigating the anti-inflammatory properties of β-lactam based
chlorhexidine GUMBOS via endotoxin sequestration in vitro have arisen. Endotoxemia, or the
presence of lipopolysacharride (LPS) endotoxins circulating in the blood, often occurs postantibiotic treatment and is therefore, contraindicated for Gram-negative bacterial infections. The
presence of endotoxin in the blood can induce a systemic inflammatory cascade of responses
leading to severe morbidity or even mortality. This problem necessitates advancements in
prevention or treatment for systemic inflammatory response to endotoxin that is separate from
targeting individual cellular mediators. Therefore, nontoxic systemic endotoxin sequestrants
derived from anti-infective GUMBOS would be suitable for this effort. In this way, bacteria
vitality can be inhibited and bacteria toxic wastes can be removed in vivo. Moreover, LPS
consists of different glycoforms that vary in activity. Thus, the affinities of GUMBOS to each
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endotoxin glycoform may predicate their potential to be used as inhibitors of antibiotic-induced
inflammation specific to a particular form of endotoxin.
The development of multimodal gel-based GUMBOS is also plausible from this research
using the modular concept. More specifically, GUMBOS can be synthesized to be species
selective sensing agents that offer rapid and sensitive detection and antimicrobial therapy in
tandem. In this effort, the tunable properties of GUMBOS can be exploited by using antiseptic
and antibiotic GUMBOS reacted with a species-selective chromogen that can allow for the
simultaneous treatment and detection of multi-drug resistant bacteria, topically.
This research also provides the groundwork to apply this technology to other vectors of
infectious disease. In addition to targeting drug-resistant or pathogenic bacteria, the
consideration of GUMBOS as anti-parasitic and antiviral agents can be segmented from this
research. Incorporating functional groups onto charged drug scaffolds that are sensitive and
active to a particular vector of disease is an ideal extension of this work. Likewise, this may
serve useful in designing potent agents effective against some sporulating bacteria. The facile
and rapid synthesis of GUMBOS from active pharmaceuticals approved by the U.S. Food and
Drug Administration allow this modular, pragmatic approach to lead to the next generation of
combination drug therapy equipped for disease control, detection, prevention, and eradication.
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